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ABSTRACT 
Medications, including many that are widely used in children, are rarely tested in 
children. Their safety and effectiveness have not been established in children or have 
been established only for children of a certain ages. For example, 53 of 140 new 
medications were labeled for use in children when they were initially approved. Much 
of pediatric practice, particularly in hospitals and by specialists, has involved “off-
label” use of medications.  As a consequence, about one-third of the drugs prescribed 
in office-based pediatric practices and about two-thirds of those prescribed to children 
in hospital settings are unlicensed or off-label. This proportion reaches 90% in 
intensive care units. Thus, accurate information about dosage in different age groups is 
particularly important, otherwise, children might be over or under treated. The safety 
of a drug in children often cannot be extrapolated from data in adults; medications 
may be more or less toxic in children and require specific studies. The effectiveness of 
a drug can be extrapolated from an adult when no relevant differences can be 
anticipated in disease, disease progression or exposure-effect relationships. Such data 
are usually supplemented with pharmacokinetic studies. Drug clearance (CL) is a 
principle PK parameter determining the age-dependent difference. Therefore, 
predicting pediatric clearance accurately is crucial for appropriate pediatric dosage 
regimen.  
Body weight normalized clearance is widely used because of its simplicity but it 
does not account the maturation of enzymatic and organ functions. As a result, 
children is often overdosed because of the over estimation of clearance, especially in 
neonates and young infants. Recently, anticipation of clearance is built based on more 
  
complex mathematical models, which could take a data or knowledge-driven approach 
by employing either observed data (top-down) or knowledge of human body (bottom-
up). These two approaches depend on different starting information and are likely to 
be used in conjunction with each other for the purposes of defining pediatric dosing 
guidelines.  
This research first focused on the bottom-up, mechanistic models for predicting 
age-dependent hepatic and renal elimination. The maturation of specific cytochrome 
P450 enzymes was modeled based the in vitro ontogeny data from hepatic microsomal 
studies. The age-related function then was incorporated into a well-stirred liver model 
with the developmental changes of other physiological factors, achieving the 
extrapolation from in vitro to in vivo. The model predictions using this physiology-
based approach proved to be more accurate and precise than the allometric functions, 
in neonates and young infants less than 1 year of old for renal and hepatic enzyme 
eliminated drugs.  
In the top-down approach, population analysis is commonly used in pediatric PK 
studies because of heterogeneity of the study population and sparse sampling. The 
covariates effects such as age and size was examined in simple exponential 
relationships. However, these estimates, despite statistical validation in the observed 
population, may not suffice to predict parameters distribution and drug exposure in a 
new population. A more complex covariate-parameter relationship was explored to 
describe the maturation process and changes in physiological functions, based on the 
clearance values of renal and hepatic eliminated probe drugs. In these cases, the 
maturation information derived from metabolic probes could be used as system 
  
specific covariate models for other drugs via the same elimination routes in neonates 
or young infants.    
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PREFACE 
Manuscript Format is in use for this dissertation. 
 Chapter 1 (Manuscript-I) 
During childhood, as the body weight and its function changes dramatically with 
age, drug therapy should be arranged according to age-related changes in 
pharmacokinetics at different age stages. Although the data on drug disposition in 
infants and children increased considerably over the past 2 decades, the effects of 
development on pharmacokinetics and pharmacodynamics remain poorly understood. 
In chapter 1, the impact of developmental pharmacology on drug absorption, 
distribution, metabolism and elimination in infants and children are reviewed. 
Absorption may be affected by difference in gastric pH and stomach emptying time. 
Low plasma protein concentrations and higher body water compositions can change 
drug distribution. Metabolic processes are often immature at birth and this leads to 
reduced clearance rates and prolonged half-life for those drugs, which metabolism is a 
significant mechanism for elimination. Renal excretion is also reduced in neonates due 
to immature glomerular filtration and tubular secretion. Limited data are available on 
pharmacodynamics of drugs. Pharmacokinetics processes develop at different rates 
during the first year of life after birth, thus requiring continual modification of drug 
dose regimens for their safe and effective use in neonates, infants and children.  
Chapter 2 (Manuscript-II) 
The maturation of drug metabolizing enzymes is probably the predominant factor 
accounting for age associated changes. The group of drug-metabolizing enzymes most 
studied is the cytochrome P450 (CYP) superfamily. In chapter 2, the development of 
 vii 
 
CYP enzymes involved in xenobiotic metabolism are reviewed from fetal through the 
life span. These hepatic P450s showed discrepancy in the onset of activities and 
develops independently. The ontogeny of individual isoform could be described in 4 
groups. A first group of CYP3A7 and CYP1A1 expressed at high levels in the fetal 
liver but silenced in the postnatal period. A second group includes CYP2D6, CYP2E1 
and CYP2C19. They surged within hours after birth although proteins could not be 
detected in fetal samples. A third group of P450s develops later. CYP3A4 and 
CYP2C9 rose during the first week after parturition and CYP1A2 is the latest isoform 
to be expressed in the human liver. A fourth group fourth group includes the enzymes 
with a relatively constant level of expression during hepatic development such as 
CYP3A5. Individual CYP Enzyme expression/activity data from hepatic microsomes 
in specific infant age groups are assembled. Tentative general mathematical functions 
describing the ontogeny of hepatic CYPs are elaborated from these age-specific data. 
Combined with quantitative changes of other physiological factors during early life 
stages, these functions have permitted the development of physiological based 
pharmacokinetic models and the prediction of drug disposition in pediatric population.   
Chapter 3 (Manuscript-III) 
Drug systemic clearance mechanism matures quickly during the postnatal period 
and leads to rapid changes in an infant’s capacity to eliminate drugs. In chapter 3, a 
mathematical model describing the maturation of hepatic cytochrome P450 enzyme-
mediated clearance and renal clearance due to glomerular filtration was elaborated 
from developmental physiology and the ontogeny information of specific cytochrome 
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P450s. The model predicts an age-and elimination pathway-specific clearance for the 
ontogeny of renal clearance, and metabolic clearance of CYP1A2 and CYP3A4.  
The systemic clearance of 6 probe compounds was predicted using the model 
whose elimination is primarily mediated by a single CYP enzyme or by glomerular 
filtration. The model performs reasonably well for CYP3A4 substrates with 
predictions within 2-fold of the observed values in 87% of alfentanil and 74% of 
midazolam. However, poor predictions were obtained for CYP1A2 substrates caffeine 
and theophylline with predictions within 2-fold error less than 45%. The overall under 
predictions for CYP1A2 probes in infants less than 1 year of old suggested the 
contribution of alternative elimination pathways to the overall clearance of these drugs 
in neonates. For renal clearance due to glomerular filtration, the model provides 
reasonable predictions in neonates and young infants.  
Clearance scaling is not intended to replace the clinical trials for drugs in 
development but it will provide a valuable guide on dosing regimens for the first-time 
doing in children. Furthermore, clearance scaling can greatly benefit the dose 
adjustment of clinical drugs used in neonates and young infants.    
Chapter 4 (Manuscript-IV) 
In pediatric population, developmental changes in clearance can be predicted by 
age and size (body weight or body surface area). Clearance in children is commonly 
scaled from adults by size using either the per kilogram, body surface area or 
allometric ¾ power models. But the size model does not account for the maturation 
process of the elimination organ and therefore may not be appropriate to scale 
clearance to the very young children. The physiology-based approach accounts for 
 ix 
 
maturity but requires detailed knowledge regarding developmental changes. In chapter 
4, these approaches were compared and appropriate use of these approaches is 
dependent on the age and clearance pathway.  
 A child PK database was developed and the dataset of experimentally obtained 
clearance values was used. Predicted clearance values in children were calculated 
based on the adult clearance, age and weight data using the four approaches. The ratio 
of predicted to observed values was graphed separately for probe substrates of three 
predominant clearance pathways: CYP1A2, CYP3A4 and renal clearance due to 
glomerular filtration.  
Allometric ¾ power model and body surface area approach systemically over 
estimated clearance in children below 1 year of old for all the compounds. Physiology-
based approach accurately predicted clearance at all ages for compounds eliminated 
via CYP3A4. The clearance of CYP1A2 substrates within the first year were under 
predicted by the physiology-based approach but over estimated by the other 
approaches. In the case of renal clearance in children below 1 year of age, the per 
kilogram and physiology-based model performed similar with a few overestimations.  
Physiology-based clearance scaling accurately predicted clearance in children 
from birth to 18 years. The allometric ¾ power and body surface area model are only 
accurate when the major clearance pathway is fully matured.    
Chapter 5 (Manuscript-V) 
Population modeling in pediatric studies often uses size and age as covariates. 
Covariate-parameter correlations are described in an exponential relationship used by 
allometric scaling. However, extrapolations based on such parameter estimates have 
 x 
 
limited value due to differences in the impact of developmental growth across 
populations. The quantitative models used to describe the clearance maturation 
processes across the age range may be required to improve extrapolation and 
predictive performance.  
Previously published pharmacokinetic parameters from probe substrates of 
hepatic and renal elimination processes are used to develop clearance pathway-
specific maturation models. The postconceptional age (PCA) was used as the variable 
in the modeling practice. Clearance maturation, after standardized to a 70-kg adult, is 
best fitted with a Hill function. The two renal excreted compounds due to glomerular 
filtration, gentamicin and vancomycin, presented similar maturation half-life and Hill 
coefficient, suggesting a system-specific maturation function of glomerular filtration 
rate (GFR). Similar results were attained with CYP1A2 metabolic probes theophylline 
and caffeine. Midazolam and alfentanil demonstrated different clearance maturation 
profiles suggesting a complexity in CYP3A4 metabolism. 
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Abstract: 
Drug regimens for the pediatric population should be developed in accordance 
with an understanding of how drug’s pharmacokinetics and pharmacodynamics are 
affected by the dynamic age-related changes in body size and physiology that occur at 
different stages of development. Although the data on drug disposition in infants and 
children has increased considerably over the past 2 decades, the effects of 
development on pharmacokinetics and pharmacodynamics remain poorly understood. 
In this review, the impact of development on drug absorption, distribution, metabolism 
and elimination in infants and children is reviewed. Absorption may be affected by the 
differences in gastric pH and stomach emptying time that have been observed in the 
pediatric population. Low plasma protein concentrations and higher body water 
compositions can change drug distribution. Metabolic processes are often immature at 
birth, which can lead to reduced clearances and prolonged half-lives for those drugs 
for which metabolism is a significant mechanism for elimination. Renal excretion is 
also reduced in neonates due to immature glomerular filtration and tubular secretion. 
Limited data are available on pharmacodynamic behavior of drugs in the pediatric 
population. Pharmacokinetic processes develop at different rates during the first year 
of life after birth, thus requiring continual modification of drug dose regimens for their 
safe and effective use in neonates, infants and children. 
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Introduction 
The pediatric population is very dynamic compared to the adult population. It 
consists of a collection of highly variable groups that span from new born babies to 
adolescents of 16 years old. According to the Food and  Drug Administration (FDA) 
guidance, the pediatric population is broken down into the following age-based 
groups: neonates (birth to 1 month); infants (1 month to 2 years); developing children 
(2 to12 years); and adolescents (12 to 16 years).
1
  In addition to growth in physical 
size, dramatic changes in body proportions, body compositions, physiology, 
neurologic biochemistry, and psychological development take place during the 
transition between infancy and childhood. Growth and development occur particularly 
rapidly during the first 2 years of life. Body weight typically doubles by 6 months of 
age and triples by the first year of life. Body surface area doubles during the first 
year.
2
  Proportions of body water, fat and protein continuously change during infancy 
and childhood. Major organ systems mature in size as well as function during infancy 
and childhood. Additionally, the pathophysiology of some diseases and pharmacologic 
receptor functions change during infancy and childhood and differ from adults. For 
example, most cases of hypertension in children are secondary to renal disease, 
whereas most cases of hypertension in adults are primary or essential. This has 
profound effects on the design of antihypertensive drug trials with children. 
3
 The 
different sensitivity of the neuromuscular junction to d-tubocurarine (d-TC) among 
neonates, infants, children and adults has been determined.
4
  All of the previously 
mentioned changes can affect the pharmacokinetics and pharmacodynamics of various 
drugs and other xenobiotic compounds in the infant and developing child.  
 4 
 
Mainly due to the ethical concerns, clinical studies to investigate drug 
pharmacokinetics and pharmacodynamics in the pediatric population did not begin 
until 1970’s, which is a period also accompanied by the development of sensitive and 
specific bioanalytical assays.   Since that time, numerous studies have reported age-
related pharmacokinetic profiles, and to a lesser extent, pharmacodynamic profiles, for 
many therapeutic agents used in children.
5, 6
 Pharmacokinetic parameters including 
half-life, apparent volume of distribution and total plasma clearance, were shown to 
have  substantial differences among different age groups even when normalized by 
body weight.
7
 These findings were confirmed by  population analyses in pediatric 
patients across broad age ranges, which  indicated that in addition to body size, age is 
an important determinant of pharmacokinetic parameters the pediatric population. 
8-12
  
Age associated developmental changes, such as body compositions, organ functions, 
ontogeny of drug biotransformation pathways, disease progression, pharmacological 
receptor functions, have all been shown to affect drug dispositions and response 
profoundly, especially during the first two years of life.
13
  Understanding these age 
effects can provide a mechanistic way to identify initial doses for the pediatric 
population.  
The purpose of this review is to summarize quantitative and qualitative 
developmental changes in the neonate, infant and developing child, and discuss how 
these changes may produce age-associated changes in the drugs’ pharmacokinetics 
(bioavailability, volume of distribution, protein binding, hepatic and renal 
elimination), and pharmacodynamics.  Approaches that can determine age-specific 
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dosing regimens through a mechanistic understanding of pharmacokinetic and 
pharmacodynamic are discussed.  
Absorption 
In contrast to intravenous administration, drugs administrated extravascularly 
must undergo absorption to reach the systemic circulation. Absorption is frequently 
assumed to be a single first order process and is often quantified by absorption rate 
constant (ka), the time to reach peak concentrations (tmax), and the extent of drug 
absorption by the fraction of the dose absorbed (F) and the value of the peak plasma 
concentration (Cmax).  
In the gastrointestinal tract, several age-related anatomic and physiological 
changes have been found that may affect drug absorption (Table 1.1). Gastric pH is 
neutral at birth but falls to pH 1-3 within 24-48 hours after birth. The pH then 
gradually returns to neutral again by day 8 and subsequently declines very slowly, 
reaching adult values only after 2 years of age.
14, 15
  The higher pH or relative 
achlorhydria in neonates and very young infants may partially explain the higher 
bioavailability reported for acid-labile compounds such as beta-lactam antibiotics 
because higher gastric pH results in their reduced degradation.
16
  Bioavailability of 
orally administered weak acids, such as phenytoin, acetaminophen and phenobarbital, 
may be reduced in infants and young children due to increased ionization under 
achlorhydric conditions.
17, 18
 
Gastric emptying and intestinal motility are important determinants for the rate of 
drug absorption in the small intestine, which is the major site of drug absorption. 
Gastric emptying time during the neonatal period is prolonged relative to that of the 
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adult. This may partially account for delayed absorption for orally administered 
phenobarbital, digoxin and sulfonamides. 
19
  Other factors such as reduced intestinal 
absorption surface area and shorter gut transit time may also be responsible for the 
delayed absorption observed in neonates.  
In addition, the ability to solubilize and subsequently absorb some lipophilic 
drugs can be affected by the age-dependent changes in biliary function and activities 
of pancreatic enzymes. The infant has decreased pancreatic exocrine function and bile 
acids secretion, which may influence the absorption of prodrug esters such as 
erythromycin that require solubilization or intraluminal hydrolysis. 
20
  
Developmental changes in the activity of intestinal drug-metabolizing enzymes 
and transporters that could potentially alter the bioavailability of drugs. At this time, 
these developmental changes have not been completely characterized as few clinical 
studies have addressed this issue. Midazolam’s oral clearance (Cl/F) is markedly 
decreased in preterm infants because immature intestinal cytochrome P450 3A4 
(CYP3A4) metabolism leads to an increased oral bioavailability. 
21
  One study 
observed that intestinal biopsy specimens from young children (1- to 3- years old) had 
a 77% higher busulfan glutathione conjugation rate compared to older children (9- to 
17- year old), which may lead to an enhanced first-pass intestinal metabolism and a 
reduced absorption fraction (F) in young children. 
22
  Gabapentin is primarily excreted 
in urine as unchanged drug, and its bioavailability is dose independent because the L-
amino acid transporter in the GI membrane is saturated by high drug concentrations. 
Oral clearance of gabapentin is 33% higher in children younger than 5 years than in 
older children or adults. Because renal clearance reaches adult levels at 1-2 years of 
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age and gabapentin is not protein bound, this effect on oral clearance is not likely due 
to the altered clearance but decreased bioavailability caused by immature L-amino 
transporter activity. 
23
   
Developmental changes also can alter the absorption of drugs by other extra 
vascular routes. Percutaneous absorption of drugs through skin may be high in 
newborns and infants owing to better hydration of the epidermis, greater perfusion of 
the subcutaneous layer and the larger ratio of total body surface area to body mass 
compared to adults. Thus, the relative exposure to steroids applied topically in 
newborns and infants may exceed that in adults and result in toxic effects in some 
instances.
24
  The absorption of intramuscular administered drugs may be delayed in 
neonates from reduced blood flow to skeletal muscles, although it is often 
unpredictable in clinical practice. 
25
 
Distribution  
Independent of the route of administration, once the drug enters the blood stream; 
it is distributed into the vascular compartments of the body and extra vascular tissues. 
The volume of distribution (Vd), is mainly determined by the ratio of plasma to tissue 
binding and the physiological volumes a drug can access. A high volume of 
distribution indicates extensive drug distribution to the tissues and a low volume 
suggests that a drug is highly bound to plasma proteins. Other factors, such as lipid 
and water solubility, may also be important. 
The dramatic maturation changes in the relative amount of body water and fat 
have been well characterized by Friis-Hansen. 
26
  The total body water content, 
expressed as percentage of body weight, decreases with age, from approximately 80% 
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in newborns to 60% by 1 year of age. Conversely, body fat increases with age, from 1-
2% in a preterm neonate to 10-15% in a term neonate and 20-25% in a 1-year-old. The 
impact of these differences on the volume of distribution depends to on the 
physiochemical characteristics of the drug. Highly water-soluble compounds, such as 
gentamicin, have larger volumes of distribution in neonates compared to adults. For 
example, gentamicin’s volume of distribution is around 0.5 L/kg in neonates, 
compared to 0.25-0.3 L/kg in adults. As a result, a larger milligram per kilogram 
loading dose may need to achieve desired therapeutic concentrations. 
27
  Lipophilic 
drugs, such as diazepam, tend to have smaller volumes of distribution in infants than 
in older children and adults.
18
 
Plasma protein binding tends to be reduced in neonates and infants.
28
  Factors that 
influence the drug-protein binding during infancy include: the total amount of plasma 
proteins such as albumin and alpha1-acid glycoprotein, the binding affinity and the 
presence of endogenous compounds. Reduced protein binding may result in drugs 
being distributed more widely and an increased apparent volume of distribution. For 
example, a clear link between an increased volume of distribution in neonates and the 
decreased protein binding has been reported for phenobarbital.
18
  In addition, the 
decreased protein binding would alter the ratio of unbound to total plasma 
concentrations for the highly protein-bound antiepileptic drugs such as phenytoin, 
which makes the total concentrations of phenytoin difficult to interpret for therapeutic 
drug monitoring in neonates and young infants. 
29
  Finally, it is worthwhile to mention 
that highly bound acid drugs such as sulfonamides can compete for bilirubin-binding 
sites on albumin and displace bilirubin when plasma albumin level is low. This will 
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lead to increased blood levels of unconjugated bilirubin and increase risk of 
kernicterus in the fetus or neonate. 
30
  
Drug Transport 
Drug transporters such P-glycoprotein (P-gp), organic anion transporting 
polypeptides (OATPs), organic anion transporters (OATs), cation transporters (OCTs), 
and breast cancer resistance protein (BCRP), may influence drug absorption, 
distribution and elimination.
31
  Limited data in humans suggest that P-gp follows a 
developmental pattern. P-gp mRNA and protein were detected in human kidney and 
liver as early as 11 to 14 weeks of gestation but were only detected in brain and 
intestine in the third trimester of pregnancy. 
32
 A significant amount of P-gp is 
expressed in the intestine of neonates and infants with a large interindividual 
variability.
33
  In human intestinal and liver tissues from individuals of different age 
ranging from neonatal to 85 years, P-gp expression was relatively low in the neonatal 
group but it increased with development and reached maximum levels in young adults 
(15 – 38 years of age) and decreased to half the maximal levels in older individuals 
(67 – 85 years).34  There is differential expression of P-gp in various tissues. A study 
in 90 healthy volunteers aged 0 – 86 years showed that P-glycoprotein activity in 
peripheral blood lymphocytes was highest in cord blood and progressively declined 
with age. 
35
  The clinical significance of developmental changes in transporter 
functions has not been systemically studied in humans. 
Hepatic Metabolism  
Drug metabolism can be divided into two types of reactions: phase I and phase II 
metabolism. Phase I metabolism involves structural alterations of drug molecules by 
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introducing or unmasking a functional group (e.g. oxidation, reduction and 
hydroxylation). Phase II metabolism involves conjugation of functional groups of 
molecules (parent drug or phase I metabolites) with hydrophilic endogenous substrates 
(e.g. glucuronidation, sulfation, acetylation). Although the kidney, intestine, lung and 
skin are also capable of biotransformations, the liver is quantitatively the most 
important organ for drug metabolism. 
36
  Developmental changes in hepatic 
metabolism have been identified in the past decade and different metabolic pathways 
mature differently with age.    
Most phase I drug reactions are mediated by cytochrome P450 (CYP) enzymes, a 
super family of multiple hemeproteins, among which CYP3A, 2C9/2C19, 2D6, 1A2, 
2E1 and 2B6 are involved in the hepatic metabolism of most drugs. 
37
  Other than 
CYPs, the flavin-containing monooxygenase (FMO) enzymes are also important for 
the oxidative metabolism of a wide variety of therapeutics. Figure 1 lists the 
ontogenesis for primary cytochrome P450 (CYP) enzymes.
38-42
  Briefly, CYP3A7 is 
the primary isoenzyme during the prenatal period and declines rapidly after birth. This 
enzyme exists in barely measurable quantities in adults. CYP2E1 and CYP2D6 levels 
begin to rise at the time of birth, and CYP3A4, 2C9 and 2C19 appear within the first 
weeks of life. CYP1A2 is the last enzyme to develop and is present by 1-3 months of 
life. The activity of these enzymes increases over time but does not appear to do so in 
a direct linear manner with age. By 1 -2 years of age, the total CYP activity levels are 
similar to those of adults. 
43
  The developmental changes in the enzymatic systems are 
supported by the age-related changes in the systemic clearance, as well as changes in 
the metabolic ratios of probe substrates to their metabolites in vivo. For example, the 
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rise of the amount of CYP2D6 protein was associated with the rise in 
dextromethorphan O-demethylation, as measured in vivo by the urinary ratio of 
dextromethorphan to dextrorphan. 
44, 45
  Similarly, the delayed ontogenesis of 
CYP1A2 protein was consistent with the in vivo data where N3 and N7 demethylation 
products of caffeine (assigned to CYP1A2) represented 6-8% of the total 
biotransformation in neonates and increased to about 28% in infants aged 2-10 
months. 
46
  In addition, the developmental sequence of the CYP isoenzymes is also 
demonstrated with the developmental changes in the relative amount of metabolites 
produced from the different pathways. For example, O-demethylation of diazepam by 
CYP2D6 is reported to develop sooner than N-demethylation by CYP3A4, which is in 
line with the in vitro observations on the ontogeny of CYP2D6 and CYP3A4. 
47
    
 
The ontogeny of hepatic FMO exhibits a similar developmental pattern as the 
CYP3A family. The expression of FMO1, whose developmental pattern is like that of 
CYP3A7, is at the highest level at 8 to 15 weeks of gestation and subsequently 
declines during the fetal development and completely absent within 72 postnatal 
hours. FMO3, however, analogous to CYP3A4, is negligible in neonatal period and 
becomes detectable by 1 to 2 years of age. The delayed onset of FMO3 expression 
results a null FMO phenotype in the neonate. 
48
  
In contrast to the cytochrome P450 enzymes, isoform-specific quantitative data 
for the developmental pattern of phase II enzymes is very limited. The timelines of 
phase II enzymes detected in fetus, neonates and infants are shown in Table 1.2. 
49, 50
  
The uridine 5-diphosphoglucuronic acid glucuronyl transferases (UGT) are the major 
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contributors to phase II metabolism, and account for nearly 15% of phase II 
metabolism activity in adult human. 
51
  The ontogenesis of UGTs has been of greater 
focus than other phase II enzymes because of the common therapeutic use of several 
substrates in pediatric patients. These substrates include, acetaminophen (UGT1A6 
and, to a less extent, 1A9), morphine (UGT2B7) and zidovudine (UGT1A6). Among 
the UGT isoforms, UGT 1A1 and 2B7 develop quickly, whereas UGT1A6 and 1A9 
develop slowly. 
52
  The expression of UGT1A1, the major enzyme responsible for 
bilirubin glucuronidation, is triggered at birth and the activity reaches adult levels by 3 
to 6 months postnatal age. UGT2B7 is present in fetus, and increases at birth with 
adult levels attained by 2 to 6 months of age. UGT1A6 is undetectable in the fetus. It 
increases slightly in neonates, but does not reach adult levels until 10 years of age. 
These data are consistent with the pharmacokinetic data of UGT substrates assessed in 
vivo. For example, the systemic clearance of morphine (substrate of UGT2B7) is low 
in neonates and reaches adult levels between 2 and 6 months. 
53
  Similarly, 
acetaminophen glucuronidation (primarily mediated by UGT1A6 and 1A9 to a less 
extent), as reflected by urine metabolite data, is low in newborns and young children 
compared to adolescents and adults. 
54
  
Although glucuronidation is considerably reduced in newborns, sulfation appears 
to be well developed at birth. The variation in the function of the two phase II 
reactions can be seen with the developmental changes of acetaminophen metabolism. 
In early infancy, acetaminophen is primarily converted into the sulfate conjugates; but 
with increasing age, glucuronidation becomes the predominant form of metabolism. 
13
  
Acetylation has also been studied and has been found to have reduced activity in the 
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first month of life, although the effect of age appears to be less dominant than that of 
polymorphism of N-acetyltransferase (NAT). 
50
  Esterase activity is also reduced in 
newborn and this may partly account for the prolong effects of local anesthetics. 
55
   
In conclusion, both phase I and II metabolic processes may be immature at birth. 
These deficiencies may result in the increased risk for drug toxicity in infants and 
young children. An often cited example is “gray-baby” syndrome associated with the 
administration of chloramphenicol (substrate of UGT2B7). The syndrome consisted of 
emesis, abdominal distension, abnormal respiration, cyanosis, cardiovascular collapse 
and death. This response has been primarily assigned to the very high drug plasma 
concentrations caused by the reduced glucuronidation and clearance of 
chloramphenicol  in the neonate. 
56
  The ontogeny of drug-metabolizing enzymes in 
humans will clearly have to be addressed by age-related dosage adjustment for some 
therapeutic agents in pediatric patients. For example, a positive correlation was 
demonstrated between age and systemic clearance normalized by body weight for 
theophylline. 
57
  Other drugs that undergo extensive metabolism, including caffeine, 
diazepam, phenytoin and chloramphenicol, are often observed with prolonged 
apparent half-lives in neonates and young infants. As a result, a decreased daily 
maintenance dose or increased dosing interval may be needed to avoid drug 
accumulation. A typical example is the clinical use of theophylline in infants with 
apnea or chronic lung disease. The elimination half-life of caffeine, a metabolite of 
theophylline is ~30 hours in neonates, and is decreased to 3 hours by 1 year of age as 
CYP1A2 enzyme activity increases. Correspondingly, the initial maintenance dose of 
theophylline is adjusted for different ages to avoid the accumulation of caffeine. 
58
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The transporter-mediated uptake of drugs into the hepatocytes and efflux into the 
bile is often calledPhase III hepatic pathway. Important uptake transporters include the 
OATPs, OAT2 and OCT1, and clinically important efflux transporter at canalicular 
membrane include  P-glycoprotein (P-gp), breast cancer resistant protein (BCRP), bile 
salt export protein (BSEP) and  multidrug resistance protein 1 (MRP1). P-glycoprotein 
is also involved in efflux of compounds from the intestines.
59
  At this time, there are 
limited data in humans on the ontogeny expression of liver transporters.
60
 A single 
study suggested that P-gp in the liver follows a developmental pattern of expression in 
which activity increases during the first few months of life and adult levels reaches by 
2 years of age. 
61
 
In addition to size and ontogeny of enzyme and transporters, other factors such as 
genetic polymorphism, prenatal or postnatal exposure to inhibiting and inducing 
agents, might also have an independent impact on the phenotypic metabolic activity 
observed. 
62
  Allegaert et al. recently found that CYP2D6 polymorphisms had a 
significant impact on O-demethylation of tramadol in neonates and young infants. The 
metabolite ratio of tramadol over O-demethyl tramadol decreased progressively with 
increasing activity score of CYP2D6 (a quantitative classification of CYP2D6 
genotypes). 
63
  There is a large interindividual variability observed in CYP2B6 
expression including pediatric populations. This was likely due to the highly inducible 
and polymorphic nature of this enzyme.
64
     
Renal Elimination 
Excretion of drugs by the kidneys is dependent on three processes. First, 
glomerular filtration, a passive process whereby a drug not bound to plasma proteins is 
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filtered into the renal tubule. Clearance by glomerular filtration is principally 
determined by the glomerular filtration rate (GFR) and the extent of plasma protein 
binding. Second, drug excretion may be augmented by the action of uptake and efflux 
transporters in the renal tubule epithelium of the proximal convoluted tubule. Finally, 
drugs may be re-absorbed from the tubule back into the blood by passive diffusion, 
which is determined by the physiochemical characteristics of the drug and urinary pH. 
The renal clearance (CLr) of drugs is the sum of three processes (Eq.1). Each of these 
processes exhibit independent rate and pattern of development.  
 
 
Glomerular filtration is the major renal elimination pathway for many drugs. As 
shown in Figure 2,
65, 66
 the glomerular filtration rate (GFR), measured by the renal 
mannitol clearance, is around 10-20 mL/min/m
2
 at birth for a full-term newborn. This 
increases rapidly to 20-30 mL/min/m
2
 during the first weeks of life and typically 
reaches adult values (70 mL/min/m
2
) by 3-5 months. Furthermore, the increase in 
GFR is highly dependent on postnatal age (PNA, the chronological age since birth).  
Hayton et al. described the maturation of GFR with PNA by a nonlinear function.
 65
 A 
more practical equation (Eq.2) for estimating age-specific renal glomerular filtration 
rate (CLGFR) was proposed by Schwartz and coworkers. 
67
  
 
 
Where CLr, Cr is renal creatinine clearance (ml/min/1.73m
2
), Ht is height (cm) and 
SCr is serum creatinine concentration (mg/dl). K is a constant of proportionality and 
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different for children in different age bands. K is 0.33, 0.45, 0.55, 0.55 and 0.7 for 
infants with low birth weight (0-12 months), full term infants (0-12 months), children 
(2-12 years), female adolescents (13-21 years) and male adolescents (13-21 years), 
separately. For drugs that are mainly excreted by glomerular filtration (e.g. 
aminoglycosides), the initial dose adjustment can be made based on the knowledge of 
serum creatinine levels.   
In contrast to glomerular filtration, tubular secretary and re-absorptive capacity 
appear to mature at a much slower rate. The tubular secretion rate, measured by the 
renal clearance of p-aminohippurate (a substrate of kidney the uptake transporter, 
organic anion transporter), is reduced at birth to approximately 20-30% of adult 
capacity but matures by 15 months of age.
66
  The development of other renal uptake 
transporters such as organic cation transporters (OCT) and organic anion transporting 
polypeptides (OATPs) is unknown. Tubular reabsorption is the last renal function to 
mature and does not reach adult levels until 2 years of age. This delay in the 
development of tubular functions may have variable effect on some drugs’ clearance 
for which tubular secretion or reabsorption is important in adults. For example, 
digoxin is both filtered by the glomerulus and secreted by the tubules, and average 
renal clearance of 1.97, 5.33 and 8.67 L/h/1.73m2 have been reported in full term 
infants less than 1 week of age, 3-month-old infants and children of 1.5 years of old, 
respectively.
68
  At this time there is little information in the literature about the 
ontogeny of renal drug transport systems and their impact on renal elimination in 
infants and children. 
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Generally, for drugs principally eliminated by kidney, immature renal clearance 
processes result in the inefficient elimination of drugs and prolongation of their 
residence time in the body (e.g. the prolonged apparent half-life in the newborns for 
digoxin and penicillins 
69
).  
Pharmacodynamics  
Unlike the rapidly accumulating knowledge of the pharmacokinetic changes 
associated with development, little is known about receptor development and 
sensitivity and how maturation affects the response to the drug-receptor interaction. 
Most often, the apparent developmental differences in pharmacodynamics (e.g. higher 
acid inhibition effect of lansoprazole in young infants) or the incidence of adverse 
effects (e.g., increased hepatoxicity of valproic acid in young infants) are linked with 
pharmacokinetic differences. 
29, 70
  The existence of true age-dependent differences in 
receptor sensitivity appears to be supported by data on certain drugs (e.g., warfarin 
and tubocurarine). For example, Takahashi et al. reported that the mean international 
normalized ratio obtained from the prepubertal patients was significantly greater than 
that obtained from the adult patients, despite no differences in unbound fraction of (S)-
warfarin observed between pediatric and adult patients.
71
  This finding suggested that 
children might possess a greater sensitivity to warfarin than adults due to 
pharmacodynamic rather than pharmacokinetic differences. Marshall and Kearns 
reported the in vitro developmental pharmacodynamics for cyclosporine.
72
  The 
peripheral blood monocytes of the infants showed a twofold lower mean IC50 
(peripheral blood monocyte proliferation) and sevenfold lower mean IC90 (interleukin-
2 expression) than peripheral blood monocytes from older subjects. The study 
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provided relevant information on developmental changes in receptor binding 
characteristics in vitro, but this may not be reflective of the pharmacodynamic 
response in vivo. Future clinical research in age-related changes in the 
pharmacodynamic response chain is important to fully understand drug response in the 
pediatric population and to identify optimum therapeutic plasma concentrations in this 
group. 
Age-related Dosing Regimen  
Simple dosage formulas (normalized by body weight or body surface area) and 
allometric scaling may be clinically applicable in children older than 2 years of age.
73
  
In neonates and young infants, where age related developmental changes in drug 
disposition are underway, age-specific dosing regimens are needed based on observed 
age-related changes in bioavailability (F), volume of distribution (Vd) and overall 
clearance (CL).  
In clinical practice, when pharmacokinetic data in children is available standard 
pharmacokinetic equations can be used to estimate doses. Without established dosing 
guidelines or complete pharmacokinetic data in children, methods to approximate the 
initial dose or maintenance dose for an infant are proposed as “bottom-up” 
approaches. To date, there are several “bottom-up” approaches for pediatric dose 
selection without PK data in children. Bartelink et al. proposed a refined dosing 
guideline based on the route of administration, the characteristics of the drug, the age 
of the child. For example, the dose of drugs that are excreted by glomerular filtration 
is indexed to body surface area in children over 2 years of age, but uses GFR as 
descriptor in children < 2 years of age.
74
 This guideline is an integration of four 
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important pharmacokinetic processes: absorption, distribution, metabolism and renal 
excretion and its decision tree designation is simple to use in clinical practice. 
However, the approach ignored the complexity of PK characteristics of individual 
drugs and the large interindividual variability across the pediatric population. Another 
possibly more accurate approach is pediatric physiologically based pharmacokinetic 
(PBPK) modeling. Many pediatric PBPK models have been developed to predict 
pharmacokinetics in children, one of which is the model presented by Edginton et al. 
using PK-Sim for five compounds: acetaminophen, alfentanil, morphine, theophylline 
and levofloxacin.
75
  In general, an existing adult PBPK model is extended to reflect 
age-related physiological changes in children from birth to age eighteen. The age-
modified model was then used together with a previously developed age-specific 
clearance model to predict pediatric plasma concentrations.
76-78
  PBPK models 
combine the developmental physiological processes of the child with adult PK data, 
and require the compound-related information and compound-independent 
information on the ontogeny of anatomical, physiological and biochemical variables, 
which are often from multiple resources in the literature.
79
 However in many cases it 
seems unlikely that accurate data from humans of all ages will ever be available. 
Moreover, there is no consensual input for physiological parameters. Regression 
equations fitted from the literature sources are validated internally by each author or 
modeling team. Many of the values are often estimates or educated guesses. For 
example, the data on the tissue composition (proportion of lipids, protein and water) 
are limited and sometimes unavailable for children. Because this information is 
important to predict the tissue blood partition coefficient,
80
  assumptions are made in 
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PBPK models to consider the coefficient in children as equal to that in adults. The 
ontogeny of hepatic cytochrome P450 enzymes are still missing for some age ranges. 
81
  
Although these bottom-up approaches provide a valuable aid for the first-time 
dosing in children and for the study design, none of them could be a substitute for a 
clinical study on the effect of age on the pharmacokinetics of a specific drug.
82
  A 
population pharmacokinetic approach is commonly used to obtain these age-associated 
PK parameters. The selected population model usually includes covariates such as 
body weight and age. Weight is often included in the model using allometric scaling 
according to the formula (Eq. 3): 
                     (Equation 3) 
where θi represents the individual parameter of interest, θTV the typical value for 
the parameter, BWi the individual body weight, median BW is the median body 
weight of the population and exponent (EXP) is the power factor. The allometric 
exponent (EXP) can be either fixed or estimated during the model building 
procedure.
12
  In the example of zidovudine PK in HIV-infected infants and children, 
an allometric size model with fixed coefficients of 0.75 for clearance and 1 for volume 
of distribution were incorporated in the base model and then other potential covariates 
such as age, liver enzyme measurements were evaluated.
9
 The population approach is 
ideal for the pediatric population since a large heterogeneous population can be 
studied by taking only a few samples per patients at flexible sampling times. 
83
  
Moreover, if clinical response measurements are available, it may be possible to create 
integrated pharmacokinetic-pharmacodynamic models, which would allow better 
 21 
 
optimization of pediatric dosing. For example, a population PK-PD model was used to 
refine postoperative sedative effect and optimize the dose of midazolam in 
nonventilated infants aged 3 months to 2 year old.
84
  
Conclusion 
An advance in developmental pharmacology during the past decades have 
improved our understanding of the influence of growth and maturation on the 
disposition (and actions) of drugs. Pediatric clinical studies encouraged by regulatory 
agencies have facilitated improvements in drug therapy for this population. 
85
  Based 
on the current knowledge, it should be obvious, that the dosing regimen for adults 
cannot be simply or linearly extrapolated to children, particularly in neonates and 
infants. The application of population pharmacokinetic-pharmacodynamic methods 
has been widely advocated and is described in the FDA’s guidance document. 1, 86  
The use of physiologically based pharmacokinetic models has been recommended to 
help in the first time dosing in children as well as the study design. 
87, 88
  However 
there is a strong need for more research on developmental pharmacology such as the 
ontogeny of drug metabolizing enzymes, transporters, receptor system, and disease 
progress. As the gaps in knowledge are gradually filled in, the development of 
therapeutic pediatric dosing regimen will be enhanced, and drugs will eventually be 
provided to children with greater precision and safety.    
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Table 1 Developmental factors affecting drug pharmacokinetics in neonates and infants. 
Physiologic Factors 
Difference 
compared to 
adults 
PK implications Example Drug 
Oral absorption    
   Gastric PH ↑ 
↓ bioavailability         
(weak acids) 
phenytoin, phenobarbital, 
ganciclovir 
↑ bioavailability         
(weak bases) 
penicillin G, ampicillin, 
nafcillin 
   Gastric emptying time ↑ delayed absorption 
phenobarbital, digoxin and 
sulfonamides 
   Intestinal CYP3A4 ↓ ↑ bioavailability midazolam 
   Intestinal GST ↑ ↓ bioavailability busulfan 
   Intestinal drug 
transporters 
↓ ↓ bioavailability gabapentin 
    
Percutaneous absorption       
   hydration of epidermis ↑ ↑ bioavailability steroids 
    
Intramuscular 
absorption    
   skeletal muscle blood    
   flow 
variable unknown n.a. 
    
Distribution 
   
   Body water : body fat 
ratio 
↑ 
↑ volume of distribution 
(hydrophilic drugs) 
gentamicin, linezolid, 
phenobarbital, propofol 
↓ volume of distribution 
(lipophilic drugs) 
diazepam, lorazepam 
   Protein binding ↓ ↑ free fraction of drugs sulfonamides 
    
Hepatic metabolism 
   
   Phase I enzyme 
activity 
↓ ↓ hepatic clearance 
theophylline, caffeine, 
midazolam 
   Phase II UGT enzyme  
   activity  
↓ ↓ hepatic clearance morphine 
   
 
 
Renal excretion 
   
   Glomerular filtration 
rate 
↓ ↓ renal clearance aminoglycosides 
   Renal tubular 
absorption  
   and secretion 
↓ ↓ renal clearance digoxin 
↑ = changes increased in values; ↓ = changes decreased in values; n.a. = not available 
CYP: cytochrome P450; GST: glutathione S-transferases; UGT: UDP-glucuronosyltransferase 
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Table 2 In vitro ontogeny of human hepatic phase II enzymes (adapted from Ref. 
36-37
). 
Isoenzyme Fetus 
Neonate  (0-
1 month) 
1 month 
to 1 year 
Adult Ontogeny Facts 
UDP glucuronosyltransferase 
(UGT) 
     
UGT1A1 - + + + 
adult levels attained by 3-6 
month 
UGT1A6 - + + + 
maturation complete until 
puberty 
UGT2B7 + + + + 
adult levels attained by 2-3 
month 
Sulfotransferases (SULT)      
SULT1A3 ++ + + - 
substantial decrease in 
perinatal period 
Glutathione S-transferase (GST)      
GSTA1/2 + ++ ++ ++ 
increase dramatically to adult 
levels shortly after birth 
GSTM + ++ ++ ++ 
increase dramatically to adult 
levels shortly after birth 
GSTP ++ + + - 
substantial decrease in 
perinatal period 
Epoxide hydrolase (EPH)      
EPHX1 + + + + 
no correlation between 
EPHX1/EPHX2 activity and 
gestational or postnatal age 
EPHX2 + + + + 
N-acetyltransferase (NAT)      
NAT2 + + + + 
Enzyme polymorphisms affect 
isoniazid metabolism more 
importantly than ontogeny 
-, activity or protein not detectable; +, activity or protein detectable; ++, high level of activity or protein expression 
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Figure 1 Developmental profiles of major hepatic cytochrome P450s (A) and CYP3A7 
(B). The postnatal evolution of P450 isoforms was explored in a liver bank comprising 
samples from fetus, neonates, infants and adults. Isoform enzyme activity was 
characterized by the following measurements: methoxyresorufin demethylation 
(MEROD) for CYP1A2, tolbutamide hydroxylation and for Diazapam N-
demethylation for CYP2C9 and 2C19, dextromethorphan O-demethylation for 
CYP2D6, chlorzoxazone hydroxylation for CYP2E1, testosterone 6beta-hydroxylation 
for CYP3A4, DHEA 16alpha-hydroxylation for CYP3A7. (Data are adapted from ref. 
38-42
). 
 
Figure 2 Developmental changes of renal glomerular filtration rate (GFR) measured 
by mannitol clearance.  (Data adapted from Ref. 
65-66
).  
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Abstract  
Objectives: The maturation of drug metabolizing enzymes is the predominant 
factor that accounts for age associated changes in pediatric pharmacokinetics. Each 
enzyme demonstrates an independent rate and pattern of development. In this study, 
individual CYP Enzyme expression/activity data from hepatic microsomes in specific 
infant age groups were assembled from the literature published from 1970-2012 in 
PubMed, and the characteristic maturation patterns of the most important hepatic CYP 
enzymes including CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4, were quantified as a 
continuous function of age from birth and the age of reaching the adult level. 
Methods: Individual CYP isozyme expression/activity data from hepatic 
microsomes in specific infant age groups were assembled from the literature published 
from 1970-2012 in PubMed. The mean reported values stratified by age groups were 
compiled in the database. For those data reported in graphs instead of tables, the open 
digitizing software (Engauge Digitizer 5.1, http://digitizer.sourceforge.net/) was used 
to extract data. For each study reviewed, the in vitro enzyme expression and/or activity 
data were expressed as a fraction of the mean adult values presented in the same study. 
For each individual enzyme isoform, the mean values for each age group from 
different studies were pooled naively and fitted with several plausible non-linear 
regression functions using NONMEM version VI (Globomax LLC, Hanover, MD, 
USA). A proportional residual error model was used. Structural models were 
compared based on the visual inspection of fits and the Akaike information criteria 
(AIC).  
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Results: The development of CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 was best 
described by the hyperbolic function (Eq. 1) in the age range of observations. The 
parameter MF0 is the enzyme activity at birth (at postnatal age of 0 day) expressed as a 
fraction of the adult activity. MFmax is the maximal mean activity observed in the 
investigated samples (expressed as a fraction of the adult levels). TM50 is the postnatal 
age (day) to reach 50% of the maximal enzyme activity (MFmax) observed in the 
investigated age range. This parameter is indicative of the development rate of each 
individual isoenzyme. 
       Equation 1 
Conclusions: The high MF0 values for CYP2E1 suggested its fetal expression or 
prenatal onset, while the extremely low values of MF0 for CYP2C9 and 1A2 
suggested the two isoenzymes expression were triggered by birth effect. CYP2C9, 
2C19 and 2D6 appeared to mature faster than CYP2E1, 3A4 and CYP1A2, as shown 
by the short half-life values within days compared to those in months. Because the 
maximal ratios of CYP1A2, 2C9, 2C19 and 2D6 are way below 1 due to insufficient 
data, the models could not describe the ontogeny profiles of these four enzymes 
beyond their observed age range. 
Keywords: ontogeny, cytochrome P450, drug metabolism, maturation 
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Introduction 
The human cytochrome P450 enzymes are a haem-containing superfamily that 
consists of a total 270 CYP gene families divided into 18 families and 42 subfamilies 
of enzymes based on converged amino acid sequences [21]. Despite the large number 
of CYP genes and enzymes, only the CYP1, CYP2 and CYP3 families play a major 
role in drug and toxicant metabolism. The remaining CYP families are more 
specialized enzymes involved in the synthesis and degradation of important 
endogenous molecules. CYP3A, CYP1A2 , CYP2C  and CYP2E1  are the most 
abundant CYP enzymes comprising 29%, 13%, 18% and 7% of the total CYP protein 
content in the adult human liver, respectively [25]. When the number of known drug 
substrates is considered, CYP3A is the most important isozyme, metabolizing around 
52% of therapeutic drugs currently on the market, followed by followed by 2D6 
(31%), 2C9 (10%) and CYP1A2 (3%) [10].  
In adults, a wide inter-individual variation in hepatic P450 expression and 
associated metabolic activity has been reported for each isoform. These variations may 
be the result of genetic polymorphisms and/or the induction or inhibition of enzyme 
activity by concomitant medications or exposure to environmental xenobiotics [20,24].  
In the pediatric populations, ontogenesis, or the change of enzyme expression/activity 
as a function of age, is superimposed upon the genetic and or environmental factors, 
and adds further to variability in enzyme activity and unpredictability. The current 
knowledge of the ontogeny of hepatic CYP enzymes during the fetal and infant 
development has been reviewed in-depth [1,3,8,13,22]. It is well recognized that each 
individual CYP enzyme demonstrates an independent rate and pattern of development. 
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However the characteristic maturation patterns of each CYP enzyme have rarely been 
quantified as a continuous function of age from birth and the age of reaching adult 
level. Such enzyme maturation functions, in conjunction with other age-related 
physiological changes in neonates and infants, constitute the non-drug specific inputs 
to physiologically based pharmacokinetic (PBPK) models in pediatric studies. 
Therefore, the aim of this study is to fill in a piece of knowledge gap in the 
developmental pharmacology. In this study, published in vitro enzyme ontogeny data 
on the most important hepatic CYP enzymes: CYP1A, 2B6, 2C, 2D6, 2E1 and 3A, 
were assembled, and the age-related changes of each CYP isoenzyme were fitted with 
mathematical functions.   
 
METHODS 
Compilation of literature data 
Computerized literature search of Medline database were conducted to find 
references to publications describing ontogenesis of hepatic cytochrome P450 
enzymes, using search words such as CYP, human, liver or microsome or hepatocyte, 
fetal or infant or children or age. Additionally, bibliographies from review articles and 
pediatric clearance scaling papers were examined to identify relevant information.  
Several methods are used to investigate the ontogeny of P450 expression in the 
liver. These include: including analyzing the immunoquantifiable enzyme protein 
levels using specific antibodies; measuring mRNA levels using nucleic acid probes; 
and measuring enzyme catalytic activities using probe substrates. Significant 
discrepancies exist between developmental profiles obtained from mRNA compared to 
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protein expression or activity levels. As a result, the enzyme-specific ontogeny is 
based on in vitro literature values of age-dependent enzyme expression and activity 
from hepatic microsome or hepatocyte studies.  
In most studies individual data were not reported. The mean values and variability 
were reported and stratified by age groups. The small amount of available individual 
data from the studies was grouped into different age bands, with variability, to reduce 
residual errors generated from such data. For those data reported in graphs instead of 
tables, an open digitizing software (Engauge Digitizer 5.1, 
http://digitizer.sourceforge.net/) was used to extract data by converting image files 
into numbers. Where developmental changes were reported for age bands, the median 
age was used for modeling purpose. 
The age groups used in this study were: fetus I (<30 weeks of gestation); fetus II ( 
>30weeks of gestation), newborn (<1 day since birth), neonate (1-30 days), infant I 
((1-3 month), infant II (3-12 month), prepuberty children (1 - 10 years old), adolescent 
(10-16 years old) and adults (> 16 years old), which was similar to that used by 
McNamara and Alcorn [1]. All attempts were made to divide in vitro data into 
relatively narrow infant age groups.  
For each study reviewed, the in vitro enzyme expression and activity data were 
expressed as a ratio of adult values presented in the same study so that the absolute 
values/units were not an issue when comparing studies. The original enzyme protein 
expression and activity data compiled from published studies is summarized in Table 
1.    
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Ontogeny modeling approach 
The age-dependency for one individual enzyme isoform can be described by 
either protein or a probe substrate reaction. A naïve data pool approach was used to 
develop ontogeny models for individual isoenzymes: CYP1A2, 2C9, 2C19, 2D6, 2E1 
and CYP3A4. Changes with age were evaluated by applying four different models, 
including hyperbolic, sigmoid (hill-type), logarithmic and mono-exponential functions 
[2], with minimization of residual errors (proportional error model) using nonlinear 
regression with NONMEM (NONMEM VI; Globomax LLC, Hanover, MD, USA). 
The most parsimonious models were identified by visual inspection of fits and using 
the Akaike information criteria (AIC). AIC values were calculated from the following 
equation: AIC = NONMEM objective function value + 2 × number of parameters in 
each structural model.    
 
Development of hepatic CYP enzymes 
Total hepatic cytochrome P450s  
Not sure this is relevant. It is standard and you didn’t personally do it. Among the 
studies indentified, the P450 content in adult liver varied from 0.25 to 0.5 nmol per mg 
microsomal protein with a mean of 0.3 nmol per mg microsomal protein. Fetal liver 
was reported to contain about 0.07 nmol of P450 per mg microsomal protein. From the 
first trimester of gestation to 1 year of age, the total P450 content remained nearly 
constant at 25-50% of the adult values (0.07-0.15 nmol/mg) [33].   
The major enzyme found in fetal livers was CYP3A7 (97 pmol per mg 
microsomal protein)., which accounted for about 32% of total P450 The content of 
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CYP1A1 in fetal liver microsomes was roughly about 6 pmol per mg protein. 
Immunoblotting failed to detect other P450 enzymes such as CYP2A6, 2C, 2D6 and 
2E1 in fetal liver microsomes [26].   
CYP1A1 
CYP1A1 is the most abundant enzyme of CYP1A family in the adult lung tissue 
and is mainly involved in the biotransformation of environmental pollutants and 
carcinogens like benzopyrene in the lung. It is highly inducible by exposure to 
polycyclic aromatic hydrocarbons derived from cigarette smoking. The information 
regarding the ontogenesis of lung CYP1A1 is limited.  
CYP1A1 does not appear to be inducible or expressed constitutively in the adult 
human liver. There is some evidence for the presence of CYP1A1 in human fetal liver. 
CYP1A1 mRNA and catalytic activity were found in human embryonic hepatic tissues 
at very various stages of gestation (50-60 days) [36]. Immunoreactive CYP1A1 
protein has been detected in liver microsomes of human embryos at 11 to13 weeks of 
gestation [26]. Consistent with these reports, functional CYP1A1 may be involved in 
the demethylation of imipramine in human embryonic hepatic tissues at early stages of 
gestation (days 52-59) [5]. However, CYP1A1 mRNA and protein were not detected 
in the fetal liver samples in the middle or late gestation [4,11]. There are no other 
reports on the expression or function of CYP1A1 in fetal liver samples during the 
second and third trimester of gestation. The recent evidence appears to support the 
theory that CYP1A1 is constitutively expressed at very low levels in fetal liver during 
the first trimester, and then declines to nondetectable levels after the early gestation 
period and beyond.  
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CYP1A2 
The reported CYP1A2 content in adult human liver accounts for about 13% of the 
total P450 protein expression and varies from 19 to 67 pmol per mg microsomal 
protein, (Rowland 2003; Zhang 2007). CYP1A2 is mainly involved in the metabolism 
of wide variety drugs and chemicals including theophylline, imipramine, caffeine and 
methoxyresorufin.  
Several studies suggest an absence of quantifiable hepatic CYP1A2 mRNA and 
protein expression and negligible enzyme activity during fetal stages [5,7,11,23,26]. 
Tateishi demonstrated that CYP1A2 liver expression is about 10% of adult levels 
in infants younger than 1 year of age [31]. Two corroborating studies [4,28] provided 
convincing evidence of a maturational delay of CYP1A2 enzymatic activity.  CYP1A2 
protein rose in the group of infants aged 1-3 months and increased progressively to 
reach 50% of the adult value at one year. The ontogenic profile of the demethylation 
of methoxyresorufin (MEROD), a specific marker of CYP1A2, and the CYP1A2 
mediated demethylation of caffeine in liver microsomes paralleled the evolution of the 
protein and confirmed the delayed development of CYP1A2.   
CYP2A6 
CYP2A6 constitutes about 4% of total P450 in the adult human liver and has a 
very limited role in drug metabolism [25]. CYP2A6 does not appear to be expressed in 
fetal liver [26].  
CYP2B6 
CYP2B6 is considered primarily as a hepatic enzyme and accounts for <1% of the 
total hepatic P450 content in adults. However, the relative abundance of CYP2B6 
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exhibited about a 45-fold range from 1.0 to 45 pmol per mg microsomal protein 
[37,38], which is much larger than that of the other cytochrome P450s. This large 
interindividual variability may be partially explained by the induced expression levels 
regulated by both the constitutive androstane (CAR) and pregnane X (PXR) receptors 
and their activating ligands, such as phenytoin and alcohol. CYP2B6 plays a role in 
the metabolism of drugs used in the pediatric population including cyclophosphamide, 
ifosfamide and efavirenz. CYP2B6 is highly polymorphic but null alleles are rare. 
CYP2B6*6 is the most clinically relevant allele associated with reduced protein 
expression and enzyme activity. 
There is limited information about CYP2B6 expression during development. An 
early study found significantly low levels of CYP2B6 in 2 of 10 perinatal/infant 
samples [31]. In a recent study [9], detectable CYP2B6 protein was observed in 64% 
of the fetal samples from 10 weeks to 40 weeks gestation, which suggests it is  
expressed in the fetal stage.  
After parturition, the percentage of samples with detectable CYP2B6 protein 
increased with the postnatal age from 64% in the neonatal samples to 75% in samples 
between 1 to 6 months, and approached 95% in samples from donors 11-17 years of 
age. The same trend was observed for CYP2B6 protein levels in which the median 
amount of CYP2B6 was 0.6 pmol/ mg microsomal protein in fetal/neonatal samples 
(10 weeks gestation to 30 postnatal days), and increased to 1.3 pmol/mg microsomal 
protein in samples after the neonatal period (>30 days to 17 years). The CYP2B6 
protein levels in both groups varied 28-fold and 74-fold, respectively. The detailed 
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developmental course for CYP2B6 expression is demonstrated in Fig. 1c based on 
data from a recent publication [9].  
Although CYP2B6 is highly inducible, induction contributed little or none to the 
differences in CYP2B6 expression observed in Croom et al’s study (9), suggesting that 
a change in constitutive CYP2B6 was involved in the age-related increase in median 
CYP2B6 levels not sure I understand.  
CYP2C  
The four members of the human CYP2C family: CYP2C8, 2C18, 2C9 and 2C19, 
account for 18% of the total cytochrome P450 in the adult liver [25] and metabolize 
about 29% of clinically used drugs [10]. CYP2C9 is the major CYP2C enzyme, 
followed by 2C19, 2C8 and 2C18 [19]. The CYP2C family is highly polymorphic and 
11 genetic polymorphisms of CYP2C9 and 15 genetic polymorphisms of CYP2C19 
have been identified. Allelic variants of CYP2C9 and 2C19 are responsible for poor 
metabolizer phenotypes. 
Very little is known about the ontogeny of CYP2C8 and 2C18. Because many 
CYP2C9 and 2C19 substrates are clinically used in pediatric patients, there is 
considerable interest in the ontogeny of the two enzymes. CYP2C9 substrates include 
warfarin, phenytoin, diclofenac, ibuprofen, tolbutamide and losartan. Most proton 
pump inhibitors, such as omeprazole and lansoprazole are CYP2C19 substrates.  
Total CYP2C proteins and RNAs were found to be very low in the fetal liver 
[23,26] and increased dramatically during the first week after birth. After 1 week, the 
level of CYP2C remained fairly stable up to age 1 year but did not exceed around 30% 
of the adult level. Two enzyme activities that depend on CYP2C - the hydroxylation of 
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tolbutamide and demethylation of diazepam – were measured in these samples and 
were found to parallel the evolution and rise in the level of protein content after birth 
[33]. The bulk of the CYP2C content in this study was represented by 2C8, 2C9, 2C18 
and 2C19.  
A recent study from a different liver bank suggested that the ontogeny of 
CYP2C9 and 2C19 was different [12,16]. In fetal samples, CYP2C9-specific content 
and catalytic activity was about 1% of adult values during the first and second 
trimester, with a substantial increase (about 10% of mature values) during the third 
trimester. CYP2C19-specific protein and catalytic activities were detectable as early as 
8 weeks of gestation, but unlike CYP2C9, CYP2C19 expression was similar 
throughout the prenatal period (10~20% of mature values).  
The CYP2C9 and 2C19 developmental expression patterns were also quite 
different after birth. CYP2C9 levels increased dramatically at birth to reach about 25% 
of the reported adult values in the neonatal samples (first 30 days after birth). After 
this, CYP2C9 expression remained constant with little or no change until age 1 year. 
Between 1 to 2 years of postnatal age, CYP2C9 exhibited (achieved?) mature protein 
levels in most liver samples. In contrast, CYP2C19 expression did not change at birth 
and during the neonatal period,  but increased about 2 fold in infants and children and 
by puberty achieved levels that were nearly 50% of those observed in adults. Adult 
CYP2C19 protein concentration and activity values were observed in samples from 
children after puberty. 
The age-related changes in CYP2C protein and activities were presented in Fig. 
1d and 1e.  
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CYP2D6 
Although it only accounts for <2% of the human cytochrome P450 proteins, 
CYP2D6 is important for the oxidative metabolism of approximately 12% of 
therapeutic drugs. These include β-blockers, tricyclic antidepressants, antitussives 
drugs. Since several of these drugs are widely administered to newborns and neonates, 
the ontogenesis of this enzyme is important and has been investigated.  
CYP2D6 is highly polymorphic with over 80 different alleles identified to date, 
including several complete loss-of function, reduced function, and multiple copy 
number alleles. A wide range of metabolic capacities result from the inheritance of 
different allele combinations. In the adult Caucasian population, approximately 7% of 
individuals are poor metabolizers. Debrisoquine, spartein, bufuralol and 
dextromethorphan are used as probes to evaluate 2D6 activity.  
Low levels of CYP2D6 protein and activity (less than 3~5% of adult levels) were 
observed in the fetal liver samples [30]. In newborns, CYP2D6 protein or activity 
remained similar to third trimester fetal levels, but increased significantly thereafter. 
This postnatal increase was independent of gestational age and appeared to be 
controlled by time after birth. CYP2D6 protein content was about 25% of adult levels 
in neonates aged 1-7 days and steadily increased to 50% in neonates of 7-28 days and 
reached about two-thirds the adult values in infants over 1 month to 5 years (Fig. 1f). 
The rise of the CYP2D6 protein was associated with the rise in dextromethorphan O-
demethylation, a sensitive and selective CYP2D6 probe reaction [34]. No significant 
differences in protein levels of CYP2D6 were found between infants greater than 1 
year of age and less than 1 year of age, which suggests that CYP2D6 development was 
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completed by 1 year of age [31].  Increasing CYP2D6 protein and activity was 
significantly associated with postnatal age for those less than 1 year old, but large 
interindividual variations existed. 
The high degree of CYP2D6 polymorphism known to be present in children was 
likely to contribute to the inter-individual variability in early neonatal life. Almost 8% 
of Causasian children and 2% of Afirican-american children under 18 years of age 
were poor metabolizers. These data were consistent with known adult rates of this 
polymorphism (7~10% of whites and 1~2% African-Americans). Furthermore, 
Stevens et al. found both age and genotype to be significantly associated with 
increasing dextromethorphan O-demethylase activity in the postnatal age groups.     
CYP2E1 
CYP2E1 is an ethanol inducible enzyme and accounts for 7% of the total hepatic 
P450 enzymes. Despite its limited contribution to drug metabolism, CYP2E1 was 
considered to be toxicologically important because of its ability to convert a variety of 
agents, including environmental procarcinogens to reactive intermediates that can lead 
to organ damage and/or tumorigenesis. CYP2E1 has multiple polymorphisms 
identified to date, but only one variant of CYP2E1*1D has been linked to altered 
function.   
The fetal expression of CYP2E1 was undetectable in early/mid gestation 
[11,26,35] but exhibited readily detectable levels in the third trimester [15]. CYP2E1 
protein and its associated activity rose immediately after birth, independently of the 
gestational age, and increased gradually thereafter to reach the adult values by the first 
year of age. The detailed developmental time course of CYP2E1 is summarized in Fig. 
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1g based on two in vitro studies by Vieria et al. (1996) and Johnsrud et al. (2003). 
Generally, Neonates up to 30 days have approximately 25% of adult levels of 
CYP2E1 protein, and this increases with postnatal age. Infants 31 to 90 days of age 
may exhibit up to 50% of adult levels. By 1 year of age, the expression approached 
adult values. CYP2E1*1D variant was identified with a low allelic frequency in a 
large pool of pediatric liver samples but it did not contributed significantly to the 
differences in CYP2E1 expression in different age groups.   
CYP3A 
The CYP3A is the most abundant and clinically important cytochrome P450 
subfamily in the liver. It accounts for 33% of the total hepatic P450s and is responsible 
for the metabolism of almost 50% clinically used drugs. The subfamily consists of 
three major isoforms: CYP3A4, CYP3A5, and CYP3A7. They are structurally closely 
related, the amino acid sequence similarity between CYP3A4 and CYP3A5 is 84%, 
and it’s 88% between CYP3A4 and CYP3A7. However, the isoforms differ in terms 
of their development with age, their tissue distributions and enzymatic properties. 
CYP3A7 is the major isoenzyme expressed in the fetal liver, whereas CYP3A4 is the 
major isoform present in the adult liver. CYP3A5 is detectable in only 25-30% of liver 
microsomes of adults and is the primary CYP3A isoform expressed extrahepatically 
(e.g. kidney, intestine) (Wrighton 1990). Total hepatic CYP3A protein levels remain 
nearly constant from the early stage of gestation to adulthood [17], although the 
expression of specific isoforms change differently. Characterization of the 
developmental expression of CYP3A4, 3A5 and 3A7 has historically been difficult by 
the lack of CYP3A isoform-specific antibodies or marker enzyme activity.  
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CYP3A7 is the dominant cytochrome P450 expressed in the fetal liver, 
accounting for approximately 50% (30-85%) of total P450 in human fetal hepatic 
micrsosomes that contain only traces of CYP3A4 and CYP3A5 [17]. The CYP3A7 
present in fetal liver microsomes was able to carry out the 4-hydroxylation of retinoic 
acid, the N-demethylation of dextromethorphan, codeine and ethylmorphine, as 
efficiently as those of CYP3A4/5 in adult liver microsomes [6,14,18]. CYP3A7 
activity was highly detectable in human fetal microsomes as early as 8 weeks of 
gestation.   
The 16α-hydroxylation of dehydroepiandrosterone (DHEA), a selective marker 
for CYP3A7-dependent activities, was actively catalyzed by the fetal liver microsomes 
(aged 14-40 weeks). It displayed its maximal level during the first week following 
birth before progressively declining to reach a very low level in adult livers (Fig.  1h). 
The CYP3A7 content calculated from the amount of produced metabolite, 16α-
hydroxydehydroepiandrosterone (16α –OH-DHEA), also revealed an age-dependent 
decrease from early gestation to reach the extremely low level after1 year of age 
[12,29].   
In contrast to the sharp decline of CYP3A7 from early gestation to infancy, 
CYP3A4 protein levels (based on measurements of 7β DHEA-hydroxylase activities) 
increased slowly with age [12,29]. The 6 β-hydroxylation of testosterone, a probe 
reaction for CYP3A4 activity, was extremely low in the fetal liver (less than 10% of 
the adult level) and began to rise after birth. The activity reached 30~40% of the adult 
value after 1 month of birth and approached the adult value after 1 year of age [17]. 
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The same developmental tend was also observed based on CYP3A4 catalyzed 
imipramine demethylation and amprenavir oxidation [28,32], as shown in Fig. 1i.   
The microsomal content of CYP3A5 was determined by immunoblotting with a 
selective polycolonal antibody to CYP3A5 isoform. The expression of CYP3A5 was 
independent of age, and remained nearly constant from the early gestational age (12 
week of gestation) to adulthood. However, CYP3A5 protein expression was found 
highly variable and the large interindividual variability was most likely subject to the 
polymorphisms dictated by the frequency of CYP3A5*1/*1 or CYP3A5*3/*3 in certain 
age groups [29].   
Ontogeny functions 
The development of CYP1A2, 2C19, 2D6, 2E1 and 3A4 was best described by 
hyperbolic function in the age range of observations. CYP2C9 development was 
reasonably fitted with hyperbolic function (Eq.1).  
     Eq.1 
 
Table 2 listed ontogeny parameter estimates. The individual fitting plots were 
summarized in Fig. 2. Parameter MF0 was the fraction of enzyme activity at birth (at 
postnatal age of 0 day) against adult level, or the quantities for the postnatal onset of 
enzyme expressions. MFmax was the maximal ratio of enzyme activity (to adult level) 
during the age range of investigated samples. TM50 was the postnatal age (day) to 
reach 50% of the maximal enzyme activity (MFmax) observed in the investigated age 
range, suggesting the development rate of each individual isoenzymes to attain the 
maximum values. Because of the lack of data on when the adult values are reached, 
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the ontogeny models for CYP2C9, 2C19, 2D6 and 1A2 can’t be used to describe the 
enzymatic development beyond the specified age ranges. 
The high MF0 values for CYP2E1 suggested its fetal expression or prenatal onset, 
while the extremely low values of MF0 for CYP2C9 and 1A2 suggested the two 
isoenzymes expression were triggered by birth effect.  
CYP2C9, 2C19 and 2D6 appeared to mature faster than CYP2E1, 3A4 and 
CYP1A2, as shown by the short half-life values within days compared to those in 
months.   
Conclusion 
Overall, qualitative and quantitative analysis of these literature data allows the 
ontogeny of individual CYPs to be categorized into four groups: 
A first group of P450 enzymes (fetal enzymes) includes CYP3A7 and CYP1A1, 
which are expressed at highest level during gestation and are silenced in the postnatal 
period.  
A second group of P450 enzymes (early neonatal enzymes) includes CYP2D6, 
CYP2C9 and CYP2C19, which are not expressed or expressed at low levels in the 
fetus but expression increases substantially within hours or days after birth.  
A third group of P450 enzymes (neonatal enzymes) includes CYP3A4, CYP2E1, 
and CYP1A2, which expression increases slowly within months or years after birth.  
A fourth group includes the enzymes with a relatively constant level of 
expression during hepatic development such as CYP3A5.  
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The ontogeny functions of individual P450s can be further incorporated with 
other age-related physiological parameters to predict drug clearance in children at 
different ages and estimate pediatric doses for drugs metabolized by cytochrome P450 
enzymes. 
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Table 1 Summary of literature data on the ontogeny of hepatic cytochrome P450 enzymes 
Enzyme Assay 
Fetus 
<24 
hours 
1-7 
days 
8-28 
days 
1-3 
months 
3-12 
months 
1-10 
years 
10-18 
years 
Adults Unit Ref. <30 
weeks 
>30 
week
s 
Total 
P450 
protein  0.079 0.085 0.09 0.094 0.134 0.112   0.283 nmol/mg protein [33] 
 protein  307        540 pmol/mg protein [26] 
 protein      390   645  pmol/mg protein [31] 
 protein          344 pmol/mg protein [25] 
              
 protein          446.5 pmol/mg protein [27] 
CYP1A2 
Caffeine N-3-
demethylation 
0.206 0.083 0.057 0.098 1.283 1.018 1.906   3.73 pmol/min/mg protein [4] 
 
Methoxyresorufin 
demethylation 
N.D. N.D. 0.666 1.753 2.502 5.981 13.446 34.793  98.7 nmol/min/mg protein [28] 
 protein N.D. N.D. 0.007 0.021 0.035 0.1190 0.236 0.501  0.964 unit/mg protein [28] 
 
Ethoxyresorufin O-
deethylation 
 7.3        290 pmol/min/mg protein [26] 
 protein  6.3        55 pmol/mg protein [26] 
 protein      3.3   24.9  pmol/mg protein [31] 
 protein          52 pmol/mg protein [37] 
 protein          42 pmol/mg protein [25] 
 protein          42.4 pmol/mg protein [27] 
CYP2A6 
Coumarin 7-
hydroxylation 
 0.26        44 pmol/min/mg protein [26] 
 protein  N.D.        25 pmol/mg protein [26] 
 protein      6.38   6.75  pmol/mg protein [31] 
 protein          14 pmol/mg protein [25] 
 protein          36 pmol/mg protein [37] 
CYP2B6 protein   1.815 1.633 0.935 2.004 2.042 2.166 4.191 4 pmol/mg protein [9] 
 protein      2.65   19.36  pmol/mg protein [31] 
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Enzyme Assay 
Fetus 
<24 
hours 
1-7 
days 
8-28 
days 
1-3 
months 
3-12 
months 
1-10 
years 
10-18 
years 
Adults Unit Ref. <30 
weeks 
>30 
week
s 
 protein          1 pmol/mg protein [25] 
 protein          11 pmol/mg protein [37] 
CYP2C protein  N.D. 0.05 0.251 0.359 0.439 0.366   1.134 AU/mg protein [33] 
 protein  N.D.        83 pmol/mg protein [26] 
 protein          63.6 pmol/mg protein [27] 
 protein          60 pmol/mg protein [25] 
CYP2C8 protein      6.4   22.8  pmol/mg protein [31] 
 protein          24 pmol/mg protein [37] 
CYP2C9 
Tolbutamide 
hydroxylation 
N.D. N.D.  0.37 11.20 8.23 7.3   27.05 nmol/min/mg protein [33] 
 protein N.D. 0.4  11.3  11.3  18  40 pmol/mg protein [12,16] 
 protein      79.8   74.4  pmol/mg protein [31] 
 protein          73 pmol/mg protein [37] 
CYP2C19 
Diazapam N-
demethylation 
 1.5 7.2 21.4 18.6 28.2 46.6   56.6 nmol/min/mg protein [33] 
 protein 1.7000 4.0  4.1   8.9 11.7 14.9 25 pmol/mg protein [12,16] 
 protein          14 pmol/mg protein [37] 
CYP2D6 
Dextromethorpha
n O-demethylation 
  0.046 0.018 0.073 0.058 0.045   0.168 nmol/min/mg protein [30] 
 
Dextromethorpha
n O-demethylation 
0.09 0.39 0.39 0.86   2.52   10.44 nmol/hr/mg protein [34] 
 protein 0.28 0.54 0.1 1.02 2.1  4.1   7.22 AU/mg protein [34] 
 
Bufuralol 1-
hydroxylation 
 N.D.        58 pmol/min/mg protein [26] 
 protein  N.D.        10 pmol/mg protein [26] 
 protein      43.7   53.5  pmol/mg protein [31] 
 protein          5 pmol/mg protein [25] 
 protein          8 pmol/mg protein [37] 
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Enzyme Assay 
Fetus 
<24 
hours 
1-7 
days 
8-28 
days 
1-3 
months 
3-12 
months 
1-10 
years 
10-18 
years 
Adults Unit Ref. <30 
weeks 
>30 
week
s 
CYP2E1 
Chlorzoxazone 6-
hydroxylation 
0.032 N.D. 0.205 0.3 0.358 0.45 0.374 0.786  0.968 nmol/min/mg protein [35] 
 
7-Ethoxycoumarin 
demethylation 
 0.7        37 pmol/min/mg protein [26] 
 protein  N.D.        33 pmol/mg protein [26] 
 protein N.D. N.D. 0.52 0.74 1.24 1.65 1.87 4.31  5.39 pmol/mg protein [35] 
 protein N.D. 5.8  13.4   36.2 43.1  48.7 pmol/mg protein [15] 
 protein      94.3   136.9  pmol/mg protein [31] 
 protein          22 pmol/mg protein [25] 
 protein          61 pmol/mg protein [37] 
CYP3A4 
amprenavir 
oxidation 
  3.4 9 19.1 57.9    126.8 pmol/min/mg protein [32] 
 
imipramine 
demethylation 
0.017 0.014 0.048 0.037 0.085 0.177 0.197 0.461  0.411 nmol/min/mg protein [28] 
 
Testosterone 
(6beta-
hydroxylation) 
0.006 0.004 0.010 0.015 0.033 0.039 0.049 0.121  0.113 nmol/min/mg protein [17] 
 
Testosterone 
(6beta-
hydroxylation) 
 173        2756 pmol/min/mg protein [26] 
 protein 4.5000 10.5  6.5   8.4 12.9  128.9 pmol/mg protein [12,29] 
CYP3A5 protein 5.2 9.7  5.8   3.6   1.2 pmol/mg protein [12,29] 
CYP3A7 
16alpha_dehydroe
piandrosterone 
0.761 0.495 0.987 1.295 0.567 0.362 0.187 N.D.  0.084 nmol/min/mg protein [17] 
 protein 260.5 200.9  100.5   27.3 3.1  10 pmol/mg protein [12,29] 
 protein      538.7   96.90  pmol/mg protein [31] 
CYP3A protein 0.658 0.847 0.720 0.675 0.721 0.741 0.745 0.666  0.809 OD unit/mg protein [17] 
 protein  97        147 pmol/mg protein [26] 
 protein      173.3   239.4  pmol/mg protein [31] 
 protein          96 pmol/mg protein [25] 
  
 
6
5
 
Enzyme Assay 
Fetus 
<24 
hours 
1-7 
days 
8-28 
days 
1-3 
months 
3-12 
months 
1-10 
years 
10-18 
years 
Adults Unit Ref. <30 
weeks 
>30 
week
s 
 protein          155 pmol/mg protein [37] 
 protein          141.82 pmol/mg protein [27] 
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Table 2 Maturation parameter estimates for  individual cytochrome P450 (CYP) isoforms 
Enzyme Age range (day) MF0 MFmax TM50 
CYP1A2 0.5-2273 0.0078 0.539 100 
CYP2C9 0.5-1788 0 0.308 4.8 
CYP2C19 0.5-1788 0.0856 0.538 6.1 
CYP2D6 0.5-355 0.0128 0.461 15.1 
CYP2E1 0.5-2273 0.216 0.869 183 
CYP3A4 0.5-2273 0.0835 0.978 139 
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Figure legends: 
Fig. 1 Developmental changes of total hepatic P450 enzymes and individual 
isoenzymes. a Microsomal content of total P450 was spectrally determined by its 
absorbance at 450 nm after reduction in the presence of carbon monoxide. b The 
microsomal content of CYP1A2 protein was determined by immunoblotting. The 
microsomal activity of CYP1A2 was probed with the demethylation of 
methoxyresorufin (MEROD) or caffeine N-3-demethylation in two different studies. c 
The microsomal content of CYP2B6 protein was determined by immunoblotting. d 
The microsomal content of CYP2C9 protein was determined by immunoblotting. The 
microsomal activity of CYP2C9 was probed with hydroxylation of tolbutamide. e The 
microsomal content of CYP2C19 protein was determined by immunoblotting. The 
microsomal activity of CYP2C19 was probed with N-demethylation of diazepam. f 
The microsomal content of CYP2D6 protein was determined by immunoblotting. The 
microsomal activity of CYP2D6 was probed with O-demethylation of 
dextromethorphan. g The microsomal content of CYP2E1 protein was determined by 
immunoblotting in two different studies. The microsomal activity of CYP2E1 was 
probed with Chlorzoxazone 6-hydroxylation. h The microsomal content of CYP3A7 
protein was determined by immunoblotting. The microsomal activity of CYP3A7 was 
measured by the production of 16α-hydroxydehydroepiandrosterone (16α –OH-
DHEA). i The microsomal content of CYP3A4 activity was measured by three 
different probe reactions: 6 β-hydroxylation of testosterone, imipramine demethylation 
and amprenavir oxidation.  
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Fig. 2 Fitted curves of ontogeny data expressed as a fraction of adult values as a 
function of age for individual cytochrome P450 isoenzymes. The model given in 
equation 1 best described the data as shown. Model parameters for each CYP were 
given in Table 2. 
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Figure 2 
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Abstract  
Objectives: The apparent drug clearance (CL/F) is an important pharmacokinetic 
concept in dosing regimen determination. In pediatrics, drug clearance mechanism 
matures quickly during the postnatal period and leads to rapid changes with age and 
body size. Accurate clearance in pediatrics requires considering the developmental 
physiological and biochemical processes that govern drug elimination. In this study, 
mathematical models describing the maturation of hepatic cytochrome P450 enzyme-
mediated clearance and renal clearance due to glomerular filtration was developed and 
assessed.   
Methods: Using in vivo adult clearance data of 6 probe compounds that are 
primarily eliminated by one process, models for the ontogeny of renal clearance and 
hepatic clearance of CYP3A4 and CYP1A2 was developed from developmental 
physiology and the ontogeny information of specific enzymes, with an open software 
program R. The systemic clearance values of 6 model drugs ((alfentanil, midazolam, 
caffeine, theophylline, gentamycin and vancomycin) were predicted and compared 
with the observations from the literature. The clearance values of 6 drugs were also 
simulated for 500 virtual pediatric subjects from birth to 18 year old using the models.  
Results: The model performs reasonably well for CYP3A4 substrates with 
predictions within 2-fold of the observed values in 82% of alfentanil and 78% of 
midazolam. The predictions of CYP1A2 substrates were 77% of caffeine and 68% of 
theophylline within 2-fold error. For renal clearance due to glomerular filtration, the 
model provides reasonable predictions for gentamicin and vancomycin with 62% and 
 75 
 
66% within the 2-fold error, respectively. Overall, there was strong correlation 
between observed and predicted clearances for the model development (R > 0.85). 
Conclusions: The physiology based scaling model predicts an age-and 
elimination pathway-specific clearance for the ontogeny of renal clearance, and 
metabolic clearance of CYP1A2 and CYP3A4. As developed with an open program R, 
the model provides a valuable source for informed individuals to understand the 
physiological based clearance scaling approach and to use it, without having to use the 
“black-box” kind of simulation software.    
Key words: physiological based modeling, pharmacokinetics, pediatric, 
maturation, clearance  
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Introduction 
From birth onward, neonates, young infants and children develops with important 
age-dependent changes in body composition, in size (weight and height) and in 
maturation of hepatic and renal function (1). These processes all have a major impact 
on the pharmacokinetic (PK) profile of a drug from its absorption and distribution 
properties to metabolism and elimination. As a result, the developmental changes in 
pharmacokinetics require an age-dependent adjustment of dosing regimens in children 
to achieve the target systemic exposure of a drug (2), which is measured by the area-
under-the-plasma-concentration, AUC, or steady state plasma concentration, Css. The 
total exposure of a drug is determined by the efficiency of the elimination processes 
(Eq.1). The apparent drug clearance (CL/F) is the principle PK process determining 
age-dependent differences in drug dosage regimens.  
  
Simple allometric approaches can be applied to the estimation of pediatric clearance 
based on the adult clearance and the power function of body weight (Eq. 2). 
                  
The allometric exponent, b, typically assumes a value of 1 (the per kg model), 3/4 
(the allometric ¾ power model), or 2/3 (the body surface area model) (3). These 
models derived from body size are simple to use in clinical practice. However, they 
are often failed to predict clearance in neonates and young infants because drug 
elimination pathways in the first year of life is not matured even after size adjustment 
(4, 5). Hence, a mechanism-based approach considering the underlying physiological 
and biochemical processes that govern drug elimination has been proposed. The 
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advantage of this approach over other size models is the ability to incorporate the 
ontogeny information of the various anatomical, physiological and biochemical 
processes in drug elimination, although a tremendous input of physiological data is 
required (6). Such a model has been applied to predict clearance of model drugs for 
different pediatric age groups using commercial software such as Simcyp or PKSim 
(7, 8). The objective of this research is to develop a mechanistic model in R to 
estimate “population mean clearance value” in any age of child for selected model 
drugs, on the basis known compound-specific information in literature and published 
studies on the development physiology and enzyme ontogeny in children. For this  
study, the age-dependence of renal clearance via glomerular filtration and hepatic 
clearance via the metabolism of CYP3A4 and CYP1A2 was examined.      
 
Methods 
Selection of model drugs 
Probe substrates for cytochrome P450 phase I metabolism, and renal excretion are 
selected according to the following criteria: 
 The primary pathway of elimination due to one process in healthy adults was 
>80% of an oral dose. 
 Complete absorption (or >90%) from gastrointestinal tract after oral 
administration (po); for compounds showing incomplete absorption, only IV 
data were used.   
 Probe choice is routinely administered for clinical indications in ill neonates, 
infants and children.  
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Model drugs also need to have the established clinical use in adults and pediatric 
patients of all ages, the availability of published data on in vivo clearance for different 
age groups and, adequate published data on their in vivo absorption, distribution, 
metabolism and excretion (ADME) study, namely the contribution of each clearance 
pathway to total clearance. The list of drugs and major clearance mechanisms were 
shown in Table 1. Clearance mechanisms were identified from pharmacology textbook 
(9), a key review article (10), drug label, as well as primary literature for individual 
compounds as shown in the table.  
 
The table provides an estimate of the percentage of parent compound processed 
by the major fate pathways. These compounds are grouped according to the primary 
process of clearance, which include the process of renal, CYP3A4 and CYP1A2 
elimination.  
 
Alfentanil and midazolam are metabolized by CYP3A as the primary route of 
disposition. Alfentanil is extensively oxidized via two major N-dealkylation pathways 
both of which are mediated via CYP3A4 in human liver microsomes. Human in vivo 
studies have shown that more than 80% of an iv dose is recovered in the urine of 
healthy adult volunteers as CYP3A4 metabolites (11). Midazolam metabolism is 
mediated by CYP3A4 to 1-hydroxy and 4-hydroxy derivative corresponds to the main 
metabolite and a minimum of 70% of an oral dose and 77% of an iv dose is recovered 
in the urine within 24 h as this metabolite (11). 
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The predominant biotransformation of theophylline and caffeine are catalyzed by 
CYP1A2. Caffeine is primarily transformed via three major N-demethylation reactions 
(1-, 3- or 7-N-demethylation) producing theobromine, paraxaanthine or theophylline. 
N3-demthylation pathway is catalyzed by CYP1A2 with high affinity and accounts for 
80% of the metabolism of caffeine in humans (12). Theophylline undergoes C-8-
oxidation as the major metabolite route accounting for 49.1% of the total urinary 
excretion, together with oxidative 1- and 3-N-demethylation (17.5% and 24.5%, 
respectively). These reactions are mediated by the CYP1A2 isoform at 
pharmacological concentrations. 
 
Over 90% of gentamicin is predominantly excreted unchanged in urine through 
glomerular filtration (13). Similarly, over 80% of vancomycin is mainly eliminated 
into the urine as unchanged (9).  
 
Compilation of child clearance database 
Then computerized literature searches (PubMed, 1970-present) were conducted to 
find references or publications describing pharmacokinetics of probe substrates in 
children, using words such as, newborn, neonate, infant, children and crossing these 
with terms such as probe drug names, pharmacokinetics. Additionally, a variety of 
pediatric pharmacology reviews (14-19) were examined to identify drugs for which 
PK datasets exists for children. Next, the primary PK studies in published literature 
were evaluated to extract key data including weight, gender, age, drug administration 
route, the number of does (single or multiple doses), the number of subjects, and PK 
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findings such as total clearance or apparent volume of distribution. Through these 
sources, a database (Appendix I) of age-dependent observed clearances for 6 
therapeutic probes were presented, based upon the availability of data for pertinent age 
groups (especially very early life stages), and being able to obtain the primary data 
sources (CL and body weight), having a reasonable number of subjects (at least 3 per 
age group).  
A scan of the database shows that for these model compounds the weight 
normalized clearance in neonates and young infants appears different from the adults. 
Table 2 was extracted from the database to illustrate this pattern and to show how the 
data has been compiled and organized. The table shows the mean and SE of a single 
drug, midazolam, a CYP3A4 substrate. The observed adult clearance value was the 
weighted mean and only the mean adult clearance value was regarded in this study.   
Physiologically based hepatic clearance scaling 
The approach involves an in vitro-in vivo extrapolation of enzyme activity data 
determined in hepatic microsomal preparations from different pediatric age groups as 
well as the adult. Briefly, the adult intrinsic clearance (CLint,adult) is back calculated 
from in vivo hepatic drug clearance (CLH), the free fraction in plasma (fu), the blood to 
plasma drug concentration ratio (CB/CP), and hepatic blood flow (QH), using well-
stirred model (Eq. 3) (20, 21). The generated adult intrinsic clearance value is then 
multiplied by scaling factor that represents the activity of the specific enzyme in 
relation to the age of the child (Eq. 4). This new child-scaled intrinsic clearance 
(CLint,child) is used to generate an age-specific hepatic clearance calculated from the re-
arranged equation (Eq. 5) using age-specific body weight, liver weight, liver blood 
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flow and predicted fraction unbound (scaled from adults based binding protein 
concentrations in blood). Figure 1A describes an overview of the process involved in 
scaling clearances from adult to children. 
Because the elimination of midazolam and alfentanil are primarily due to 
CYP3A4 metabolism, their hepatic clearance is assumed to be close to their plasma 
clearance. The assumption was also applicable to theophylline and caffeine, which 
eliminations are primarily due to CYP1A2 metabolism.  
      
   
           
Physiologically based renal clearance scaling 
For renal eliminated drugs, it is well accepted that the renal clearance is 
proportional to glomerular filtration rate (GFR). For example, surrogate measures of 
GFR are often used to adjust the dosing rate in adults with impaired renal function 
(22). Extension of these concepts to adaption of the adult regimen for the child leads 
to the proposition that the renal clearance in child, expressed as a fraction of the adult 
values, is adjusted proportionally by GFR and free fractions in plasma (Eq. 6) (8). 
Figure 1B describes an overview of the process involved in scaling clearances from 
adult to children. 
               
Where CLGFR is the compound specific renal clearance (mL/min), GFR is 
glomerular filtration rate (mL/min). Gentamicin and vancomycin, are used to evaluate 
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this renal clearance model because they are excreted exclusively via filtration in the 
kidney and CLGFR is close to the plasma clearance.  
Drug and system specific input 
Table 3 listed the drug specific parameters that are obtained from the literature (9, 
11-13, 23), such as CLadult, fu, CB/CP. The adult plasma clearance values are geometric 
means from different PK studies in which drugs were administered by i.v. injections.  
The CL of alfentanil in healthy adult volunteers was obtained from total 241 
healthy adult volunteers in 9 studies after intravenous administration and the 
geometric mean CL was 4.7 ml/min/kg (SD: 2.3) (11). The typical clearance of 
midazolam in adults was estimated from total 198 healthy adult volunteers of 4 
studies, which was was 7.7 ml/min/kg (SD: 3.7)  (11).  
The mean clearance of caffeine in adults after iv administration was estimated 
from 20 subjects of 2 studies and the value was 1.97 mL/min/kg (SD: 0.92) (12). The 
theophylline clearance in healthy adults after iv administration was estimated from 
100 subjects of 12 studies and was 1.0 mL/min/kg (SD: 0.29) (12).  
The total clearance of gentamicin in healthy adults after iv administration is 
estimated from 219 subjects of 6 studies, which was 1.3 mL/min/kg (SD: 0.5) (13). 
The total clearance of vancomycin in healthy adults after iv administration was 
estimated from 121 subjects of 6 studies and the mean value was 1.22 mL/min/kg (SD: 
0.5) (24). 
The physiological parameters such as plasma protein binding level, hepatic blood 
flow, liver volume and enzyme activity are variable with age. The empirical regression 
functions that can generate age appropriate parameters and account for the 
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developmental differences between infants and adults are shown in Table 4. The mean 
physiological inputs were listed in Table 5 for a typical normal male adult from ICRP 
(25).       
 
Age-dependent plasma protein binding 
In general, plasma proteins are lower in the infant than in the adult. Human serum 
albumin (HSA) concentrations are 75 to 80% of adult values at birth and gradually 
increase with age. Alpha1-acid glycoprotein (AAG) is initially half the adult 
concentration in the infant and matures slowly with age. Alcorn et al. (26) proposed a 
model that was best fitted to albumin and alpha1-AG protein concentration as a 
function of age (in days) (Table 4). Changes in the unbound fraction (fu) of drugs in 
the plasma of pediatric subjects (fu,child) were estimated using Equation 7.  
  
Where Pchild is the binding protein concentration in the child and Padult is the 
binding protein concentration in the adult.  
Age-dependent physiological changes 
Body weight, height and body surface area 
Original data on age-related changes in human body weight and height were 
obtained collected from reference in Appendix 2 (27). The mean weight or height 
changes with age in each study were pooled and fitted with the linear regression, 
natural spline function or polynomial functions. Polynomial equations (Table 4) best 
described the age-related changes in weight and height in the age band of day 1 to 18 
year. Body surface area (BSA, cm
2
) at a certain age was estimated using Dubois and 
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Dubois function with age appropriate weight and height (Eq. 8) (28). The fitting plots 
of projected body weight, height and body surface area changes with age were 
displayed in Figure 2.       
   
In child pharmacokinetic study database, age-associated weight or mean weight 
values for individual or subgroups were not always reported in each study. The 
missing weight values were then calculated from the known age using the regression 
function listed in Table 4. The height values were not reported for subjects in most 
studies and therefore calculated values were used.   
Liver weight 
Johnson et al. (27) studied liver volume (LV) in 5036 children and young adults 
(ages from birth to 18 years) and derived a model (Table 4). The value of liver weight 
(LW) can be converted from liver volume by multiplying the density of liver of 1.08 
kg/L. The predicted liver weight was validated against the independent data (Figure 
2).  
 
Cardio output and hepatic blood flow 
Hepatic blood flow (QH) in adult was derived as the sum of the pre-portal organ 
blood flows, which includes the intestines, stomach, pancreas and spleen plus the 
arterial liver blood flow. The adult liver blood flow is scaled to children by 
maintaining the same percentage of cardiac output (CO) to the total sum of arterial 
blood flow and the portal blood flow, representing 25.5-27% for adults in the 
International Commission on Radiological Protection (ICRP) publication (25).  
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Age related change in cardiac output was modeled from Williams et al. (29) for 
their investigated CO in more than 50 studies involving normotensive children, 
adolescents and healthy adults. For children age 0.2 to 4 y, linear regressions of CO on 
age seemed appropriate with r
2
=0.75. For older children (age 5 to 19 y), a nonlinear 
regression using body weight as the predictor is better with r
2
=0.81. The predicted 
cardiac output rate was validated against independent data (30). The hepatic blood 
flow was calculated using Equation 9 by assuming the same portion of blood flow to 
the liver between children and adults. The simulated changes in hepatic blood flow 
with age were presented in Figure 3. 
  
Age-dependent drug metabolism 
In vitro intrinsic clearance (CLint) is determined either by drug depletion or 
metabolite kinetics reported for human liver microsomes. In vitro intrinsic clearance 
values can be scaled to the in vivo equivalent in the whole liver using average liver 
weight (LW; g of liver weight) with a microsomal recovery factor (MPPGL; mg of 
microsomal protein per g liver) (Eq. 10) (31). If the assumptions hold true that the 
enzyme affinity value (Km) value for a particular enzyme isoform remains constant 
with adult values throughout infant development and that infants and adults express 
the same complement of hepatic enzymes, the in vivo intrinsic clearance for the infant 
is calculated using Equation 11. Thus, functional immaturity of the specific CYP 
enzyme and age-dependent liver growth (MPPGL and LW) explained the observed 
differences in CLint between the child and adult.  
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Ontogeny scaling factor (OSF) represents the elimination capacity of a specific 
enzyme in the infant relative to the adult. OSF is a unitless fraction of adult activity 
and is a function of both age and the particular enzyme. Liver scaling factor (LSF) 
represents the product of microsomal protein yield per gram liver and liver mass. 
Therefore, based on the age of child and the specific hepatic metabolic pathway, the 
prediction of intrinsic clearance in child is made based on the scaling factor for liver 
content and ontogenesis of a specific enzyme, in combination with the adult intrinsic 
clearance.   
The human microsomal protein yield for adult livers is 40 mg per g liver, the 
most commonly used value (32) . Age was identified as a statistically significant 
covariate of MPPGL (33). However, the relationship between age and MP observed 
was difficult to be assessed. Consequently, the adult value of 40 mg microsomal 
protein/g of liver was used as the MPPGL recovery factor in all the age groups. The 
liver scaling factor (LSF) was then reduced to the ratio of liver mass between child 
and adult.  
In vitro literature values of age-dependent CYP1A2 and CYP3A4 activity (34, 
35), based on hepatic microsome studies using probe substrates or enzyme protein 
expression, were initially used to describe the enzyme-specific ontogeny. For each 
experimental study, the ratio of child to adult liver enzyme activity was sought so that 
absolute values and units were not an issue when comparing different studies. The 
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functions to describe changes with age summarized in Table 4 and model fitting was 
displayed in Figure 4.  
Age-dependent glomerular filtration rate (GFR) 
The glomerular filtration value, as measured by the mannitol clearance, was 
reported from 63 children between the ages of 2 days and 12 years (36). A model that 
characterized the maturation and growth of glomerular filtration was developed by 
Hayton (Equation 12) (37). The predicted changes of GFR were validated against the 
data (Figure 5). 
  
  
Where GFRchild was the calculated glomerular filtration rate in children (mL/min), 
BW was the body weight in kg, and age in month. 
 
Model compilation and evaluation  
The model was compiled as a function package in R (38). Clearance predictions 
were compared against literature values. To determine the ability of the ontogeny 
models to predict the observed clearances, the correlation between observed and 
predicted clearances for the model compounds was determined, as well as a measure 
of precision (the percentage of prediction values within 2-fold of the observed values). 
The Person’s correlation coefficient between observations and predictions were 
calculated with R.   
Simulation 
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Simulations were performed using 500 virtual pediatric subjects with age ranging 
from birth to 18 years. The cubic spline curves of predicted clearance versus age were 
generated and evaluated against observed in vivo clearance values for probe substrates 
in children.    
Results 
 
Clearance predictions for each of the model compounds were plotted against the 
observations in Figure 6. For CYP3A4 substrates, 82% (89/108) of predicted values 
were within 2-fold of the observed values of alfentanil while 78% (26/38) were within 
2-fold of the observed values of midazolam. For CYP1A2 probe substrate, 77% 
(41/53) of predicted values were within 2-fold of the observed values of caffeine and 
68% (125/183) were within 2-fold of the observed values of theophylline. About 62% 
of predicted values were within 2-fold of the observed values of gentamicin (58/94) 
and 66% for vancomycin (47/77). There were good correlation between the observed 
versus predicted values for each of the model drugs (Table 6). The overall coefficients 
of correlation were 0.883, 0.909 and 0.962, respectively, for CYP1A2, CYP3A4 
metabolized elimination and GFR-mediated renal excretion.  
The log ratio of predicted to observed clearances versus age indicated that model 
performance was both age and process-dependent (Figure 7). For CYP1A2 metabolic 
elimination, the data blow the identity line across the age range indicated the under 
estimation of the model for both CYP1A2 substrates. For CYP3A4 metabolic 
elimination, the under estimation trend for alfentanil was not changed until 2 year old 
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of age. For GFR-mediated renal elimination, the clearances of both gentamicin and 
vancomycin was over estimated in children less than 1 year of old.    
500 virtual pediatric subjects from born to age 18 with simulated boy weight and 
height were created for each of the model compounds. The simulated clearance values 
(normalized by weight) versus age were compared against observed in vivo clearance 
values for probe substrates in children (Figure 8). Most observations were within the 
2-fold confidence interval.   
Removal of premature data points did not improve the overall model 
performance. The prediction precisions of model for preterm neonate subpopulation 
decreased except for CYP1A2 substrates (Table 6).   
Discussion 
Clearance is an important pharmacokinetic concept for scaling dosage, 
understanding the risks of drug-drug interactions and environmental risk assessment in 
children. Body weight normalized clearance values often exceed those of standard 
adult values (39, 40). Clinicians often interpret these findings as if children had greater 
enzyme activities in a unit weight (or volume) of the liver than adults. This might be 
true if hepatic metabolic enzymes mature at birth. However, drug metabolism enzymes 
activity often express low at birth and develop quickly in a few months after birth, and 
by 1 year of old most enzymes reach the adult activity. The physiology-based scaling 
approach not only incorporates the ontogeny of enzymes and other physiological 
functions but also the growth in size. Theoretically, it should be a better model to 
predict the clearance across the age range from neonates to adults, especially in young 
infants than other methods based only on size.  
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Recently, the importance of age to drug clearance has been assessed by some 
pivotal papers from Bjorkman and Alcorn and MacNamara, and commercial software 
PK-sim and Simcyp. In Alcorn and McNamara’s paper, an exponential growth 
function was used to fit the in vitro microsomal ontogeny data from birth to 6 month 
old and clearance was thereafter scaled for term neonates to 6 month of age (18). 
Furthermore, Bjorkman used the same in vitro enzyme ontogeny function to predict 
clearance of alfentanil and midazolam as a function of age from birth to 20 years of 
age (15). Both studies suggested that additional data are required and it is critical to 
know at what age the enzyme activities reach the maturation level. Simcyp 
successfully predicted clearance for 11 drugs in children from birth to adults with 
inter-subject variability incorporated using a population algorithm but the software 
and source data are not open (7). Edginton et al. used both in vitro activity measures 
and in vivo clearance in children from model compounds to gap the age discrepancy 
with PKSim (8), but the model validation is not convincing because the observed in 
vivo data used in model development were also used for validation purpose. Our study 
provided a reliable mechanistic scaling method based on a large scale in vitro enzyme 
ontogeny database and in vivo child-adult clearance database. Furthermore, it is an 
open algorithm with models written as R function package.  
The metabolic clearance of theophylline was under estimated in young infants <1 
year of age, compared to caffeine. It could be the alternative pathways to contribute 
the overall clearance of theophylline or caffeine in neonates. In the adult, CYP1A2 
eliminates >70% of a theophylline dose and the remaining 20% is through renal 
elimination, while 90% of caffeine elimination is mediated by CYP1A2 in adult with 
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1-1.5% excreted renally (14). The lower predicted clearance values may lie in the 
enhanced contribution of renal clearance to theophylline elimination in young infants, 
which was not considered in the model. It had been reported that renal excretion 
accounts for the majority of theophylline elimination in the very young infants, with 
limited N-demethylation by another CYP enzyme (41). In the neonate –infant group, 
the N-3-demethylation of caffeine was reported to correlate with CYP3A4, CYP1A2 
activity, and CYP3A7. Thepresence of CYP3A7 has been detected in neonatal liver 
but absent in adult liver may contribute to its overall under predictions for caffeine 
clearance in this age group. In the current model, alternative elimination pathways are 
not taken into account and caused additional uncertainty in the prediction.  
The interindividual variability of in vitro ontogeny observed in pediatric 
populations is remarkably large and is, in most cases, greater than the variability 
observed in adults (42). If the microsomal experiments could study a wide age range 
with data analyzed in small enough age groups to examine the age-related changes, 
especially for metabolically cleared compounds from birth to 1 year of age, the 
resolution of clearance prediction would be greatly improved. 
There are many other parameters and assumptions in the model that require 
further investigation and validation. For example, it is not sure whether the amount of 
MPPGL is similar in pediatric and adult livers. Studies have found that microsomal 
recovery did not change with time. However, a recent study suggest a decrease in 
MPPGL with an average of 40 mg·g
-1
 for a 30 year old individual and 31 mg·g
-1
 for a 
60 year old individual (33). This study has been extended using a set of pediatric 
samples and suggested an increase in microsomal protein content from birth to the 
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maximum observed at approximately 30 years of age. The average neonate exhibits a 
microsomal protein content of only 26 mg per gram liver.  
Many other enzymes exist that are responsible for drug elimination. These 
include many more CYPs (e.g. CYP2D6, CYP2E1 and CYP2C) and non-cytochrome 
P450 enzymes such as esterase, alcohol dehydrogenases. Other phase II processes 
include glutathione and glycine conjugation, UGT and sulfotransferase are not 
discussed in this study. Liver and renal transporters are not discussed either due to the 
lack of ontogeny data. Further experimentations to increase the ontogeny database will 
be needed to increase the scope of PB-based clearance scaling.       
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Table 1 Elimination pathways for probe substrates in healthy adult volunteers.  
Drug  Route % Excreted Metabolic Pathways Reference 
Alfentanil IV >90% metabolized CYP3A4 (>80%) Dorne, 2003 
Midazolam IV >90% metabolized CYP3A4 (>80%) Dorne, 2003 
Caffeine IV >90% metabolized CYP1A2 (>90%) Dorne, 2001 
Theophylline IV >90% metabolized CYP1A2 (>90%) Dorne, 2001 
Gentamicin IV 82±10% in urine Glomerular filtration Dorne, 2004 
Vancomycin IV >90% in urine Glomerular filtration Bertz,  1997 
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Table 2 A section of children's clearance database. 
pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 midazolam Rey 1991 6 39 2.5 y 15.2 13.30 4.3 
CYP3A4 midazolam Muchohi 2008 13 39 27 m 10.4 14.40 2.7 
CYP3A4 midazolam Mathews 1988 6 39 5.2 y 18.4 11.98 6.68 
CYP3A4 midazolam Mathews 1988 6 39 4.7 y 15.9 8.53 1.8 
CYP3A4 midazolam Mathews 1988 5 39 1.3 y 8.8 9.07 3.35 
CYP3A4 midazolam Reed 2001 5 39 0.96 y 7.88 11.33 6.33 
CYP3A4 midazolam Reed 2001 13 39 5.2 y 19.2 10.00 3.83 
CYP3A4 midazolam Reed 2001 2 39 15.4 y 62 9.33 3.83 
CYP3A4 midazolam Payne 1989 8 39 5.52 m 17.3 9.11 1.21 
CYP3A4 midazolam Mulla 2003 20 39.5 3.8 d 3.4 1.40 0.15 
CYP3A4 midazolam Lee 1999 60 27 4.5 d 0.965 9.11 1.21 
CYP3A4 midazolam Jacqz-Aigrain 1992 15 32.8 3 d 1.9 1.70 1.8 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 35 3.5 d 2.3 1.39 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 34 3.5 d 2.7 1.41 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 35 3.5 d 2.7 1.07 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 37 3.5 d 2.7 0.74 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 39 3.5 d 3 0.87 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 41 3.5 d 3.2 2.69 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 38 3.5 d 3.2 1.16 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 37 3.5 d 3.6 3.50 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 38 3.5 d 3.8 3.76 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 40 3.5 d 3.9 3.72 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 10 37 3.5 d 3.1 2.03 1.24 
CYP3A4 midazolam de Wildt 2001 24 29 5.5 d 1.02 1.80 n.a. 
CYP3A4 midazolam Salonen 1987 3 39 7.33 y 32.8 6.67 5.5 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 midazolam Salonen 1987 6 39 6.72 y 28 4.83 2.33 
CYP3A4 midazolam Salonen 1987 6 39 6.07 y 21.6 8.67 2.5 
CYP3A4 midazolam Salonen 1987 6 39 6.11 y 22.3 11.20 1.33 
CYP3A4 midazolam Harte 1997 10 27.9 3 d 1.045 1.66 1.37 
CYP3A4 midazolam Tolia 1991 20 39 13.5 y 43.75 10.00 5 
CYP3A4 midazolam Clausen 1988 8 39 27 y 68 6.28 1.03 
CYP3A4 midazolam Pentikainen 1989 7 39 44.3 y 79.4 5.63 0.43 
CYP3A4 midazolam Mandema 1992 8 39 22 y 69 7.50 1.26 
CYP3A4 midazolam Greenblatt 1984 10 39 27.9 y 68.8 7.75 0.41 
CYP3A4 midazolam Greenblatt 1984 10 39 28.5 y 58.5 9.39 0.86 
CYP3A4 midazolam Dorne 2003 198 39 18 y 70 7 1.5 
n=number of subjects in study; GA= gestational age; PNA=postnatal age; BW=body weight; CL=plasma clearance   
wk=week; y=year; m=month; d=day; n.a.=not available        
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Table 3 Summary of drug specific input in adults 
Drug 
Major binding plasma 
protein 
Unbound fraction in 
plasma, fu 
Blood:plasma partition 
ratio (Cb/Cp) 
Adult drug CL 
(mL/min/kg) 
Midazolam Albumin 0.02 0.55 7.7 
Alfentanil alpha1-acid glycoprotein 0.1 0.63 4.7 
Theophylline Albumin 0.44 0.82 1.0 
Caffeine Albumin 0.68 1 1.97 
Gentamicin Albumin 0.95 n.a. 1.3 
Vancomycin Albumin 0.7 n.a. 1.22 
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Table 4 A summary of regression equations to calculate age-specific physiology and biochemical input.  
Parameter Unit 
Age range of 
observation 
Regression equations Source 
Body weight (BW)* kg day 1 – 18 yr  derived 
Height (HT)* cm day 1 – 18 yr 
 
 
derived 
Body surface area 
(BSA) 
cm2   Lack, 1997 
Glomerular filtration 
rate (GFR)** 
mL/min day 2– 12 yr  
Hayton, 
2000 
Binding protein 
concentration ratio 
(HSA) 
-   
McNamara, 
2002 
Binding protein 
concentration ratio 
(AAG) 
 
- 
 
 
 
 
McNamara, 
2002 
Liver volume (LV) L day 0– 18 yr  
Johnson, 
2005 
 
 
Cardiovascular output 
(CO) 
L/min 
0.2 yr- 4 yr  
Williams, 
1994 
5 yr- 19 yr  
Williams, 
1994 
CYP3A4 ontogeny 
scaling factor (OSF) 
-   derived 
CYP1A2 ontogeny 
scaling factor (OSF) 
-   derived 
*a is the postnatal age in year 
**BW is body weight in kg, and age is the postnatal age in month 
“-“ is the unitless fraction 
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Table 5 Physiological input used in the physiologically based clearance scaling model for a normal 
male adult 
Parameter Unit Input 
Body weight (BW) kg 70 
Body surface area (BSA) m
2
 1.9 
Cardiac output (CO) mL/min 6500 
Liver blood flow rate (% cardiac output) fraction 25.5% 
Liver blood flow (QH) mL/min 1657.5 
Microsomal protein per gram liver (MPPGL) mg/gram 45 
Liver weight (LW) gram 1800 
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Table 6 Percentage of clearance predictions within 2-fold of the observed values 
(success rate) and correlation coefficient between observations and predictions 
Drug 
Success Rate 
Pearson's Correlation 
Coefficient 
overall preterm neonate overall preterm neonate 
Alfentanil 82% (89/108) 67% (4/6) 0.85 0.73 
Midazolam 78% (26/38) 43% (3/7) 0.96 -0.183 
Caffeine 77% (41/53) 78% (28/36) 0.93 0.99 
Theophylline 68% (125/183) 71% (34/48) 0.88 0.948 
Gentamicin 62% (58/94) 40% (21/53) 0.96 0.757 
Vancomycin 66% (47/71) 40% (16/40) 0.97 0.933 
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Figure legends: 
Figure 1 A summary of workflow for scaling clearance from adults to children for 
enzymatic hepatic clearance pathway (A) and renal elimination pathway (B).  
Figure 2 Fitting plots for mean changes in body weight, height, body surface area 
and liver weight with age. 
Figure 3 Age-related changes in cardiac output (A) and hepatic blood flow (B).   
Figure 4 Fitted curves of ontogeny data expressed as a fraction of adult values as 
a function of age for CYP3A4 and CYP1A2.  
Figure 5 Simulated changes in glomerular filtration rate (GFR) with age 
Figure 6 Predicted clearance values versus observed in vivo clearance values 
(solid lines represent unity and dashed lines represent 2-fold error). 
Figure 7 Ratio (log) of predicted to observed clearance versus age. Solid lines 
represent lines of unity, and the area between the dashed lines represents an area 
within 2-fold error. 
Figure 8 Predicted and observed age-dependence of clearance for (a) caffeine; (b) 
theophylline; (c) alfentanil; (d) midazolam; (e) gentamicin; (f) vancomycin.   
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Figure 1
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Figure 2 
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Figure 3 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.1 1 10 100 1000
E
n
z
y
m
e
 a
c
ti
v
it
y
 a
s
 a
 f
ra
c
ti
o
n
 o
f 
a
d
u
lt
 
Age (day) 
yobs
ypred
a 
CYP1A2 
0
0.2
0.4
0.6
0.8
1
1.2
0.1 10 1000
E
n
z
y
m
e
 a
c
ti
v
it
y
 a
s
 a
 f
ra
c
ti
o
n
 o
f 
a
d
u
lt
 
Age (day) 
CYP3A4 
yobs
ypred
b 
 111 
 
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
Age (month)
G
lo
m
e
ru
la
r 
fi
lt
ra
ti
o
n
 r
a
te
 (
m
L
/m
in
)
0 20 40 60 80 100 120 140
2
0
4
0
6
0
8
0
Rubin data
Hayton function
  
 
1
1
2
 
Figure 6 
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Figure 7 
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Abstract  
Objectives: In pediatric population, developmental changes in clearance can be 
predicted by age and size (body weight or body surface area). Clearance in children is 
commonly scaled from adults by size using either the per kilogram, body surface area 
or allometric ¾ power models. But the size model does not account for the maturation 
process of the elimination organ and therefore may not be appropriate to scale 
clearance to the very young children. The physiology-based approach accounts for 
maturity but requires detailed knowledge regarding developmental changes. In this 
study, these approaches were compared and appropriate use of these approaches is 
dependent on the age and clearance pathway.  
Methods: A child PK database was developed and the dataset of experimentally 
obtained clearance values was used. Predicted clearance values in children were 
calculated based on the adult clearance, age and weight data using the four 
approaches. The ratio of predicted to observed values was graphed separately for 
probe substrates of three predominant clearance pathways: CYP1A2, CYP3A4 and 
renal clearance due to glomerular filtration.  
Results: Allometric ¾ power model and body surface area approach systemically over 
estimated clearance in children below 1 year of old for all the compounds. Physiology-
based approach accurately predicted clearance at all ages for compounds eliminated 
via CYP3A4. The clearance of CYP1A2 substrates within the first year were under 
predicted by the physiology-based approach but over estimated by the other 
approaches. In the case of renal clearance in children below 1 year of age, the per 
kilogram and physiology-based model performed similar with a few overestimations.  
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Conclusions: Physiology-based clearance scaling accurately predicted clearance in 
children from birth to 18 years. The allometric ¾ power and body surface area model 
are only accurate when the major clearance pathway is fully matured.    
Key words: clearance, allometric scaling, physiology-based modeling, pediatrics 
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Introduction 
The pharmacokinetic (PK) profiles of many drugs are different between children 
and adults (1, 2). A principle PK parameter determining age-dependent difference is 
drug clearance. Predicting clearance in children based on the clearance in adult has 
been the topic of recent publications (3, 4). Empirical approaches that focus on linear 
body weight (W) or body surface area (BSA) have traditionally been used. The third 
size model, using an exponent of weight (W
3/4
), is termed the “allometric ¾ power 
model.” This allometric equation can be predictive of clearance in children following a 
specific age (5). It becomes invalid when used below a certain age where the activities 
of the eliminating processes are not fully developed. This is because the size based 
approaches do not account for the maturation of hepatic and renal elimination (6).   
A physiology-based approach has been proposed to incorporate maturation of CL 
for several major enzymatic (e.g. CYP3A4) and physiological (e.g. glomerular 
filtration) elimination processes (7-9). The drawback of this approach is that detailed 
knowledge about eliminating processes in adults is required and further, the ontogeny 
of these clearance processes is needed.  
The objective of this study is to retrospectively compare the accuracy of the three 
size scaling approaches (linear weight, body surface area and 3/4 power model) with 
the physiology-based approach using compounds eliminated via various enzymatic or 
physiological processes (glomerular filtration). Furthermore, by using probe substrates 
for which the clearance process in adults is dominated (>85%) by one clearance 
pathway after intravenous administration, the pathway-specific age range of 
appropriate use for each scaling approach will be determined.  
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Methods 
 Selection of test drugs 
The drugs to evaluate the prediction approaches were selected according to the 
following criteria: (1) The drug is routinely administered for clinical indications in ill 
neonates, infants and children. (2) The drug mainly binds to human serum albumin 
(HAS) or alpha-glycol acid protein (AGP). (3) The drug is primarily eliminated due to 
one process in healthy adults, which accounts >85% of an oral or i.v. dose. (4) The 
selected elimination processes include hepatic CYP3A4, CYP1A2 metabolism and 
renal excretion. (5) The drug shows complete absorption (or >90%) from 
gastrointestinal tract after oral administration (po). If the compound is showing 
incomplete absorption, only IV data are used. (6) Mean or individual clearance data 
for children and adults have been published.  
Using the criteria described in (1)-(6), alfentanil and midazolam, theophylline and 
caffeine, gentamicin and vancomycin were selected separately, for CYP3A4 
metabolism, for CYP1A2 metabolism and for renal clearance due to glomerular 
filtration.  
Children PK database and age-dependent clearance dataset  
The pharmacokinetics of the 6 drugs has been evaluated in children to determine 
the appropriate dose levels for specific ages. A search of the literature produced a 
limited number of studies that reported systemic clearance values of these probe 
substrates in neonate, infants and children. Appendix I provided the observed systemic 
clearances of selected probe substrates for children aged from premature to 18 years.    
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The observed adult clearance value was the weighted mean as preciously 
presented (10-12) and, for vancomycin, was the adult clearance value taken from 
Guay et al. (13).   
Physiology-based clearance scaling  
This approach used information regarding clearance pathways in adults and 
scaled them to children. Briefly, the adult intrinsic clearance (CLint,adult) is back 
calculated from in vivo hepatic drug clearance (CLH), the free fraction in plasma (fu), 
the blood to plasma drug concentration ratio (CB/CP), and hepatic blood flow (QH), 
using the well-stirred model (Eq. 1). The generated adult intrinsic clearance value is 
then multiplied by scaling factors (ontogeny scaling factor [OSF] and liver scaling 
factor [LSF]) that represents the activity of the specific enzyme in relation to the age 
of the child (Eq. 2). This new child-scaled intrinsic clearance (CLint,child) is used to 
generate an age-specific hepatic clearance calculated from the re-arranged equation 
(Eq. 3) using age-specific body weight, liver weight, liver blood flow and predicted 
fraction unbound (scaled from adults based binding protein concentrations in blood).  
      
   
           
Ontogeny scaling factor (OSF) represents the elimination capacity of a specific 
enzyme in the infant relative to the adult; and it is a unitless fraction of adult activity 
with a function of both age and the particular enzyme. Liver scaling factor (LSF) 
represents the product of microsomal protein yield per gram liver and liver mass.  
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The clearance of a drug due to glomerular filtration rate in children was 
calculated by the following equation (Eq. 4): 
               
The age dependence of renal clearance in children by the process of glomerular 
filtration was studied by Hayton (14).  
The age-dependent regression functions including ontogeny functions, the 
maturation function of glomerular filtration rate (GFR) were shown in Table 1.   
Allometric scaling  
In a child, the clearance can be predicted based on the known adult clearance and 
the power function of body weight (Eq. 4):  
  
b=1, per kg model; 
b= ¾, power model 
Where BWchild is the body weight of the child and BWadult is the body weight of 
the adult. The mean body weight of the pediatric population from each study was used 
in the equation. If this value was not reported in the study, the mean weight value was 
taken for the mean age (or middle of the age range in some cases) using information 
from the International Commission on Radiological Protection (ICRP) (15). The adult 
body weight was set at 70 kg for all calculations. Both CLchild and CLadult are given in 
flow units, e.g. mL/min). 
The clearance in a child can also be calculated based on the adult clearance and 
body surface area (Eq. 5): 
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Where BSAchild is the body surface area of the child and BSAadult is the body 
surface area of the adult. The surface area is calculated from body weight and height 
using Dubios and Dubios equation (16). The mean body weight of the pediatric 
population from each study was used in the equation. If this value was not reported in 
the study, the mean weight value was taken for the mean age (or middle of the age 
range in some cases) using information from the International Commission on 
Radiological Protection (ICRP). Most pediatric studies did not report height. The 
height was taken for the mean age (or middle of the age range in some cases) using 
information from the International Commission on Radiological Protection 
(ICRP).The adult body surface area was set at 1.9 m
2
 for all calculations.  
Approach comparison 
The ratios of experimentally predicted to observed clearance values (ml/min), 
using allometric, linear, and body surface area and physiology-based scaling, were 
calculated and plotted against age for each compound. The compounds were grouped 
according to their primary elimination pathways, which included the process of 
CYP3A4, CYP1A2 and renal clearance. The line of unity at which the predicted 
values was equal to the observed values was plotted together with the lines for where 
predicted clearance was either twice or half the observed clearance. To determine the 
age range for which allometric scaling was appropriate, and to determine if this age 
range depended on the process of clearance, the ratios of experimentally predicted to 
observed clearances (ml/min), using different scaling approaches, were calculated and 
plotted against age for each compound that is cleared via one prominent pathway.   
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To determine the ability of the defined scaling models to predict observed 
clearances, the correlation between observed and predicted clearances for each scaling 
method was determined, as well as bias and success rate (the percentage of prediction 
values within 2-fold of the observed values) . The bias (accuracy) was assessed by the 
geometric mean of the ratio of predicted and observed values or the average fold error 
(afe) metric using Equation 6: 
  
(under-predition=1/afe)  
Where N represents the number of data inputs used for the calculation. “i” in the 
above equations represents the age points in the age brackets defined in this study (17, 
18).  
This approach prohibited poor overpredictions from being canceled out by 
equally poor underpredictions; underpredictions were of equal value to 
overpredictions (19). It also did not allow any single outlier prediction from biasing 
conclusions concerning a particular prediction method. A method that predicted all 
actual values perfectly would have a value of 1; one that made predictions that were 
on average 2-fold off (100% above or 50% below) would have a value of 2 and so 
forth.  
In addition, the success rate was measured for each predefined age group. These 
groups were preterm neonates (0-30 days, <30 weeks of gestation), full term neonate 
(1-30 days, >=30 week of gestation), infant (1-12 months), children 1 - 5 years, 
children 6-11 years, adolescents 12-17 years, and adults (> =18 years old). The 
success rate was simply the number of successful predictions using the method 
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divided by the total number of predictions made using the method and then multiplied 
by 100.  A prediction within an average -fold error of 2 was considered successful 
(19). 
Results 
For each elimination process, there were 2 drugs that had adequate clinical data 
available for assessment of prediction.   
Figure 1-3 summarized the prediction results of four scaling approaches, divided 
by the process responsible (>85%) for clearance. For each process; CYP3A4 (Figure 
1), CYP1A2 (Figure 2) and renal (Figure 3), the clearance was scaled via physiology-
based approach (A), per kg body weight (B), ¾ allometric power model (C) and body 
surface area (D).  
For hepatic enzymes CYP3A4, physiology-based approach (method A) predicted 
clearance values within 2-fold of observed values for 53 of 66 data inputs (Table 2). 
The accuracy of prediction using method A was better than the other methods as 
indicated by the lowest geometric mean accuracy value of 2.9 (Table 2).  
For hepatic enzymes CYP1A2, the most predictive method was physiology-based 
method, in which 98 of 143 predictions were within 2-fold of observed, and the 
geometric mean prediction accuracy was 3.8. Allometric approaches (power model 
and BSA model) resulted in significant overestimations of CL for the low observed 
values and thereby decreased the predictive power of these approaches. Thus, only 
~40% of the predictions were within 2-fold of observations for methods C and D, and 
geometric mean prediction accuracy was poor, with values of 36.4 and 56.8.   
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Overall for hepatic eliminated drugs, predicted clearance values resembled the 
observed values more closely in the physiology-based model. The accuracy of the 
predictions in each model was confirmed by comparing the average fold error (AFE) 
(Table 2). The prediction accuracy decreased in the order physiology-based > linear 
weight > ¾ allometric power > BSA.  
In the case of renal elimination, the simplest approach, per kg body weight 
(method B) predicted clearance within 2-fold of observed for 101 of 135 data inputs 
(75%; Table 2). The geometric mean prediction accuracy value for method B was 3.0. 
Physiology-based approach (method A) predicted clearance within 2-fold of observed 
for 81 of 135 data inputs (60% of success). The geometric mean accuracy value for 
method A was 4.3. The BSA scaling (method D) was the poorest predictor in that only 
35 of 135 predictions were within 2-fold of observed. Corresponding rankings of 
decreasing prediction accuracy were linear weight > physiology-based > ¾ allometric 
power > BSA.  
 
Figure 4-6 summarized the ratios of predicted to observed clearance values across 
the entire age range, for the renal eliminated and hepatic metabolized (CYP3A4 and 
1A2) drugs. The consistency of data above the lines of 2-fold error appeared to be age 
and model-dependent.  
For hepatic enzyme metabolized drugs, there was evidence that physiology-based 
approach was more appropriate at young age. Physiology-based method produced 
little bias around the line of unity in neonates less than 1 month (Figure 5 and 6). The 
3/4 allometric power equation and BSA scaling consistently overestimated clearance 
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in neonates. Success rates for the prediction methods by age groups were shown in 
Figure 7. For children greater than 1 year of age, the four prediction approaches were 
comparable, with values ranging from 68% to 100% success.  
In the case of renal elimination, the linear scaling method appeared to be the most 
predictive method in neonates and infants under 1 year old, in which more than 75% 
of predictions were within 2 fold of observed values (Figure 7). The 3/4 allometric 
power equation and BSA scaling resulted in poor predictions in neonates and infants 
under 1 year old. The two methods consistently overestimated clearance for children 
under 1 year old.  
Overall, the linear scaling, 3/4 allometric power equation and BSA scaling 
systemically overestimated clearance in the young age groups as evidenced by the lack 
of data points at or below the 2-fold error line. The physiology-based approach 
appeared not to be biased towards either over or under estimation of clearance in 
neonates or infants under 1 year age. When assessed by success rate criteria, 
physiology-based approach appeared to be the most appropriate prediction method 
across the age range of neonate to 18 years.    
Discussion 
The body surface area model is widely used to scale drug dose in children out of 
infancy (16, 20). This model requires the measure of height, as well as body weight, to 
estimate size and is usually determined from nomograms, which introduce the 
possibility of additional errors. Surface area can also be estimated from an allometric 
model with a power parameter of 2/3. However, the surface area model does not fit 
known observations. The body area of animals rises more slowly than the surface law 
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would suggest, as larger animals are stockier. The surface law refers to an animal’s 
skin. The mass of empirical evidence suggests that the appropriate scaling factor is 
significantly different from 0.67 and is actually 0.75 (21).   
Thus, the ¾ power model has been proposed to scale metabolic and physiological 
processes among species based on body size, including scaling to human. This easy-
to-use equation presents significant improvement over the surface area model. When 
the clearance is calculated using the allometric surface area and compared to the ¾ 
power model, the two models are in close agreement for the human weight range 
above 20 kg (5). The surface area model overpredicts clearance by more than 10% at 
body weights below 20 kg (an approximate age of 5 year old child’s mean weight) (6).  
In our study, both body surface area model and ¾ power model tend to 
systemically overestimate clearance in neonates and infants under 1 year old of age, 
when the maturity of the process responsible for clearance are immature. This was 
likely because allometric scaling approaches account for development of body size but 
not for the ontogeny of hepatic and renal elimination pathways. Thereby, the 
allometric equations (BSA model and ¾ power model) are not appropriate for 
predicting clearance in neonates and young infants, where the intrinsic activity of the 
elimination process has not yet reached the activity in adults. This was also 
demonstrated in a study that compared the allometric approach to the physiology-
based approach for the two CYP3A4 substrates, midazolam and alfentanil (22). 
The per kilogram model is the poorest model but remains the most commonly 
used in human. In humans, an under-prediction of clearance of more than 10% occurs 
at bodyweights less than 47 kg compared to allometric ¾ power model. This error 
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increases as size decreases and approaches 50% for a newborn of 3.4 kg. However, 
this gross under prediction is not seen for neonates and young infants in our study 
because of immaturity of enzyme systems or glomerular filtration (the right answer for 
the wrong reason!). In our study, the per kilogram model resulted in better predictions 
for neonates and young infants compared to allometric approaches. In the case of renal 
elimination, the per kg model appeared to yield more accurate predictions than 
physiology-based approach for neonates. The significant underpredictions of CL using 
per kilogram model was seen in children greater than 1 year old for renal eliminated or 
CYP3A4 metabolized drugs, where CYP3A4 enzyme activity and glomerular 
filtration has reached adult activity (23).  
As demonstrated in Figure 7, the physiology-based approach, which explicitly 
accounts for the age dependence of hepatic enzyme activity or renal function, appears 
to be the most predictive in neonates and young infants under 1 year old. For children 
greater than 5 years, allometric methods (BSA model and ¾ power model) were 
appropriate for clearance prediction.  
Premature neonates represent a specific subgroup, with variable clearances 
dependent on weight, gestational and postnatal age. For example, the fluconazole 
population clearance in young infants required adjustment for gestational age at birth 
(BGA) and postnatal age (PNA) (24, 25). The disposition of theophylline in premature 
neonate presented a much longer elimination half-life (26). Furthermore, premature 
neonates generally receive drugs for varying clinical conditions, which may alter the 
neonate’s physiology and the drug’s pharmacokinetics.  Despite the enzyme ontogeny 
divergence in premature neonates was not considered in the physiology –based 
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approach due to the lack of data in enzyme ontogeny and physiological factors, our 
study demonstrated that physiology-based approach more accurately predicted 
premature clearances in comparison to allometric approach and per kilogram model.  
For hepatic enzymes, different isoenzymes develop at different rate. For example, 
the development of CYP1A2 is relatively slow compared with CYP3A4. It takes about 
3 years for CYP1A2 to reach 80% of its activity in adults. At 1 year after birth, only 
50% of the adult CYP1A2 activity was reached, while about 80% of the adult CYP3A 
activity was reached at the same time. The physiology-based approach under predicted 
the theophylline clearance in the children greater than 1 year old. The possible 
explanation could be the enhanced renal excretion to theophylline elimination before 
CYP1A2 develops. The contribution of CYP1A2 to theophylline clearance increases 
with CYP1A2 development. This phenomenon is not unusual that the neonate use 
alternative routes for certain drugs’ elimination in very early life before its primary 
pathway develops. The sulphate pathway is the dominant metabolite route for 
paracetamol (acetaminophen) in infancy before glucuronidation enzyme pathways 
mature.  
Clearance scaling is the first step towards the scaling of pharmacokinetics profiles 
from adults to children. The next step is to determine the age-dependent of distribution 
of volumes using allometric scaling or physiological approach. Together, the two 
parameters or a physiology-based pharmacokinetic (PBPK) simulation can lead to a 
reasonable prediction of a child’s PK profile and decisions regarding dosing and 
potential therapeutic or adverse effect events can be informed.   
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Table 1 A summary of regression equations to calculate age-specific physiology and biochemical input.  
Parameter Unit 
Age range of 
observation 
Regression equations Source 
Body weight (BW)* kg day 1 – 18 yr  derived 
Height (HT)* cm day 1 – 18 yr 
 
 
derived 
Body surface area 
(BSA) 
cm2   Lack, 1997 
Glomerular filtration 
rate (GFR)** 
mL/min day 2– 12 yr  
Hayton, 
2000 
Binding protein 
concentration ratio 
(HSA) 
-   
McNamara, 
2002 
Binding protein 
concentration ratio 
(AAG) 
 
- 
 
 
 
 
McNamara, 
2002 
Liver volume (LV) L day 0– 18 yr  
Johnson, 
2005 
 
 
Cardiovascular output 
(CO) 
L/min 
0.2 yr- 4 yr  
Williams, 
1994 
5 yr- 19 yr  
Williams, 
1994 
CYP3A4 ontogeny 
scaling factor (OSF) 
-   derived 
CYP1A2 ontogeny 
scaling factor (OSF) 
-   derived 
*a is the postnatal age in year 
**BW is body weight in kg, and age is the postnatal age in month 
“-“ is the unitless fraction 
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Table 2 Prediction accuracy and successful rate using four prediction methods, divided by the 
process responsible for clearance. 
Elimination 
process 
Physiology-
based 
Linear body 
weight 
3/4 allometric 
weight 
Body surface 
area 
Accuracy     
CYP3A4 (n=66) 2.9 5.3 4.7 5.1 
CYP1A2 (n=143) 3.8 10.7 36.4 56.8 
Renal (n=135) 4.3 3.0 12.1 22.6 
Success rate     
CYP3A4 (n=66) 81% 52% 71% 69% 
CYP1A2 (n=143) 69% 51% 40% 41% 
Renal (n=135) 60% 75% 28% 26% 
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Figure legends 
Figure 1 Predicted versus observed clearance values (mL/min) for alfentanil and 
midazolam eliminated via hepatic CYP3A4 metabolism, using the physiology-based 
(A), per kg body weight (B), allometric body weight (C) and BSA (D) scaling 
approach. Solid lines represent lines of unity, and the area between the dashed lines 
represents an area within 2-fold error. 
Figure 2 Predicted versus observed clearance values (mL/min) for caffeine and 
theophylline eliminated via hepatic CYP1A2 metabolism, using the physiology-based 
(A), per kg body weight (B), allometric body weight (C) and BSA (D) scaling 
approach. Solid lines represent lines of unity, and the area between the dashed lines 
represents an area within 2-fold error. 
Figure 3 Predicted versus observed clearance values (mL/min) for gentamicin and 
vancomycin eliminated via renal clearance due to glomerular filtration, using the 
physiology-based (A), per kg body weight (B), allometric body weight (C) and BSA 
(D) scaling approach. Solid lines represent lines of unity, and the area between the 
dashed lines represents an area within 2-fold error. 
Figure 4 The ratio (natural log) of predicted to observed clearance plotted against 
age for alfentanil and midazolam eliminated via hepatic CYP3A4 metabolism, using 
the physiology-based (A), per kg body weight (B), allometric body weight (C) and 
BSA (D) scaling approach. The solid line of 0 represents the line of identity and the 
dashed lines indicates where predicted clearance was twice or half the observed 
clearance.   
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Figure 5 The logarithmic ratio (base 10) of predicted to observed clearance 
plotted against age for caffeine and theophylline eliminated via hepatic CYP1A2 
metabolism, using the physiology-based (A), per kg body weight (B), allometric body 
weight (C) and BSA (D) scaling approach. The solid line of 0 represents the line of 
identity and the dashed lines indicates where predicted clearance was twice or half the 
observed clearance.   
Figure 6 The logarithmic ratio (base 10) of predicted to observed clearance 
plotted against age for gentamicin and vancomycin eliminated via renal clearance due 
to glomerular filtration, using the physiology-based (A), per kg body weight (B), 
allometric body weight (C) and BSA (D) scaling approach. The solid lines of 0 
represent the lines of identity and the dashed lines indicate where predicted clearance 
was twice or half the observed clearance.   
Figure 7 Histogram of success rates for clearance predictions obtained by four 
prediction methods for different age groups of preterm neonates, term neonates, 
infants 1-12 months, children 1-5 year, children 6-12 year, adolescents 12-17 year or 
adults >=18 year. Graph A is for CYP3A4 metabolized drugs. Graph B is for CYP1A2 
metabolized drugs. Graph C is for renally eliminated drugs. 
 
 
 
 
 
 
 139 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
Observed Clearance (mL/min)
P
re
d
ic
te
d
 C
le
a
ra
n
c
e
 (
m
L
/m
in
)
1 5 10 50 100 500
5
1
0
5
0
A)  Physiology-based model
alfentanil
midazolam
Observed Clearance (mL/min)
P
re
d
ic
te
d
 C
le
a
ra
n
c
e
 (
m
L
/m
in
)
1 5 10 50 100 500
5
1
0
5
0
1
0
0
5
0
0
B)  Linear scaling model
alfentanil
midazolam
Observed Clearance (mL/min)
P
re
d
ic
te
d
 C
le
a
ra
n
c
e
 (
m
L
/m
in
)
1 5 10 50 100 500
1
0
0
2
0
0
4
0
0
C)  Allometric scaling model
alfentanil
midazolam
Observed Clearance (mL/min)
P
re
d
ic
te
d
 C
le
a
ra
n
c
e
 (
m
L
/m
in
)
1 5 10 50 100 500
1
0
0
2
0
0
4
0
0
D)  BSA scaling model
alfentanil
midazolam
 140 
 
Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Abstract 
Population modeling in pediatric studies often uses size and age as covariates. 
Covariate-parameter correlations are described in an exponential relationship used by 
allometric scaling. However, extrapolations based on such parameter estimates have 
limited value due to differences in the impact of developmental growth across 
populations. The quantitative models used to describe the clearance maturation 
processes across the age range may be required to improve extrapolation and 
predictive performance.  
Previously published pharmacokinetic parameters from probe substrates of 
hepatic and renal elimination processes are used to develop clearance pathway-
specific maturation models. The postconceptional age (PCA) or postnatal age (PNA) 
are used as covariates in the modeling practice. Clearance maturation of hepatic and 
renal elimination, after standardized to a 70-kg adult, is appropriately described with a 
Hill function of postconceptional age. The two renal excreted compounds due to 
glomerular filtration, gentamicin and vancomycin, presented similar maturation half-
life and Hill coefficient, suggesting a system-specific maturation of glomerular 
filtration function. Similar results were attained with CYP1A2 metabolic probes 
theophylline and caffeine. Midazolam and alfentanil demonstrated different clearance 
maturation profiles suggesting a complexity in CYP3A4 metabolism maturation. 
Key words: maturation, clearance, CYP, renal GFR 
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Introduction 
The pharmacokinetic (PK) profiles of many drugs are different between children 
and adults (1). Organ maturation, body composition and ontogeny of drug elimination 
pathways have marked effects on pharmacokinetics parameters in the first few years 
of life (2). A principle PK parameter determining age-dependent difference is drug 
clearance. Understanding the relationship between clearance (CL) and age is useful for 
drug dosing.  
Predicting pediatric CL of drugs used in children has been approached by using 
physiologically based pharmacokinetic (PBPK) simulation (3). PBPK simulation 
required detailed physiology data such as in vivo portions of individual elimination 
pathways contributed to CL, enzyme ontogeny information derived from 
measurements of enzyme expression and activity in postmortem livers, continuous 
input on age-related protein binding and physiological data into the simulation 
algorithm (4, 5). The predicted results have been used to assist with first-time dosing 
in children when the complete pharmacokinetic data is absent in children (6).  
An alternative approach is to use the population PK modeling to obtain age-
associated parameters when sparse drug concentration data in children is available. 
Population modeling in pediatric pharmacokinetic (PK) studies often uses size and age 
as covariates (7). Covariate-parameter correlations are often described in simple 
exponential relationships used by allometric scaling (8). However, extrapolations 
based on such parameter estimates have limited value due to the differences in the 
impact of developmental growth across populations and the complexity of maturation 
process (9). The quantitative models that can describe the clearance maturation 
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processes across the age range, therefore, are required to improve extrapolation and 
predictive performance. In this study, we collected individual or summary clearance 
estimates from pediatric PK studies in literature for drugs that are primarily eliminated 
through CYP3A4 or CYP1A2 metabolism, and renal glomerular filtration. These 
studies are often restricted to a particular age band e.g. neonates, infants or 
prepubescent children. It is possible to use CL estimates from these different age 
groups to develop models for the maturation of renal clearance, and hepatic clearance 
for CYP3A4 or CYP1A2.   
 
Methods 
Age-dependent clearance dataset 
A MEDLINE (Medical Literature Analysis and Retrieval System Online) search 
(1976-present) were, using words such as, neonate, infant, children and crossing these 
with terms such as drug names, pharmacokinetics. Additionally, a variety of pediatric 
pharmacology reviews were examined. A database of age-dependent observed 
clearances (Appendix I), in neonates, young infants, children, adolescents and adults 
was created for therapeutic probes, which alfentanil and midazolam representing 
CYP3A4 metabolism, caffeine and theophylline representing CYP1A2 metabolism, 
gentamicin and vancomycin representing renal glomerular filtration. Table 1 was 
extracted from the database to illustrate this pattern and to show how the data has been 
compiled and organized.     
Modeling CL maturation 
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Two developmental models were evaluated for all the six model compounds, 
using nonlinear regression with NONMEM VI (Globomax LLC, Hanover, MD, USA). 
The first model used post conception age (PCA) as a covariate (Eq. 1). In the second 
model, postnatal age (PNA) was used (Eq. 2).  
             
 
 
  
Where CLi is the observed clearance (mL/min) in the individual person of weight 
Wi, CLstd (mL/min/70 kg) is the typical clearance value in a standard size adult of 70 
k; θ is the Hill coefficient of for clearance; βcl is a parameter estimating the fraction 
above or below clearance; Tcl is a parameter describing the maturation half-lives of 
the age-related changes of CL. These functions have been used in the developmental 
population PK analysis in pediatric clinical studies. Ages (PNA and PCA) were 
expressed in months by suing the following rules: 1 year = 12 months and 1 month = 
30 days = 4.33 weeks, so that 1 year = 52 weeks. For all subjects older than age 3 
months, PCA was calculated as PNA + 9.   
The allometric weight scaling describes the size effect and the Hill function in 
this equation is used as an empirical capacity limited model for the maturation of renal 
function. The descriptive performance was compared between two models for all the 
model compounds, using visual inspection of fits and precision of estimates. The 
predictive performance was assessed by comparing with the observed data set to the 5 
and 95
th
 percentiles of model-simulated data (n=500). 
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Results 
Gentamicin and vancomycin clearance maturation was better described using 
PCA model (model 1) than PNA model (model 2). The descriptive performance of 
model 1 was slightly better than the model 2, based on evaluation of objective 
function, basic goodness-of-fit plots (Figure 1) and the precision of parameter 
estimates (Table 2). The predictive performance of the model using model 1 was 
similar compared to the model 2 considering the visual predictive check results 
(Figure 2).   
The adult clearance (Clstd) of gentamicin and vancomycin predicted by the two 
models were similar. In the first model, the time to reach 50% of adult clearance was 
11 months (PCA) for gentamicin and 9.5 month (PCA) for vancomycin. By 1 year of 
age, both vancomycin and gentamicin clearance had attained more than 90% of the 
adult level.  
 
PCA sigmoidal hyperbolic model produced better prediction for alfentanil and 
midazolam clearance data than PNA model, according to performance plots (Figure 3 
and 4) and the precision of parameter estimates (Table 3). Alfentanil CL at birth in a 
term neonate was 50% of an adult value and reached the adult level by 6 month. 
Midazolam clearance at birth in a term neonate was 27% of an adult, reaching 64% by 
1 year of old and 80% of the matured CL at the age of 2 years. The half-life estimates 
(Tcl) indicated that alfentanil metabolism developed faster than midazolam 
metabolism.      
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The maturation of caffeine and theophylline clearance was better fitted using 
PCA sigmoidal model (Figure 5 and 6). The parameters were presented in Table 4. In 
a term neonate, the caffeine clearance at birth was 8% of an adult, increasing to 50% 
at 6 months and by 2 years of age achieved 95% of matured activity. Theophylline 
clearance developed in a similar rate, reaching 50% level at 4 month of age and 95% 
by 2 years. 
 
Discussion  
Growth and development are two major aspects of children not seen in adults. 
These aspects can be investigated by using size and age as covariates in pediatric PK 
studies. To identify other covariates other than body size, it is highly desirable to 
standardize the PK parameters to an appropriate body size measure. Once size is 
standardized, age or other physiological factors (i.e. GFR) can be investigated within a 
given dataset describing time-concentration profiles in a population. The quantitative 
models used to describe the maturation process vary depending on the range of the 
ages under investigation. An exponential age model is commonly used for population 
samples limited to a defined age band (10). However, this exponential function 
extrapolates badly beyond the range of observations. An exponential asymptotic 
model, similar to models based on first-order processes in biology systems, has been 
previously used to investigate acetaminophen age-related clearance maturation (11). A 
sigmoidal Emax model has been used to investigate acyclovir clearance in neonates 
and infants (12).  
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In our study, we found a sigmoidal Emax model is a robust model to describe 
clearance maturation during infancy for different hepatic and renal elimination 
processes.    
A plot of maturation profiles of 6 drugs representing 3 clearance processes is 
displayed in Figure 7. The alfentanil clearance matures more rapid, compared to the 
clearance of renal probes and theophylline and caffeine. The results are consistent with 
the in vitro development profiles of CYP3A4 and CYP1A2 enzymatic activities (13-
15).  
While maturation profile of midazolam in our study is similar to that predicted by 
Anderson et al. (16), it is slower than that observed in other drugs cleared by CYP3A4 
such as alfentanil in our study and sildenafil. It has been proposed that CYP3A4 
possesses three substrate binding types (Kenworthy, et al., 1999). Three CYP3A4 
marker activities: testosterone 6β-hydroxylase, midazolam 1’-hydroxylase, and 
felodipine dehydrogenase activities represent the aforementioned three substrate 
binding types. Metabolism of midazolam by 1- and 4-hydroxylation closely resembles 
the probe reactions utilizing testosterone and diazepam. The predominating metabolic 
reactions for alfentanil are piperidine and amid N-dealkylation, catalyzed by CYP3A4, 
CYP3A5 and CYP3A7. CYP3A5 and CYP3A7 may have contributed significantly to 
the high clearance of alfentanil in neonates at birth and the rapid maturation profile, in 
comparison with midazolam. The substrate dependency of CYP3A4 maturation 
produced multiple developmental models for CYP3A4 metabolized drugs.  
Renal function is influenced by physiological changes such as glomerular 
filtration rate (GFR) and tubular secretion/absorption processes at different stages of 
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development. Gentamicin and vancomycin are almost entirely eliminated by kidney 
(17). In our study, the maturation rates of clearance values of the two antibiotics are 
similar. Thus, a developmental model for GFR was developed from clearance values 
of the two drugs throughout pediatric life until adults. It is anticipated that the renal 
developmental model can be used to describe maturation in clearance of other renally 
excreted antibiotics in neonates and infants. This approach will make a distinction 
between system specific and drug specific information in pediatric pharmacokinetics 
models (Eq. 3).   
            
 
 
Using this approach, CLp is considered a drug specific property and is therefore 
estimated for each of drugs separately. The remaining information in this equation is 
considered system specific information that can be applied for all renally excreted 
drugs.  
A critical question in the prediction of CL using physiology-based approach is 
when the activity of the applicable CYP isoforms attains adult levels. There are not 
enough data on this from in vitro studies. CYP1A2 develops relatively slow compared 
with CYP2C, 2D6 and 3A. For example, about half of the adult CYP1A2 activity was 
reached at 1-year after birth, while about 80% the adult CYP3A activity was reached 
at 1 year of age (18). The in vitro ontogeny data is still not available for CYP1A2 of 
which activity reaches 80% of the adult level (15). Thus, using bottom-up PBPK 
approach to predict clearance in children from birth to 18 year old led to under 
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predictions in older children. In addition, in vitro assays used to determine the age-
dependency of enzyme activity can vary greatly depending on the substrates, which 
led to variable clearance predictions. Therefore, maturation rates based on in vivo PK 
studies can be used as a systemic maturation function to obtain more accurate 
predictions in children.   
It may not always be necessary to repeat PK studies in children when similar 
examples exist in literature. Literature information from similar compounds that 
mechanistically describes the maturation process and changes in organ functions can 
be used in the covariate analysis for the other compounds, or be extrapolated to a new 
population. The current study, using published CL values, demonstrated that size and 
age models yields a reasonable maturation profiles for CYP1A2 probe drugs and renal 
elimination. The maturation models and rate estimates can be generalized as systemic 
information in the PK simulations of drugs that are cleared via the two pathways.  
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Table 1 A section of children's clearance database. 
pathway drug study subjn GA GA.unit PNA PNA.unit BW BW.unit CL CL.sd CL.unit 
renal gentamicin Rodvold 1993 19 28.7 wk 34.6 d 1.78 kg 1.04 0.37 mL/min/kg 
renal gentamicin Kildoo 1984 15 28.4 wk 1 d 1 kg 0.38 0.14 mL/min/kg 
renal gentamicin Kildoo 1984 15 28.4 wk 18.7 d 0.887 kg 0.44 0.18 mL/min/kg 
renal gentamicin Kildoo 1984 6 28.4 wk 67.5 d 1.49 kg 1.21 0.39 mL/min/kg 
renal gentamicin Rocha 2000 68 29.5 wk 3 d 1.2 kg 1.05 0.29 mL/min/kg 
renal gentamicin Rocha 2000 34 27 wk 3 d 0.875 kg 0.48 0.13 mL/min/kg 
renal gentamicin Rocha 2000 34 32 wk 3 d 1.5 kg 0.57 0.16 mL/min/kg 
renal gentamicin Ho 1995 14 39 wk 3.8 y 15.3 kg 2.91 0.60 mL/min/kg 
renal gentamicin Ho 1995 7 39 wk 2.9 y 13.1 kg 2.64 0.54 mL/min/kg 
renal gentamicin Ho 1995 13 39 wk 2.9 y 14.9 kg 2.74 0.63 mL/min/kg 
renal gentamicin Ho 1995 8 39 wk 9.8 y 33.9 kg 2.29 0.72 mL/min/kg 
renal gentamicin Ho 1995 6 39 wk 10.4 y 31.5 kg 2.11 0.53 mL/min/kg 
renal gentamicin Ho 1995 5 39 wk 9 y 27 kg 2.34 0.46 mL/min/kg 
renal gentamicin Ho 1995 7 39 wk 14 y 55.1 kg 2.23 0.77 mL/min/kg 
renal gentamicin Ho 1995 10 39 wk 15.6 y 50.2 kg 1.82 0.37 mL/min/kg 
renal gentamicin Ho 1995 7 39 wk 15.3 y 53.5 kg 2.35 0.57 mL/min/kg 
renal gentamicin Pons 1988 15 37 wk 1 d 3.2 kg 1.03 0.37 mL/min/kg 
renal gentamicin Pons 1988 8 37 wk 5 d 3.3 kg 1.79 0.64 mL/min/kg 
renal gentamicin Pons 1988 1 37 wk 18 d 3.7 kg 1.67 0.00 mL/min/kg 
renal gentamicin Pons 1988 27 39 wk 1 d 3.2 kg 1.40 0.46 mL/min/kg 
renal gentamicin Pons 1988 16 39 wk 5 d 3.3 kg 1.78 0.39 mL/min/kg 
renal gentamicin Pons 1988 14 39 wk 18 d 3.7 kg 1.97 0.44 mL/min/kg 
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Table 2 Gentamicin and vancomycin maturation clearance parameter estimates. 
Parameter Gentamicin Vancomycin 
Model 1         
OBJ 582 423 
CLstd (ml/min/70 
kg) 109 (6.5%) 103 (8.4%) 
Tcl (PCA, month) 10.9 (5.9%) 9.93 (5.0%) 
θ 3.13 (11.6%) 4.31 (10.5%) 
RUV 0.137 (13.0%) 0.08 (16.6%) 
Model 2 
    OBJ 629 478 
CLstd (ml/min/70 
kg) 101 (7.4%) 98.8 (8.5%) 
Tcl (PNA, month) 1.54 (93.5%) 4.79 (19.8%) 
βcl -0.78 (4.5%) -0.76 (4.1%) 
RUV 0.209 (12.7%) 0.159 (15.2%) 
OBJ: objective function value; RUV: residual unexplained variability 
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Table 3 Alfentanil and midazolam maturation clearance parameter estimates. 
Parameter Alfentanil Midazolam 
Model 1         
OBJ 861 278 
CLstd (ml/min/70 
kg) 371 (5.4%) 452 (6%) 
Tcl (PCA, month) 10.4 (7.6%) 15.4 (16.4%) 
θ 4.7 (20.2%) 1.82 (25.8%) 
RUV 0.165 (16.2%) 0.318 (24.6%) 
Model 2 
    OBJ 873 246 
CLstd (ml/min/70 
kg) 371 (5.2%) 459 (5.1%) 
Tcl (PNA, month) 3.5 (25.9%) 0.14 (26.3%) 
βcl -0.69 (12.6%) -1.51 (13.3%) 
RUV 0.18 (16.5%) 0.154 (24.7%) 
OBJ: objective function value; RUV: residual unexplained variability 
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Table 4 Caffeine and theophylline maturation clearance parameter estimates. 
Parameter Caffeine Theophylline 
Model 1         
OBJ 690 656 
CLstd (ml/min/70 
kg) 138 (22.8%) 59.7 (4%) 
Tcl (PCA, month) 15.2 (.1%) 12.8 (5.3%) 
θ 4.81 (8.9%) 2.88 (8.7%) 
RUV 0.289 (28.4%) 0.196 (11.7%) 
Model 2 
    OBJ 760 631 
CLstd (ml/min/70 
kg) 65.6 (23.5%) 60 (3.7%) 
Tcl (PNA, month) 0.532 (40.9%) 5.27 (1.3%) 
βcl -1.21 (8.4%) -0.892 (2%) 
RUV 0.706 (28.8%) 0.176 (3%) 
OBJ: objective function value; RUV: residual unexplained variability 
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Figure legends 
Figure 1 Observed vs predicted clearance for gentamicin and vancomycin using 
sigmoidal hyperbolic model (model 1: A and C) and first order model ( model 2: B 
and D)  
Figure 2 Observed and Predicted clearance values vs age (PCA and PNA) for 
gentamicin and vancomycin.  
Figure 3 Observed vs predicted clearance for alfentanil and midazolam using 
sigmoidal hyperbolic model (model 1: A and C) and first order model (model 2: B and 
D)  
Figure 4 Observed and Predicted clearance values vs age (PCA and PNA) for 
alfentanil and midazolam.  
Figure 5 Observed vs predicted clearance for caffeine and theophylline using 
sigmoidal hyperbolic model (model 1: A and C) and first order model (model 2: B and 
D)  
Figure 6 Observed and Predicted clearance values vs age (PCA and PNA) for caffeine 
and theophylline.  
Figure 7 Predicted clearance maturation profiles using model 1 for renal GFR excreted 
drugs-gentamicin and vancomycin (A), CYP3A4 substrates-midazolam and alfentanil 
(B) and CYP1A2 substrates-caffeine and theophylline (C). 
 
 
 
 
 163 
 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
Predicted clearance (mL/min)
O
b
s
e
rv
e
d
 c
le
a
ra
n
c
e
 (
m
L
/m
in
)
0.5 1.0 5.0 10.0 50.0
0
.5
5
.0
5
0
.0
A. Gentamicin (Model 1)
Predicted clearance (mL/min)
O
b
s
e
rv
e
d
 c
le
a
ra
n
c
e
 (
m
L
/m
in
)
1 5 10 50 100
0
.5
5
.0
5
0
.0
B. Gentamicin (Model 2)
Predicted clearance (mL/min)
O
b
s
e
rv
e
d
 c
le
a
ra
n
c
e
 (
m
L
/m
in
)
0.5 1.0 5.0 50.0
0
.5
5
.0
5
0
.0
C. Vancomycin (Model 1)
Predicted clearance (mL/min)
O
b
s
e
rv
e
d
 c
le
a
ra
n
c
e
 (
m
L
/m
in
)
0.5 1.0 5.0 10.0 50.0
0
.5
5
.0
5
0
.0
D. Vancomycin (Model 2)
 164 
 
Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
Postconception Age (month)
C
le
a
ra
n
c
e
 (
m
L
/m
in
/7
0
k
g
)
5 10 50 100 500
0
1
0
0
2
0
0
3
0
0
4
0
0
A. Caffeine (model 1)
—
—
term
preterm
median
90% CI
Postnatal Age (month)
C
le
a
ra
n
c
e
 (
m
L
/m
in
/7
0
k
g
)
0.1 1.0 10.0 100.0
0
1
0
0
2
0
0
3
0
0
4
0
0
B. Caffeine (model 2)
—
—
term
preterm
median
90% CI
Postconception Age (month)
C
le
a
ra
n
c
e
 (
m
L
/m
in
/7
0
k
g
)
5 10 50 100 500
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
C. Theophylline (model 1)
—
—
term
preterm
median
90% CI
Postnatal Age (month)
C
le
a
ra
n
c
e
 (
m
L
/m
in
/7
0
k
g
)
0.1 1.0 10.0 100.0 1000.0
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
D. Theophylline (model 2)
 169 
 
Figure 7 
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APPENDICES 
Appendix I Age-dependent clearance dataset 
pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 alfentanil Wiest 1991(1) 1 35 1 d 2 2.65 0 
CYP3A4 alfentanil Wiest 1991 1 41 1 d 3.6 3.47 0 
CYP3A4 alfentanil Wiest 1991 1 41 1 d 5.1 1.66 0 
CYP3A4 alfentanil Wiest 1991 1 35 1 d 2.79 5.00 0 
CYP3A4 alfentanil Wiest 1991 1 37 1 d 3.47 2.56 0 
CYP3A4 alfentanil Wiest 1991 1 39 1 d 5.44 8.40 0 
CYP3A4 alfentanil Wiest 1991 1 37 4 d 2.58 1.14 0 
CYP3A4 alfentanil Wiest 1991 1 36 2 d 2.8 2.31 0 
CYP3A4 alfentanil Wiest 1991 1 41 2 d 3.48 2.00 0 
CYP3A4 alfentanil Wiest 1991 9 38 1.33 d 3.47 3.24 2.23 
CYP3A4 alfentanil Marlow 1990 22 30 2 d 1.34 0.87 0.00 
CYP3A4 alfentanil Killian 1990 5 29.3 3 d 1.33 1.35 0.69 
CYP3A4 alfentanil Davis 1989 6 29.5 2 d 1.33 2.20 2.4 
CYP3A4 alfentanil Davis 1989 9 39 5 y 20 5.60 2.4 
CYP3A4 alfentanil Killian 1990 5 36.8 3 d 2.97 1.70 0.47 
CYP3A4 alfentanil Bower 1982 7 39 41.3 y 70.3 3.40 8.01 
CYP3A4 alfentanil Bower 1982 5 39 39 y 71.6 4.80 13.95 
CYP3A4 alfentanil Bovill 1982 6 39 42 y 73 7.58 2.39 
CYP3A4 alfentanil Bovill 1982 5 39 45 y 69 5.06 1.06 
CYP3A4 alfentanil Scott 1987 17 39 51.5 y 70 2.80 1.6 
CYP3A4 alfentanil Persson 1988 10 39 45.5 y 68.2 3.70 1.6 
CYP3A4 alfentanil Van den Nieuwenhuyzen 1993 20 39 33.8 y 75.8 5.25 1.3 
CYP3A4 alfentanil Hudson 1991 11 39 64.3 y 74.7 6.40 1.9 
CYP3A4 alfentanil den Hollander 1988 6 39 0.56 y 6.45 8.21 2.13 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 alfentanil den Hollander 1988 5 39 5.1 y 18.6 6.30 0.8 
CYP3A4 alfentanil den Hollander 1988 1 39 0.3 y 4.3 5.07 0 
CYP3A4 alfentanil den Hollander 1988 1 39 0.4 y 6.3 7.64 0 
CYP3A4 alfentanil den Hollander 1988 1 39 0.5 y 5.8 7.80 0 
CYP3A4 alfentanil den Hollander 1988 1 39 0.5 y 5.3 9.16 0 
CYP3A4 alfentanil den Hollander 1988 1 39 0.75 y 8.7 8.02 0 
CYP3A4 alfentanil den Hollander 1988 1 39 0.9 y 8.3 11.58 0 
CYP3A4 alfentanil den Hollander 1988 1 39 2.5 y 13.7 7.22 0 
CYP3A4 alfentanil den Hollander 1988 1 39 5 y 20.9 6.53 0 
CYP3A4 alfentanil den Hollander 1988 1 39 5 y 13 6.05 0 
CYP3A4 alfentanil den Hollander 1988 1 39 5 y 14.3 6.78 0 
CYP3A4 alfentanil den Hollander 1988 1 39 8 y 31 5.04 0 
CYP3A4 alfentanil Goresky 1987 6 39 0.6 y 7.57 8.36 1.6 
CYP3A4 alfentanil Goresky 1987 12 39 5.98 y 22.67 7.70 1.83 
CYP3A4 alfentanil Goresky 1987 1 39 0.9 y 10.9 9.02 0 
CYP3A4 alfentanil Goresky 1987 1 39 0.2 y 5.2 10.84 0 
CYP3A4 alfentanil Goresky 1987 1 39 0.3 y 4.8 8.69 0 
CYP3A4 alfentanil Goresky 1987 1 39 0.9 y 9.2 6.18 0 
CYP3A4 alfentanil Goresky 1987 1 39 0.3 y 6.8 7.22 0 
CYP3A4 alfentanil Goresky 1987 1 39 4.6 y 17.7 7.42 0 
CYP3A4 alfentanil Goresky 1987 1 39 1 y 8.5 8.21 0 
CYP3A4 alfentanil Goresky 1987 1 39 1.6 y 11.2 8.77 0 
CYP3A4 alfentanil Goresky 1987 1 39 4.7 y 21.3 7.17 0 
CYP3A4 alfentanil Goresky 1987 1 39 3.7 y 14.5 5.35 0 
CYP3A4 alfentanil Goresky 1987 1 39 4 y 15 10.33 0 
CYP3A4 alfentanil Goresky 1987 1 39 8.5 y 30 9.10 0 
CYP3A4 alfentanil Goresky 1987 1 39 14.7 y 43 5.49 0 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 alfentanil Goresky 1987 1 39 1.3 y 11.2 8.16 0 
CYP3A4 alfentanil Goresky 1987 1 39 1.5 y 12.4 10.90 0 
CYP3A4 alfentanil Goresky 1987 1 39 1.1 y 8.1 6.78 0 
CYP3A4 alfentanil Goresky 1987 1 39 14 y 51 7.42 0 
CYP3A4 alfentanil Goresky 1987 1 39 12 y 36.6 5.56 0 
CYP3A4 alfentanil Meistelman 1987 8 39 5.4 y 21 4.70 1.74 
CYP3A4 alfentanil Meistelman 1987 5 39 31.3 y 58 4.20 1.75 
CYP3A4 alfentanil Meistelman 1987 1 39 4.7 y 20 3.40 0 
CYP3A4 alfentanil Meistelman 1987 1 39 5.5 y 22 5.90 0 
CYP3A4 alfentanil Meistelman 1987 1 39 7.7 y 23 8.30 0 
CYP3A4 alfentanil Meistelman 1987 1 39 4.5 y 14 4.60 0 
CYP3A4 alfentanil Meistelman 1987 1 39 4.8 y 24 3.70 0 
CYP3A4 alfentanil Meistelman 1987 1 39 4.5 y 20 4.80 0 
CYP3A4 alfentanil Meistelman 1987 1 39 6.2 y 23 4.40 0 
CYP3A4 alfentanil Meistelman 1987 1 39 4.9 y 22 2.70 0 
CYP3A4 alfentanil Meistelman 1987 1 39 28 y 66 7.20 0 
CYP3A4 alfentanil Meistelman 1987 1 39 35 y 55 3.90 0 
CYP3A4 alfentanil Meistelman 1987 1 39 32 y 58 2.70 0 
CYP3A4 alfentanil Meistelman 1987 1 39 34 y 60 3.90 0 
CYP3A4 alfentanil Meistelman 1987 1 39 27 y 60 3.30 0 
CYP3A4 alfentanil Rautiainen 1991 13 39 0.55 y 5.86 6.81 2.19 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.08 y 2.85 4.60 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.12 y 3.6 5.20 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.17 y 4.93 8.20 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.21 y 5.02 3.10 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.25 y 5.27 6.60 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.42 y 5.07 8.20 0 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.46 y 7.08 5.80 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.58 y 6.04 8.00 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.67 y 5.63 4.90 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.75 y 5.85 11.00 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 0.83 y 6.65 9.30 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 1.17 y 6.12 7.90 0 
CYP3A4 alfentanil Rautiainen 1991 1 39 1.42 y 12.1 5.70 0 
CYP3A4 alfentanil Roure 1987 20 39 34 m 14.3 11.10 3.9 
CYP3A4 alfentanil Roure 1987 10 39 55 y 65 5.90 1.6 
CYP3A4 alfentanil Roure 1987 1 39 10 m 8.25 14.20 0 
CYP3A4 alfentanil Roure 1987 1 39 10 m 8.25 11.50 0 
CYP3A4 alfentanil Roure 1987 1 39 11 m 8.58 9.70 0 
CYP3A4 alfentanil Roure 1987 1 39 21 m 11.47 20.70 0 
CYP3A4 alfentanil Roure 1987 1 39 21 m 11.47 10.70 0 
CYP3A4 alfentanil Roure 1987 1 39 23 m 11.96 11.80 0 
CYP3A4 alfentanil Roure 1987 1 39 24 m 12.19 12.70 0 
CYP3A4 alfentanil Roure 1987 1 39 24 m 12.19 7.60 0 
CYP3A4 alfentanil Roure 1987 1 39 27 m 12.86 13.40 0 
CYP3A4 alfentanil Roure 1987 1 39 27 m 12.86 8.10 0 
CYP3A4 alfentanil Roure 1987 1 39 28 m 13.07 9.80 0 
CYP3A4 alfentanil Roure 1987 1 39 31 m 13.68 10.50 0 
CYP3A4 alfentanil Roure 1987 1 39 33 m 14.06 13.30 0 
CYP3A4 alfentanil Roure 1987 1 39 41 m 15.45 13.40 0 
CYP3A4 alfentanil Roure 1987 1 39 42 m 15.61 12.10 0 
CYP3A4 alfentanil Roure 1987 1 39 50 m 16.83 7.70 0 
CYP3A4 alfentanil Roure 1987 1 39 50 m 16.83 17.00 0 
CYP3A4 alfentanil Roure 1987 1 39 60 m 18.31 6.00 0 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 alfentanil Roure 1987 1 39 70 m 19.86 8.60 0 
CYP3A4 alfentanil Roure 1987 1 39 78 m 21.24 3.20 0 
CYP3A4 alfentanil Dorne 2003 241 39 18 y 70 4.1 1.5 
CYP3A4 midazolam Rey 1991 6 39 2.5 y 15.2 13.30 4.3 
CYP3A4 midazolam Muchohi 2008 13 39 27 m 10.4 14.40 2.7 
CYP3A4 midazolam Mathews 1988 6 39 5.2 y 18.4 11.98 6.68 
CYP3A4 midazolam Mathews 1988 6 39 4.7 y 15.9 8.53 1.8 
CYP3A4 midazolam Mathews 1988 5 39 1.3 y 8.8 9.07 3.35 
CYP3A4 midazolam Reed 2001 5 39 0.96 y 7.88 11.33 6.33 
CYP3A4 midazolam Reed 2001 13 39 5.2 y 19.2 10.00 3.83 
CYP3A4 midazolam Reed 2001 2 39 15.4 y 62 9.33 3.83 
CYP3A4 midazolam Payne 1989 8 39 5.52 m 17.3 9.11 1.21 
CYP3A4 midazolam Mulla 2003 20 39.5 3.8 d 3.4 1.40 0.15 
CYP3A4 midazolam Lee 1999 60 27 4.5 d 0.965 9.11 1.21 
CYP3A4 midazolam Jacqz-Aigrain 1992 15 32.8 3 d 1.9 1.70 1.8 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 35 3.5 d 2.3 1.39 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 34 3.5 d 2.7 1.41 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 35 3.5 d 2.7 1.07 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 37 3.5 d 2.7 0.74 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 39 3.5 d 3 0.87 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 41 3.5 d 3.2 2.69 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 38 3.5 d 3.2 1.16 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 37 3.5 d 3.6 3.50 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 38 3.5 d 3.8 3.76 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 1 40 3.5 d 3.9 3.72 0 
CYP3A4 midazolam Jacqz-Aigrain 1990 10 37 3.5 d 3.1 2.03 1.24 
CYP3A4 midazolam de Wildt 2001 24 29 5.5 d 1.02 1.80 n.a. 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP3A4 midazolam Salonen 1987 3 39 7.33 y 32.8 6.67 5.5 
CYP3A4 midazolam Salonen 1987 6 39 6.72 y 28 4.83 2.33 
CYP3A4 midazolam Salonen 1987 6 39 6.07 y 21.6 8.67 2.5 
CYP3A4 midazolam Salonen 1987 6 39 6.11 y 22.3 11.20 1.33 
CYP3A4 midazolam Harte 1997 10 27.9 3 d 1.045 1.66 1.37 
CYP3A4 midazolam Tolia 1991 20 39 13.5 y 43.75 10.00 5 
CYP3A4 midazolam Clausen 1988 8 39 27 y 68 6.28 1.03 
CYP3A4 midazolam Pentikainen 1989 7 39 44.3 y 79.4 5.63 0.43 
CYP3A4 midazolam Mandema 1992 8 39 22 y 69 7.50 1.26 
CYP3A4 midazolam Greenblatt 1984 10 39 27.9 y 68.8 7.75 0.41 
CYP3A4 midazolam Greenblatt 1984 10 39 28.5 y 58.5 9.39 0.86 
CYP3A4 midazolam Dorne 2003 198 39 18 y 70 7 1.5 
CYP1A2 theophylline Loughnan 1976 1 39.0 1.7 y 10.4 1.95 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 2.0 y 13.3 0.95 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 2.0 y 13.7 1.33 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 2.0 y 11.2 2.72 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 2.5 y 11.5 2.07 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 2.7 y 11.4 1.75 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 3.0 y 14.8 2.42 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 3.2 y 13.2 1.20 0.00 
CYP1A2 theophylline Loughnan 1976 1 39.0 4.4 y 16.4 1.12 0.00 
CYP1A2 theophylline Loughnan 1976 10 39.0 2.5 y 12.5 1.67 0.61 
CYP1A2 theophylline Giacoia 1976 1 28.0 29.0 d 1.2 1.14 0.00 
CYP1A2 theophylline Giacoia 1976 1 29.0 30.0 d 1.2 0.60 0.00 
CYP1A2 theophylline Giacoia 1976 1 28.0 57.0 d 1.8 0.86 0.00 
CYP1A2 theophylline Giacoia 1976 1 28.0 55.0 d 1.9 0.74 0.00 
CYP1A2 theophylline Giacoia 1976 1 26.0 48.0 d 1.9 0.60 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline Giacoia 1976 1 26.0 47.0 d 1.4 0.38 0.00 
CYP1A2 theophylline Giacoia 1976 1 32.0 37.0 d 2.2 0.49 0.00 
CYP1A2 theophylline Giacoia 1976 1 29.0 25.0 d 2.1 0.40 0.00 
CYP1A2 theophylline Giacoia 1976 8 28.3 41.0 d 1.7 0.65 0.26 
CYP1A2 theophylline Simmons 1978 1 39.0 3.0 m 5.6 0.68 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 3.0 m 5.6 0.47 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 4.0 m 6.0 0.66 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 4.0 m 6.0 0.92 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 5.0 m 6.4 1.29 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 8.0 m 7.5 1.55 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 8.0 m 7.5 0.54 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 10.0 m 8.2 1.35 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 10.0 m 8.2 1.15 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 17.0 m 10.4 0.98 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 18.0 m 10.7 1.39 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 20.0 m 11.2 2.41 0.00 
CYP1A2 theophylline Simmons 1978 1 39.0 23.0 m 12.0 0.50 0.00 
CYP1A2 theophylline Simmons 1978 13 39.0 10.2 m 8.1 1.07 0.55 
CYP1A2 theophylline Rosen 1979 1 39.0 4.0 m 6.0 0.77 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 4.5 m 6.2 0.80 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 5.0 m 6.4 0.97 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 6.5 m 7.0 1.72 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 7.5 m 7.4 2.17 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 8.0 m 7.5 1.45 0.00 
CYP1A2 theophylline Rosen 1979 6 39.0 5.9 m 6.8 1.31 0.56 
CYP1A2 theophylline Rosen 1979 1 39.0 12.0 m 8.9 2.60 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 13.0 m 9.2 1.28 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline Rosen 1979 1 39.0 15.0 m 9.8 1.67 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 16.0 m 10.1 1.30 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 17.0 m 10.4 1.28 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 18.0 m 10.7 1.78 0.00 
CYP1A2 theophylline Rosen 1979 1 39.0 18.0 m 10.7 1.47 0.00 
CYP1A2 theophylline Rosen 1979 7 39.0 15.6 m 10.0 1.63 0.47 
CYP1A2 theophylline Franko 1982 1 39.0 0.9 m 5.0 0.40 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 1.0 m 4.3 0.43 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 1.8 m 2.6 0.31 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 1.8 m 5.5 0.39 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 2.0 m 4.2 1.10 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 2.0 m 3.8 0.51 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 3.0 m 5.7 0.58 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 4.5 m 3.9 0.53 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 5.0 m 5.8 0.73 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 5.0 m 5.7 0.75 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 5.0 m 6.6 0.67 0.00 
CYP1A2 theophylline Franko 1982 1 39.0 6.5 m 9.7 0.52 0.00 
CYP1A2 theophylline Franko 1982 12 39.0 3.2 m 5.2 0.58 0.21 
CYP1A2 theophylline el Desoky 1997 1 39.0 2.0 y 12.0 1.23 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 2.5 y 12.5 1.22 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 2.5 y 12.3 1.32 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 3.5 y 14.0 1.16 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 3.5 y 14.2 1.16 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 5.0 y 18.5 1.04 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 5.0 y 18.0 1.14 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 6.5 y 20.0 1.04 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline el Desoky 1997 1 39.0 6.5 y 21.0 1.05 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 7.0 y 22.0 0.73 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 8.0 y 23.5 1.08 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 9.0 y 24.0 1.55 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 11.0 y 27.0 0.90 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 11.5 y 26.8 0.84 0.00 
CYP1A2 theophylline el Desoky 1997 1 39.0 12.0 y 30.0 1.06 0.00 
CYP1A2 theophylline el Desoky 1997 15 39.0 6.4 y 19.7 1.10 0.20 
CYP1A2 theophylline Igarashi 2009 28 39.0 1.1 y 9.4 0.94 0.26 
CYP1A2 theophylline Igarashi 2009 10 39.0 1.2 y 9.7 0.84 0.24 
CYP1A2 theophylline Igarashi 2009 23 39.0 3.0 y 13.2 0.98 0.31 
CYP1A2 theophylline Igarashi 2009 12 39.0 3.0 y 13.9 0.81 0.11 
CYP1A2 theophylline Igarashi 2009 16 39.0 5.8 y 20.1 1.10 0.20 
CYP1A2 theophylline Igarashi 2009 11 39.0 6.2 y 19.9 0.87 0.28 
CYP1A2 theophylline Jones 1979 1 28.0 4.0 d 1.1 0.40 0.00 
CYP1A2 theophylline Jones 1979 1 27.0 4.0 d 1.1 0.32 0.00 
CYP1A2 theophylline Jones 1979 1 25.0 3.0 d 1.1 0.34 0.00 
CYP1A2 theophylline Jones 1979 1 29.0 30.0 d 1.1 0.29 0.00 
CYP1A2 theophylline Jones 1979 1 27.0 0.0 d 1.1 0.23 0.00 
CYP1A2 theophylline Jones 1979 1 27.0 19.0 d 1.1 0.22 0.00 
CYP1A2 theophylline Jones 1979 1 28.0 36.0 d 1.1 0.47 0.00 
CYP1A2 theophylline Jones 1979 1 29.0 7.0 d 1.1 0.29 0.00 
CYP1A2 theophylline Jones 1979 1 29.0 10.0 d 1.1 0.36 0.00 
CYP1A2 theophylline Jones 1979 1 30.0 19.0 d 1.1 0.21 0.00 
CYP1A2 theophylline Jones 1979 1 27.0 19.0 d 1.1 0.28 0.00 
CYP1A2 theophylline Jones 1979 11 27.8 12.4 d 1.1 0.31 0.08 
CYP1A2 theophylline Kraus 1993 20 28.9 46.9 d 5.0 0.36 0.12 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline Kraus 1993 15 30.1 98.0 d 5.7 0.51 0.17 
CYP1A2 theophylline Kraus 1993 17 31.2 224.0 d 7.3 1.01 0.24 
CYP1A2 theophylline Arnold 1981 1 39.0 9.3 y 29.3 2.27 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 7.3 y 23.1 2.17 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 8.3 y 25.9 2.08 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 12.3 y 42.2 0.73 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 8.5 y 26.6 0.78 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 10.0 y 31.9 0.90 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 9.4 y 29.6 0.67 0.00 
CYP1A2 theophylline Arnold 1981 1 39.0 12.3 y 42.2 0.92 n.a. 
CYP1A2 theophylline Arnold 1981 8 39.0 9.7 y 31.4 1.31 0.72 
CYP1A2 theophylline Islam 2004 42 30.0 15.0 d 1.3 0.32 0.10 
CYP1A2 theophylline Gilman 1986 179 30.0 14.0 d 1.2 0.31 0.10 
CYP1A2 theophylline Vichyanond 1994 13 39.0 9.0 y 28.7 1.50 0.03 
CYP1A2 theophylline Stile 1986 9 28.0 1.0 d 1.1 0.77 0.23 
CYP1A2 theophylline Hilligoss 1980 17 30.5 50.1 d 1.1 0.38 0.07 
CYP1A2 theophylline Brazier 1979 33 33.6 2.9 d 1.5 0.40 0.08 
CYP1A2 theophylline Aranda 1976 6 27.5 7.5 d 0.9 0.29 0.04 
CYP1A2 theophylline Ellis 1976 30 39.0 10.7 y 34.9 1.45 0.58 
CYP1A2 theophylline Latini 1977 1 33.0 4.0 d 2.4 0.28 0.00 
CYP1A2 theophylline Latini 1977 1 33.0 6.0 d 1.7 0.13 0.00 
CYP1A2 theophylline Latini 1977 1 32.0 6.0 d 1.7 0.23 0.00 
CYP1A2 theophylline Latini 1977 1 30.0 7.0 d 1.7 0.11 0.00 
CYP1A2 theophylline Latini 1977 1 32.0 8.0 d 1.6 0.13 0.00 
CYP1A2 theophylline Latini 1977 1 29.0 8.0 d 1.5 0.50 0.00 
CYP1A2 theophylline Latini 1977 1 30.0 8.0 d 1.0 0.14 0.00 
CYP1A2 theophylline Latini 1977 7 31.3 6.7 d 1.6 0.22 0.14 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline Neese 1977 1 29.0 26.0 d 1.2 0.27 0.00 
CYP1A2 theophylline Neese 1977 1 33.0 5.0 d 1.2 0.26 0.00 
CYP1A2 theophylline Neese 1977 1 33.0 10.0 d 1.2 0.13 0.00 
CYP1A2 theophylline Neese 1977 1 33.0 21.0 d 1.2 0.24 0.00 
CYP1A2 theophylline Neese 1977 1 33.0 17.0 d 1.3 0.14 0.00 
CYP1A2 theophylline Neese 1977 1 32.0 9.0 d 1.4 0.22 0.00 
CYP1A2 theophylline Neese 1977 1 32.0 18.0 d 1.4 0.07 0.00 
CYP1A2 theophylline Neese 1977 1 33.0 14.0 d 1.6 0.30 0.00 
CYP1A2 theophylline Neese 1977 1 34.0 5.0 d 1.7 0.10 0.00 
CYP1A2 theophylline Neese 1977 9 32.4 13.9 d 1.4 0.19 0.08 
CYP1A2 theophylline Miller 1984 1 39.0 27.0 y 70.0 1.17 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 22.0 y 70.0 0.86 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 20.0 y 70.0 0.83 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 19.0 y 70.0 1.00 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 25.0 y 70.0 0.60 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 19.0 y 70.0 0.70 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 20.0 y 70.0 0.74 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 19.0 y 70.0 0.53 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 27.0 y 70.0 0.54 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 35.0 y 70.0 0.94 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 57.0 y 70.0 0.69 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 44.0 y 70.0 1.01 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 18.0 y 70.0 1.60 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 22.0 y 70.0 1.24 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 19.0 y 70.0 0.70 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 18.0 y 70.0 1.51 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 20.0 y 70.0 0.43 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline Miller 1984 1 39.0 27.0 y 70.0 0.64 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 41.0 y 70.0 1.28 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 23.0 y 70.0 0.70 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 20.0 y 70.0 0.68 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 20.0 y 70.0 0.98 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 19.0 y 70.0 0.62 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 21.0 y 70.0 0.50 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 21.0 y 70.0 0.93 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 21.0 y 70.0 0.92 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 36.0 y 70.0 1.12 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 28.0 y 70.0 0.61 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 33.0 y 70.0 1.07 0.00 
CYP1A2 theophylline Miller 1984 1 39.0 50.0 y 70.0 0.64 0.00 
CYP1A2 theophylline Miller 1984 30 39.0 26.4 y 70.0 0.86 0.05 
CYP1A2 theophylline Chester 1982 1 39.0 27.0 y 70.0 0.72 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 23.0 y 70.0 0.95 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 23.0 y 70.0 1.16 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 26.0 y 70.0 0.69 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 20.0 y 70.0 0.75 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 20.0 y 70.0 0.31 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 22.0 y 70.0 0.66 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 18.0 y 70.0 0.61 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 24.0 y 70.0 0.77 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 28.0 y 70.0 0.45 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 23.0 y 70.0 0.43 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 24.0 y 70.0 0.52 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 19.0 y 70.0 0.80 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 theophylline Chester 1982 1 39.0 18.0 y 70.0 0.84 0.00 
CYP1A2 theophylline Chester 1982 1 39.0 19.0 y 70.0 0.71 0.00 
CYP1A2 theophylline Chester 1982 15 39.0 22.3 y 70.0 0.69 0.21 
CYP1A2 theophylline Dorne 2001 100 39.0 18.0 y 70.0 1.00 0.29 
CYP1A2 caffeine Aranda 1979 12 28.5 11.5 d 1.2 0.15 0.09 
CYP1A2 caffeine Aranda 1979 5 39.0 2.5 m 5.6 0.63 n.a. 
CYP1A2 caffeine Aranda 1979 3 39.0 4.5 m 7.0 1.74 n.a. 
CYP1A2 caffeine Aranda 1979 2 39.0 6.0 m 8.0 5.53 n.a. 
CYP1A2 caffeine Gorodischer 1982 13 30.6 5.8 d 1.4 0.14 0.01 
CYP1A2 caffeine Gorodischer 1982 1 28.0 18.0 d 1.4 0.12 0.00 
CYP1A2 caffeine Gorodischer 1982 1 25.0 21.0 d 0.9 0.14 0.00 
CYP1A2 caffeine Gorodischer 1982 1 30.0 5.0 d 1.2 0.21 0.00 
CYP1A2 caffeine Gorodischer 1982 1 31.0 6.0 d 1.4 0.11 0.00 
CYP1A2 caffeine Gorodischer 1982 1 33.0 3.5 d 1.5 0.15 0.00 
CYP1A2 caffeine Gorodischer 1982 5 29.4 10.7 d 1.3 0.14 0.04 
CYP1A2 caffeine Pons 1988 1 33.0 19.0 d 2.3 0.16 0.00 
CYP1A2 caffeine Pons 1988 1 32.0 22.0 d 0.2 0.11 0.00 
CYP1A2 caffeine Pons 1988 1 31.0 22.0 d 1.5 0.12 0.00 
CYP1A2 caffeine Pons 1988 1 31.0 22.0 d 1.9 0.11 0.00 
CYP1A2 caffeine Pons 1988 1 31.0 30.0 d 2.4 0.22 0.00 
CYP1A2 caffeine Pons 1988 1 40.0 33.0 d 3.8 0.37 0.00 
CYP1A2 caffeine Pons 1988 1 41.0 52.0 d 4.4 0.61 0.00 
CYP1A2 caffeine Pons 1988 1 38.0 54.0 d 3.6 0.49 0.00 
CYP1A2 caffeine Pons 1988 1 39.0 174.0 d 5.1 2.56 0.00 
CYP1A2 caffeine Pons 1988 1 36.0 273.0 d 6.4 1.70 0.00 
CYP1A2 caffeine Pons 1988 1 37.0 434.0 d 9.1 1.26 0.00 
CYP1A2 caffeine Pons 1988 1 36.0 588.0 d 9.1 2.39 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 caffeine Pons 1988 1 41.0 92.0 d 5.3 1.13 0.00 
CYP1A2 caffeine Pons 1988 1 38.0 112.0 d 4.6 0.60 0.00 
CYP1A2 caffeine Pons 1988 1 38.0 196.0 d 5.7 1.03 0.00 
CYP1A2 caffeine Pons 1988 1 38.0 252.0 d 5.8 1.25 0.00 
CYP1A2 caffeine Pons 1988 5 31.6 23.0 d 1.7 0.14 0.04 
CYP1A2 caffeine Pons 1988 4 40.0 57.8 d 4.3 0.65 0.34 
CYP1A2 caffeine Pons 1988 5 37.8 201.4 d 5.5 1.43 0.75 
CYP1A2 caffeine Pons 1988 2 36.5 511.0 d 9.1 1.83 0.80 
CYP1A2 caffeine Lee 2002 18 28.9 5.0 d 1.1 0.09 0.02 
CYP1A2 caffeine Lee 2002 10 28.8 5.0 d 1.1 0.10 0.02 
CYP1A2 caffeine Lee 2002 1 33.0 5.0 d 1.7 0.06 0.00 
CYP1A2 caffeine Lee 2002 1 27.0 5.0 d 0.7 0.21 0.00 
CYP1A2 caffeine Lee 2002 1 29.0 5.0 d 1.1 0.09 0.00 
CYP1A2 caffeine Lee 2002 1 24.0 5.0 d 0.7 0.13 0.00 
CYP1A2 caffeine Lee 2002 1 28.0 5.0 d 1.1 0.10 0.00 
CYP1A2 caffeine Lee 2002 1 27.0 5.0 d 1.0 0.14 0.00 
CYP1A2 caffeine Lee 2002 1 29.0 5.0 d 1.3 0.09 0.00 
CYP1A2 caffeine Lee 2002 1 29.0 5.0 d 1.1 0.13 0.00 
CYP1A2 caffeine Lee 2002 1 31.0 5.0 d 1.1 0.12 0.00 
CYP1A2 caffeine Lee 2002 1 27.0 5.0 d 1.0 0.12 0.00 
CYP1A2 caffeine Lee 2002 1 32.0 5.0 d 1.6 0.09 0.00 
CYP1A2 caffeine Lee 2002 1 28.0 5.0 d 1.2 0.10 0.00 
CYP1A2 caffeine Lee 2002 1 29.0 5.0 d 1.3 0.10 0.00 
CYP1A2 caffeine Lee 2002 1 32.0 5.0 d 1.3 0.11 0.00 
CYP1A2 caffeine Lee 2002 1 29.0 5.0 d 0.9 0.16 0.00 
CYP1A2 caffeine Lee 2002 1 30.0 5.0 d 1.2 0.11 0.00 
CYP1A2 caffeine Lee 2002 1 28.0 5.0 d 1.0 0.14 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
CYP1A2 caffeine Lee 2002 1 28.0 5.0 d 0.8 0.18 0.00 
CYP1A2 caffeine Denaro 1996 12 39.0 45.0 y 70.0 2.33 1.12 
CYP1A2 caffeine Blanchard 1983 10 39.0 21.8 y 79.5 1.15 0.54 
CYP1A2 caffeine Dorne 2001 20 39.0 18.0 y 70.0 1.97 0.92 
renal gentamicin Rodvold 1993 19 28.7 34.6 d 1.78 1.04 0.37 
renal gentamicin Kildoo 1984 15 28.4 1 d 1 0.38 0.14 
renal gentamicin Kildoo 1984 15 28.4 18.7 d 0.887 0.44 0.18 
renal gentamicin Kildoo 1984 6 28.4 67.5 d 1.49 1.21 0.39 
renal gentamicin Rocha 2000 68 29.5 3 d 1.2 1.05 0.29 
renal gentamicin Rocha 2000 34 27 3 d 0.875 0.48 0.13 
renal gentamicin Rocha 2000 34 32 3 d 1.5 0.57 0.16 
renal gentamicin Ho 1995 14 39 3.8 y 15.3 2.91 0.60 
renal gentamicin Ho 1995 7 39 2.9 y 13.1 2.64 0.54 
renal gentamicin Ho 1995 13 39 2.9 y 14.9 2.74 0.63 
renal gentamicin Ho 1995 8 39 9.8 y 33.9 2.29 0.72 
renal gentamicin Ho 1995 6 39 10.4 y 31.5 2.11 0.53 
renal gentamicin Ho 1995 5 39 9 y 27 2.34 0.46 
renal gentamicin Ho 1995 7 39 14 y 55.1 2.23 0.77 
renal gentamicin Ho 1995 10 39 15.6 y 50.2 1.82 0.37 
renal gentamicin Ho 1995 7 39 15.3 y 53.5 2.35 0.57 
renal gentamicin Pons 1988 15 37 1 d 3.2 1.03 0.37 
renal gentamicin Pons 1988 8 37 5 d 3.3 1.79 0.64 
renal gentamicin Pons 1988 1 37 18 d 3.7 1.67 0.00 
renal gentamicin Pons 1988 27 39 1 d 3.2 1.40 0.46 
renal gentamicin Pons 1988 16 39 5 d 3.3 1.78 0.39 
renal gentamicin Pons 1988 14 39 18 d 3.7 1.97 0.44 
renal gentamicin Watterberg 1987 16 29.9 4.5 d 1.12 0.93 0.33 
  
 
1
8
5
 
pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
renal gentamicin Watterberg 1987 1 29 3 d 0.74 1.55 0.00 
renal gentamicin Watterberg 1987 1 29 2 d 0.87 0.93 0.00 
renal gentamicin Watterberg 1987 1 26 2 d 0.94 1.05 0.00 
renal gentamicin Watterberg 1987 1 29 13 d 0.99 1.65 0.00 
renal gentamicin Watterberg 1987 1 31 2 d 1.12 0.65 0.00 
renal gentamicin Watterberg 1987 1 29 2 d 1.28 0.68 0.00 
renal gentamicin Watterberg 1987 1 30 2 d 1.36 0.77 0.00 
renal gentamicin Watterberg 1987 24 28.8 4.2 d 1.04 0.83 0.40 
renal gentamicin Watterberg 1987 1 29 7 d 0.74 0.82 0.00 
renal gentamicin Watterberg 1987 1 29 10 d 0.87 0.57 0.00 
renal gentamicin Watterberg 1987 1 26 12 d 0.94 0.28 0.00 
renal gentamicin Watterberg 1987 1 29 17 d 0.99 0.70 0.00 
renal gentamicin Watterberg 1987 1 31 8 d 1.12 0.63 0.00 
renal gentamicin Watterberg 1987 1 29 6 d 1.28 1.05 0.00 
renal gentamicin Watterberg 1987 1 30 14 d 1.36 0.50 0.00 
renal gentamicin Vervelde 1999 29 32 6 d 1.8 0.86 0.21 
renal gentamicin Vervelde 1999 5 33 15 d 1.95 1.71 0.17 
renal gentamicin Assael 1980 1 27 1 d 0.98 0.78 0.00 
renal gentamicin Assael 1980 1 30.3 1 d 1.1 0.58 0.00 
renal gentamicin Assael 1980 1 30.5 1 d 1.1 0.51 0.00 
renal gentamicin Assael 1980 1 31.4 1 d 1.65 0.46 0.00 
renal gentamicin Assael 1980 1 33.4 1 d 2.1 0.27 0.00 
renal gentamicin Assael 1980 1 34 1 d 1.45 0.76 0.00 
renal gentamicin Assael 1980 1 34 1 d 1.2 0.87 0.00 
renal gentamicin Assael 1980 1 34 1 d 2.25 0.60 0.00 
renal gentamicin Assael 1980 1 34 1 d 2.75 1.08 0.00 
renal gentamicin Assael 1980 1 38.3 1 d 3.15 0.61 0.00 
  
 
1
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6
 
pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
renal gentamicin Assael 1980 1 32.4 1 d 1.37 0.79 0.00 
renal gentamicin Assael 1980 1 38 1 d 2.7 0.27 0.00 
renal gentamicin Assael 1980 1 38 1 d 3.1 0.60 0.00 
renal gentamicin Assael 1980 13 33.5 1 d 1.92 0.63 0.23 
renal gentamicin Assael 1980 1 39 1 m 3.3 1.30 0.00 
renal gentamicin Assael 1980 1 39 2.5 m 3.45 1.59 0.00 
renal gentamicin Assael 1980 1 39 3 m 2.6 1.10 0.00 
renal gentamicin Assael 1980 1 39 3 m 4 2.57 0.00 
renal gentamicin Assael 1980 1 39 36 m 11 1.86 0.00 
renal gentamicin Assael 1980 1 39 72 m 19 1.80 0.00 
renal gentamicin Assael 1980 1 39 86 m 23 0.80 0.00 
renal gentamicin Assael 1980 7 39 29.07 m 9.48 1.57 0.58 
renal gentamicin Koren 1985 48 31.6 1.5 d 1.5 1.01 0.23 
renal gentamicin Gonzalez-Martin 1986 5 39 6.4 y 20.5 2.80 0.50 
renal gentamicin Gonzalez-Martin 1986 5 39 6.1 y 20.3 3.70 0.70 
renal gentamicin Giacoia 1986 9 34.7 3.1 d 2.11 0.88 0.25 
renal gentamicin Giacoia 1986 10 34.8 2.4 d 2.08 0.66 0.14 
renal gentamicin Sato 1997 3 39 0 d 2.5 1.21 n.a. 
renal gentamicin Sato 1997 6 39 1 d 2.5 0.79 n.a. 
renal gentamicin Sato 1997 4 39 2 d 2.5 1.41 n.a. 
renal gentamicin Sato 1997 4 39 3 d 2.5 1.45 n.a. 
renal gentamicin Sato 1997 3 39 4 d 2.5 1.72 n.a. 
renal gentamicin Sato 1997 3 39 5 d 2.5 1.69 n.a. 
renal gentamicin Sato 1997 4 39 6 d 2.5 1.97 n.a. 
renal gentamicin Sato 1997 2 39 7 d 2.5 1.95 n.a. 
renal gentamicin Sato 1997 3 30 0 d 2 0.85 n.a. 
renal gentamicin Sato 1997 5 30 1 d 2 0.84 n.a. 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
renal gentamicin Sato 1997 4 30 2 d 2 0.94 n.a. 
renal gentamicin Sato 1997 2 30 3 d 2 0.89 n.a. 
renal gentamicin Sato 1997 2 30 4 d 2 0.76 n.a. 
renal gentamicin Sato 1997 1 30 5 d 2 0.93 0.00 
renal gentamicin Sato 1997 4 30 6 d 2 1.46 n.a. 
renal gentamicin Sato 1997 1 30 7 d 2 1.30 0.00 
renal gentamicin Sato 1997 1 28 0 d 1.5 0.83 0.00 
renal gentamicin Sato 1997 1 28 1 d 1.5 0.41 0.00 
renal gentamicin Sato 1997 1 28 2 d 1.5 0.51 0.00 
renal gentamicin Sato 1997 1 28 3 d 1.5 0.82 0.00 
renal gentamicin Sato 1997 1 28 5 d 1.5 0.92 0.00 
renal gentamicin Sato 1997 1 28 7 d 1.5 0.98 0.00 
renal gentamicin Walker 1979 10 39 27 y 70.5 1.03 0.23 
renal gentamicin Bauer 1983 12 39 29.1 y 73.2 1.31 0.42 
renal gentamicin Bauer 1983 51 39 28.8 y 72.8 1.29 0.52 
renal gentamicin Bauer 1983 59 39 51.2 y 70.6 1.35 0.48 
renal gentamicin Dorne 2004 219 39 18 y 70 1.30 0.50 
renal vancomycin Jarret 1993 1 25.00 7.00 d 0.43 0.52 0.00 
renal vancomycin Jarret 1993 1 24.57 10.00 d 0.59 0.59 0.00 
renal vancomycin Jarret 1993 1 24.71 9.00 d 0.76 0.38 0.00 
renal vancomycin Jarret 1993 1 28.57 10.00 d 1.03 0.86 0.00 
renal vancomycin Jarret 1993 1 29.14 13.00 d 1.08 0.92 0.00 
renal vancomycin Jarret 1993 1 30.00 7.00 d 1.30 0.76 0.00 
renal vancomycin Jarret 1993 1 28.71 16.00 d 1.32 1.11 0.00 
renal vancomycin Jarret 1993 1 30.57 17.00 d 1.58 0.78 0.00 
renal vancomycin Jarret 1993 1 34.14 6.00 d 1.69 0.78 0.00 
renal vancomycin Jarret 1993 1 34.43 4.00 d 2.14 0.82 0.00 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
renal vancomycin Jarret 1993 1 34.43 11.00 d 1.96 0.65 0.00 
renal vancomycin Jarret 1993 11 29.48 10.00 d 1.26 0.74 0.20 
renal vancomycin Culter 1984 1 39.00 26.00 y 83.20 0.96 0.00 
renal vancomycin Culter 1984 1 39.00 26.00 y 72.60 1.26 0.00 
renal vancomycin Culter 1984 1 39.00 21.00 y 82.10 1.08 0.00 
renal vancomycin Culter 1984 1 39.00 25.00 y 74.60 0.85 0.00 
renal vancomycin Culter 1984 1 39.00 20.00 y 76.50 0.94 0.00 
renal vancomycin Culter 1984 1 39.00 20.00 y 72.80 1.08 0.00 
renal vancomycin Culter 1984 6 39.00 23.00 y 76.97 1.03 0.14 
renal vancomycin Lisby-Sutch 1988 1 28.00 13.00 d 1.14 0.79 0.00 
renal vancomycin Lisby-Sutch 1988 1 27.00 21.00 d 0.91 0.31 0.00 
renal vancomycin Lisby-Sutch 1988 1 29.00 21.00 d 1.17 0.81 0.00 
renal vancomycin Lisby-Sutch 1988 1 29.00 28.00 d 1.10 0.81 0.00 
renal vancomycin Lisby-Sutch 1988 1 36.00 23.00 d 2.00 1.61 0.00 
renal vancomycin Lisby-Sutch 1988 5 29.80 21.20 d 1.26 0.87 0.47 
renal vancomycin Lisby-Sutch 1988 1 28.00 42.00 d 0.96 0.90 0.00 
renal vancomycin Lisby-Sutch 1988 1 27.00 52.00 d 1.38 1.05 0.00 
renal vancomycin Lisby-Sutch 1988 1 27.00 53.00 d 1.29 1.39 0.00 
renal vancomycin Lisby-Sutch 1988 1 27.00 84.00 d 1.83 1.18 0.00 
renal vancomycin Lisby-Sutch 1988 1 32.00 49.00 d 2.50 1.37 0.00 
renal vancomycin Lisby-Sutch 1988 1 28.00 92.00 d 2.30 2.85 0.00 
renal vancomycin Lisby-Sutch 1988 1 37.00 122.00 d 4.18 2.22 0.00 
renal vancomycin Lisby-Sutch 1988 1 32.00 183.00 d 6.12 3.42 0.00 
renal vancomycin Lisby-Sutch 1988 8 29.77 84.60 d 2.57 2.21 0.95 
renal vancomycin Asbury 1993 19 29.30 33.90 d 1.78 1.20 0.53 
renal vancomycin Asbury 1993 4 26.00 17.60 d 0.81 0.60 0.17 
renal vancomycin Gous 1995 20 39.00 3.00 m 6.40 1.50 0.50 
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pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
renal vancomycin Gous 1995 15 39.00 3.00 m 6.40 1.20 0.40 
renal vancomycin Wrishko 2000 6 39.00 6.90 y 21.20 1.83 0.30 
renal vancomycin Kildoo 1990 15 29.00 29.00 d 1.24 1.07 0.34 
renal vancomycin Schaad 1980 7 32.00 3.30 d 1.23 0.85 n.a. 
renal vancomycin Schaad 1980 7 34.00 4.70 d 1.57 1.39 n.a. 
renal vancomycin Schaad 1980 7 40.00 2.60 d 3.07 1.19 n.a. 
renal vancomycin Rodvold 1997 3 25.86 29.00 d 0.83 1.10 0.29 
renal vancomycin Rodvold 1997 6 27.06 39.50 d 1.38 1.05 0.21 
renal vancomycin Reed 1987 15 28.40 20.50 d 1.07 1.14 0.65 
renal vancomycin McDougal 1995 16 26.60 18.00 d 0.97 1.00 0.27 
renal vancomycin McDougal 1995 15 29.40 23.00 d 1.38 1.17 0.32 
renal vancomycin McDougal 1995 13 35.90 24.00 d 2.62 1.33 0.30 
renal vancomycin Rodvold 1995 29 31.20 17.70 d 1.86 1.01 0.37 
renal vancomycin Schaad 1980 12 39.00 0.26 y 4.90 1.65 n.a. 
renal vancomycin Schaad 1980 4 39.00 0.36 y 5.20 2.70 n.a. 
renal vancomycin Rodvold 1997 6 39.00 4.00 m 6.50 1.67 0.60 
renal vancomycin Chang 1994 28 39.00 4.00 y 16.20 2.55 0.55 
renal vancomycin Chang 1995 33 39.00 5.70 y 19.90 2.48 0.47 
renal vancomycin Chang 1995 31 39.00 4.20 y 15.40 1.90 0.52 
renal vancomycin Schaad 1980 5 39.00 3.92 y 15.50 3.95 n.a. 
renal vancomycin Schaad 1980 7 39.00 5.58 y 20.00 2.95 n.a. 
renal vancomycin Schaad 1980 6 39.00 7.58 y 26.70 2.78 n.a. 
renal vancomycin Birt 1990 22 39.00 52.40 y 71.00 1.12 0.48 
renal vancomycin Pou 1996 45 39.00 50.80 y 71.00 1.31 0.82 
renal vancomycin Pou 1996 45 39.00 50.80 y 71.00 1.13 0.72 
renal vancomycin Guay 1993 121 39.00 37.30 y 79.60 1.22 0.50 
renal vancomycin Pleasants 1996 10 39.00 27.10 y 51.20 1.55 0.32 
  
 
1
9
0
 
pathway drug study subjn GA (wk) PNA PNA.unit BW (kg) CL (mL/min/kg) CL.sd 
renal vancomycin Hoie 1990 1 37.00 2.00 d 4.10 1.19 0.00 
renal vancomycin Hoie 1990 1 41.00 2.00 d 3.50 1.62 0.00 
renal vancomycin Hoie 1990 1 38.00 2.00 d 3.30 1.22 0.00 
renal vancomycin Hoie 1990 1 37.00 4.00 d 3.40 0.91 0.00 
renal vancomycin Hoie 1990 1 36.00 1.00 d 3.00 0.67 0.00 
renal vancomycin Hoie 1990 1 40.00 1.00 d 2.50 1.04 0.00 
renal vancomycin Hoie 1990 6 38.00 2.00 d 3.30 1.10 0.32 
n=number of subjects in study; GA= gestational age; PNA=postnatal age; BW=body weight; CL=plasma clearance   
wk=week; y=year; m=month; d=day; n.a.=not available        
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Appendix II Pediatric weight, height, body surface area and liver size database (Johnson et al) 
Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
ICRP, 1975 122 0.001 3.5 51 0.226 0.124 0.026 M NA Autopsy 1975 
ICRP, 1975 93 0.125 5.4 56.2 0.297 0.132 0.027 M NA Autopsy 1975 
ICRP, 1975 106 0.625 8.7 69.8 0.418 0.22 0.044 M NA Autopsy 1975 
ICRP, 1975 69 0.875 9.7 73.6 0.453 0.271 0.053 M NA Autopsy 1975 
ICRP, 1975 186 1.5 11.4 82 0.515 0.225 0.042 M NA Autopsy 1975 
ICRP, 1975 114 2.5 13.6 91 0.59 0.425 0.074 M NA Autopsy 1975 
ICRP, 1975 78 3.5 15.6 99 0.646 0.491 0.08 M NA Autopsy 1975 
ICRP, 1975 62 4.5 17.5 106 0.713 0.525 0.082 M NA Autopsy 1975 
ICRP, 1975 36 5.5 20 113 0.79 0.548 0.082 M NA Autopsy 1975 
ICRP, 1975 22 6.5 22 119 0.854 0.612 0.089 M NA Autopsy 1975 
ICRP, 1975 29 7.5 24.3 125 0.924 0.64 0.092 M NA Autopsy 1975 
ICRP, 1975 20 8.5 27 130.5 0.997 0.748 0.11 M NA Autopsy 1975 
ICRP, 1975 21 9.5 30 136 1.074 0.745 0.11 M NA Autopsy 1975 
ICRP, 1975 27 10.5 33 141 1.148 0.862 0.13 M NA Autopsy 1975 
ICRP, 1975 17 11.5 36.3 146 1.226 0.835 0.125 M NA Autopsy 1975 
ICRP, 1975 12 12.5 40 151 1.309 0.914 0.14 M NA Autopsy 1975 
ICRP, 1975 15 13.5 46 158 1.436 1.021 0.17 M NA Autopsy 1975 
ICRP, 1975 16 14.5 52 166 1.568 1.08 0.18 M NA Autopsy 1975 
ICRP, 1975 20 15.5 58 171 1.678 1.137 0.2 M NA Autopsy 1975 
ICRP, 1975 24 16.5 62.5 175 1.761 1.341 0.25 M NA Autopsy 1975 
ICRP, 1975 97 18 67.1 176.9 1.829 1.49 0.31 M NA Autopsy 1975 
ICRP, 1975 93 0.001 3.4 50.2 0.221 0.126 0.027 F NA Autopsy 1975 
ICRP, 1975 83 0.125 4.5 55 0.267 0.123 0.026 F NA Autopsy 1975 
ICRP, 1975 102 0.375 6.7 63.5 0.35 0.165 0.033 F NA Autopsy 1975 
ICRP, 1975 87 0.625 8.2 67.5 0.4 0.22 0.044 F NA Autopsy 1975 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
ICRP, 1975 88 0.875 9.1 72 0.433 0.247 0.048 F NA Autopsy 1975 
ICRP, 1975 164 1.5 10.8 80.5 0.497 0.298 0.056 F NA Autopsy 1975 
ICRP, 1975 105 2.5 13 90 0.574 0.397 0.069 F NA Autopsy 1975 
ICRP, 1975 68 3.5 15.3 98 0.636 0.454 0.075 F NA Autopsy 1975 
ICRP, 1975 32 4.5 17.3 105 0.705 0.518 0.081 F NA Autopsy 1975 
ICRP, 1975 36 5.5 19 112 0.768 0.547 0.082 F NA Autopsy 1975 
ICRP, 1975 29 6.5 22 118 0.849 0.559 0.082 F NA Autopsy 1975 
ICRP, 1975 20 7.5 24 124 0.913 0.632 0.091 F NA Autopsy 1975 
ICRP, 1975 13 8.5 27 130 0.994 0.678 0.1 F NA Autopsy 1975 
ICRP, 1975 16 9.5 30.5 135.4 1.078 0.799 0.12 F NA Autopsy 1975 
ICRP, 1975 11 10.5 34 141 1.163 0.838 0.12 F NA Autopsy 1975 
ICRP, 1975 8 11.5 38 147 1.256 0.778 0.12 F NA Autopsy 1975 
ICRP, 1975 9 12.5 43 152.5 1.36 0.97 0.15 F NA Autopsy 1975 
ICRP, 1975 15 13.5 48 157.5 1.459 0.924 0.15 F NA Autopsy 1975 
ICRP, 1975 13 14.5 52 161 1.533 1.119 0.19 F NA Autopsy 1975 
ICRP, 1975 18 15.5 54.5 163 1.578 1.249 0.22 F NA Autopsy 1975 
ICRP, 1975 21 16.5 56 163.2 1.598 1.309 0.24 F NA Autopsy 1975 
ICRP, 1975 70 18 57.5 163.5 1.619 1.36 0.28 F NA Autopsy 1975 
Altman, 1962 63 0.001 3.4 50.5 0.222 0.115 0.024 M NA Autopsy 1962 
Altman, 1962 37 0.5 7.6 66 0.38 0.278 0.056 M NA Autopsy 1962 
Altman, 1962 34 1 10.1 75 0.466 0.37 0.071 M NA Autopsy 1962 
Altman, 1962 24 2 12.6 87 0.557 0.426 0.077 M NA Autopsy 1962 
Altman, 1962 27 3 14.6 95 0.624 0.472 0.08 M NA Autopsy 1962 
Altman, 1962 26 4 16.5 102 0.676 0.514 0.08 M NA Autopsy 1962 
Altman, 1962 27 5 19.4 112 0.775 0.551 0.084 M NA Autopsy 1962 
Altman, 1962 20 6 21.9 119 0.853 0.583 0.086 M NA Autopsy 1962 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
Altman, 1962 16 7 24.5 126 0.932 0.616 0.089 M NA Autopsy 1962 
Altman, 1962 13 8 27.3 131.5 1.007 0.662 0.095 M NA Autopsy 1962 
Altman, 1962 16 9 29.9 136 1.072 0.713 0.1 M NA Autopsy 1962 
Altman, 1962 8 10 32.6 138 1.124 0.787 0.11 M NA Autopsy 1962 
Altman, 1962 4 11 35.2 144 1.198 0.88 0.13 M NA Autopsy 1962 
Altman, 1962 14 12 38.3 150 1.279 0.972 0.15 M NA Autopsy 1962 
Altman, 1962 8 13 42.2 152 1.346 1.065 0.17 M NA Autopsy 1962 
Altman, 1962 12 14 48.8 162 1.5 1.148 0.19 M NA Autopsy 1962 
Altman, 1962 7 15 54.5 168 1.613 1.218 0.21 M NA Autopsy 1962 
Altman, 1962 19 16 58.8 172 1.695 1.278 0.23 M NA Autopsy 1962 
Altman, 1962 14 17 61.8 174 1.746 1.343 0.26 M NA Autopsy 1962 
Altman, 1962 24 18 63.1 175 1.768 1.398 0.28 M NA Autopsy 1962 
Altman, 1962 36 0.001 3.4 50.2 0.221 0.116 0.024 F NA Autopsy 1962 
Altman, 1962 5 0.5 7.3 65.5 0.37 0.222 0.044 F NA Autopsy 1962 
Altman, 1962 14 1 9.8 75 0.458 0.361 0.07 F NA Autopsy 1962 
Altman, 1962 11 2 12.3 87 0.549 0.417 0.075 F NA Autopsy 1962 
Altman, 1962 12 3 14.4 96 0.622 0.463 0.078 F NA Autopsy 1962 
Altman, 1962 13 4 16.4 102 0.674 0.509 0.081 F NA Autopsy 1962 
Altman, 1962 9 5 18.8 110.5 0.757 0.546 0.084 F NA Autopsy 1962 
Altman, 1962 8 6 21.1 117 0.829 0.588 0.087 F NA Autopsy 1962 
Altman, 1962 6 7 23.7 123 0.903 0.634 0.092 F NA Autopsy 1962 
Altman, 1962 9 8 26.4 128 0.973 0.69 0.099 F NA Autopsy 1962 
Altman, 1962 5 9 28.9 133 1.04 0.75 0.11 F NA Autopsy 1962 
Altman, 1962 5 10 31.9 137.5 1.111 0.815 0.12 F NA Autopsy 1962 
Altman, 1962 8 11 35.7 143 1.199 0.889 0.13 F NA Autopsy 1962 
Altman, 1962 8 12 39.7 149 1.292 1 0.15 F NA Autopsy 1962 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
Altman, 1962 3 13 45 155 1.403 1.093 0.17 F NA Autopsy 1962 
Altman, 1962 4 14 49.2 159 1.484 1.176 0.19 F NA Autopsy 1962 
Altman, 1962 7 15 51.5 160.8 1.526 1.231 0.21 F NA Autopsy 1962 
Altman, 1962 7 16 53.1 162 1.554 1.259 0.23 F NA Autopsy 1962 
Altman, 1962 7 17 54 162.5 1.569 1.278 0.24 F NA Autopsy 1962 
Altman, 1962 9 18 54.4 163 1.577 1.292 0.26 F NA Autopsy 1962 
Ogiu, 1997 55 0.001 2.9 49.2 0.202 0.119 0.03 M J Autopsy 1996 
Ogiu, 1997 14 0.083 4.2 54.7 0.257 0.161 0.033 M J Autopsy 1996 
Ogiu, 1997 19 0.167 5.4 58.1 0.301 0.192 0.032 M J Autopsy 1996 
Ogiu, 1997 16 0.25 7.2 63.6 0.364 0.24 0.042 M J Autopsy 1996 
Ogiu, 1997 21 0.33 6.7 63.8 0.35 0.235 0.036 M J Autopsy 1996 
Ogiu, 1997 12 0.417 7.1 65.4 0.365 0.256 0.04 M J Autopsy 1996 
Ogiu, 1997 13 0.5 7.6 66.3 0.381 0.249 0.031 M J Autopsy 1996 
Ogiu, 1997 11 0.583 8.9 69.9 0.423 0.302 0.03 M J Autopsy 1996 
Ogiu, 1997 10 0.67 8.3 70.5 0.409 0.304 0.028 M J Autopsy 1996 
Ogiu, 1997 8 0.75 9 72.2 0.431 0.346 0.07 M J Autopsy 1996 
Ogiu, 1997 6 0.833 8.4 66.1 0.401 0.293 0.05 M J Autopsy 1996 
Ogiu, 1997 5 0.92 8.3 72.3 0.41 0.326 0.03 M J Autopsy 1996 
Ogiu, 1997 34 3 10 80.4 0.476 0.376 0.06 M J Autopsy 1996 
Ogiu, 1997 16 2 11.5 85.5 0.526 0.447 0.06 M J Autopsy 1996 
Ogiu, 1997 20 3 14.3 97.8 0.624 0.464 0.09 M J Autopsy 1996 
Ogiu, 1997 13 4 15.6 105.4 0.676 0.564 0.09 M J Autopsy 1996 
Ogiu, 1997 13 5 17.8 110.4 0.74 0.595 0.11 M J Autopsy 1996 
Ogiu, 1997 8 6 19.9 115.6 0.802 0.65 0.11 M J Autopsy 1996 
Ogiu, 1997 12 7 21.7 118.1 0.845 0.625 0.063 M J Autopsy 1996 
Ogiu, 1997 10 8 22.8 124.5 0.896 0.763 0.11 M J Autopsy 1996 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
Ogiu, 1997 11 9 29.4 133.2 1.049 0.835 0.11 M J Autopsy 1996 
Ogiu, 1997 12 10 29.3 135.5 1.06 0.878 0.13 M J Autopsy 1996 
Ogiu, 1997 10 11 34.5 142.5 1.179 0.94 0.15 M J Autopsy 1996 
Ogiu, 1997 9 12 40.7 153.5 1.335 1.029 0.12 M J Autopsy 1996 
Ogiu, 1997 9 13 41.6 152.3 1.339 0.966 0.14 M J Autopsy 1996 
Ogiu, 1997 9 14 50.8 163.6 1.536 1.206 0.14 M J Autopsy 1996 
Ogiu, 1997 19 15 58.7 169.6 1.676 1.224 0.28 M J Autopsy 1996 
Ogiu, 1997 21 16 58.6 169.1 1.672 1.231 0.24 M J Autopsy 1996 
Ogiu, 1997 25 17 57.3 168.1 1.649 1.15 0.2 M J Autopsy 1996 
Ogiu, 1997 17 18 58.2 167.2 1.653 1.115 0.14 M J Autopsy 1996 
Ogiu, 1997 44 18 62.7 167.9 1.711 1.272 0.2 M J Autopsy 1996 
Ogiu, 1997 75 0.001 3.6 50.2 0.228 0.139 0.035 F J Autopsy 1996 
Ogiu, 1997 12 0.083 3.8 53.2 0.24 0.15 0.03 F J Autopsy 1996 
Ogiu, 1997 17 0.167 5 59 0.29 0.194 0.02 F J Autopsy 1996 
Ogiu, 1997 10 0.25 6 60 0.322 0.216 0.026 F J Autopsy 1996 
Ogiu, 1997 14 0.33 6.6 63.3 0.347 0.219 0.031 F J Autopsy 1996 
Ogiu, 1997 15 0.417 6.4 64.8 0.344 0.219 0.037 F J Autopsy 1996 
Ogiu, 1997 7 0.5 7.4 65.6 0.37 0.254 0.031 F J Autopsy 1996 
Ogiu, 1997 5 0.583 7.1 68.3 0.371 0.306 0.048 F J Autopsy 1996 
Ogiu, 1997 8 0.67 7.8 66.7 0.387 0.293 0.05 F J Autopsy 1996 
Ogiu, 1997 10 0.75 8 72.8 0.406 0.295 0.049 F J Autopsy 1996 
Ogiu, 1997 3 0.833 8.4 73.2 0.418 0.29 0.027 F J Autopsy 1996 
Ogiu, 1997 3 0.92 8 71 0.402 0.347 0.02 F J Autopsy 1996 
Ogiu, 1997 38 1 9.5 77.5 0.457 0.359 0.06 F J Autopsy 1996 
Ogiu, 1997 21 2 11.7 86.5 0.534 0.414 0.083 F J Autopsy 1996 
Ogiu, 1997 18 3 14.6 96.5 0.628 0.44 0.07 F J Autopsy 1996 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
Ogiu, 1997 10 4 16.3 103.2 0.678 0.529 0.089 F J Autopsy 1996 
Ogiu, 1997 7 5 16.8 107.4 0.707 0.586 0.13 F J Autopsy 1996 
Ogiu, 1997 9 6 19.9 114.2 0.795 0.596 0.11 F J Autopsy 1996 
Ogiu, 1997 10 7 21.2 119.1 0.842 0.6 0.1 F J Autopsy 1996 
Ogiu, 1997 8 8 26.9 129.3 0.988 0.772 0.1 F J Autopsy 1996 
Ogiu, 1997 10 9 26.7 129.7 0.987 0.797 0.14 F J Autopsy 1996 
Ogiu, 1997 4 10 33.6 140.6 1.154 0.933 0.08 F J Autopsy 1996 
Ogiu, 1997 10 11 39.4 147.8 1.281 1.02 0.13 F J Autopsy 1996 
Ogiu, 1997 6 12 37.4 147.5 1.251 0.993 0.15 F J Autopsy 1996 
Ogiu, 1997 4 13 45.1 148.3 1.36 1.014 0.1 F J Autopsy 1996 
Ogiu, 1997 6 14 52.7 157.8 1.52 1.19 0.15 F J Autopsy 1996 
Ogiu, 1997 8 15 48.5 158.1 1.469 0.885 0.2 F J Autopsy 1996 
Ogiu, 1997 5 16 50.5 153.4 1.462 1.05 0.21 F J Autopsy 1996 
Ogiu, 1997 9 17 49.3 156 1.465 1.045 0.13 F J Autopsy 1996 
Ogiu, 1997 23 18 49.3 158.3 1.481 1.132 0.17 F J Autopsy 1996 
Murry, 1995 3 3.88 16.2 101.2 0.666 0.508 0.036 U NA Radio 1997 
Murry, 1995 5 7.89 25.48 126.9 0.955 0.729 0.16 U NA Radio 1997 
Murry, 1995 5 12.66 42.65 153 1.358 1.035 0.041 U NA Radio 1997 
Murry, 1995 4 16.52 58.3 167.9 1.66 1.258 0.27 U NA Radio 1997 
Coppoletta, 1933 23 0.0041 3.1 49 0.209 0.072 0.03 U NA Autopsy 1933 
Coppoletta, 1933 12 0.0109 3.1 49 0.209 0.089 0.03 U NA Autopsy 1933 
Coppoletta, 1933 37 0.038 3.75 52 0.237 0.114 0.03 U NA Autopsy 1933 
Coppoletta, 1933 34 0.083 3.75 52 0.237 0.118 0.03 U NA Autopsy 1933 
Coppoletta, 1933 18 0.115 4.1 53 0.25 0.123 0.031 U NA Autopsy 1933 
Coppoletta, 1933 41 0.153 4.6 55 0.27 0.126 0.035 U NA Autopsy 1933 
Coppoletta, 1933 55 0.166 4.7 56 0.275 0.13 0.041 U NA Autopsy 1933 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
Coppoletta, 1933 34 0.33 5.6 59 0.309 0.148 0.042 U NA Autopsy 1933 
Coppoletta, 1933 36 0.41 6.2 61 0.33 0.174 0.035 U NA Autopsy 1933 
Coppoletta, 1933 46 0.5 6.45 62 0.34 0.185 0.05 U NA Autopsy 1933 
Coppoletta, 1933 36 0.58 7.3 65 0.37 0.21 0.04 U NA Autopsy 1933 
Coppoletta, 1933 37 0.67 7.3 65 0.37 0.235 0.051 U NA Autopsy 1933 
Coppoletta, 1933 20 0.75 7.8 67 0.388 0.241 0.062 U NA Autopsy 1933 
Coppoletta, 1933 25 0.83 8.4 69 0.408 0.254 0.056 U NA Autopsy 1933 
Coppoletta, 1933 28 0.91 8.6 70 0.416 0.256 0.059 U NA Autopsy 1933 
Coppoletta, 1933 11 1 9.37 73 0.443 0.267 0.071 U NA Autopsy 1933 
Coppoletta, 1933 34 1.16 9.65 74 0.452 0.281 0.065 U NA Autopsy 1933 
Coppoletta, 1933 32 1.33 10.47 77 0.48 0.306 0.067 U NA Autopsy 1933 
Coppoletta, 1933 30 1.5 10.5 78 0.484 0.319 0.087 U NA Autopsy 1933 
Coppoletta, 1933 19 1.67 10.65 79 0.489 0.343 0.045 U NA Autopsy 1933 
Coppoletta, 1933 14 1.83 11.3 82 0.513 0.352 0.06 U NA Autopsy 1933 
Coppoletta, 1933 28 2 11.8 84 0.53 0.365 0.07 U NA Autopsy 1933 
Coppoletta, 1933 53 3 12.65 88 0.56 0.387 0.08 U NA Autopsy 1933 
Coppoletta, 1933 19 4 15.55 99 0.645 0.478 0.075 U NA Autopsy 1933 
Coppoletta, 1933 19 5 17.4 106 0.711 0.552 0.095 U NA Autopsy 1933 
Coppoletta, 1933 53 6 17.75 109 0.732 0.594 0.09 U NA Autopsy 1933 
Coppoletta, 1933 42 7 21.45 113 0.786 0.63 0.09 U NA Autopsy 1933 
Coppoletta, 1933 26 8 22 119 0.854 0.681 0.09 U NA Autopsy 1933 
Coppoletta, 1933 29 9 24.75 125 0.931 0.7 0.08 U NA Autopsy 1933 
Coppoletta, 1933 27 10 27.1 130 0.995 0.789 0.09 U NA Autopsy 1933 
Coppoletta, 1933 12 11 29.5 135 1.061 0.842 0.09 U NA Autopsy 1933 
Coppoletta, 1933 14 12 32 139 1.121 0.867 0.09 U NA Autopsy 1933 
Urata, 1995 3 0.47 7.45 66.9 0.378 0.237 0.03 M J Radio 1995 
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Study N Age (yr) 
Weight 
(kg) 
Height 
(cm) 
BSA (m2) 
Liver 
volume (L) 
Liver volume 
SD (L) 
Sex Race Method 
Study 
year 
Urata, 1995 8 0.74 7.84 68.2 0.391 0.235 0.03 M J Radio 1995 
Urata, 1995 8 1.65 10.19 79.7 0.478 0.318 0.08 M J Radio 1995 
Urata, 1995 3 4.33 17.6 105.4 0.712 0.514 0.03 M J Radio 1995 
Urata, 1995 4 6.46 21.35 117.7 0.837 0.565 0.06 M J Radio 1995 
Urata, 1995 5 8.02 21.5 121.04 0.856 0.568 0.09 M J Radio 1995 
Urata, 1995 3 10.75 33.6 138.7 1.14 0.747 0.08 M J Radio 1995 
Urata, 1995 10 13.55 44.02 155.85 1.393 0.902 0.11 M J Radio 1995 
Urata, 1995 10 17.36 57.65 168.9 1.656 1.122 0.13 M J Radio 1995 
Urata, 1995 3 0.353 6.47 65.13 0.345 0.212 0.07 F J Radio 1995 
Urata, 1995 7 0.67 8.57 69.64 0.414 0.296 0.05 F J Radio 1995 
Urata, 1995 3 4.5 17.75 105 0.713 0.505 0.19 F J Radio 1995 
Urata, 1995 3 7.21 21.5 120.5 0.853 0.52 0.011 F J Radio 1995 
Urata, 1995 3 11.5 45.05 153.6 1.386 0.92 0.38 F J Radio 1995 
Urata, 1995 5 14.134 55.8 163.38 1.595 1.001 0.14 F J Radio 1995 
Urata, 1995 6 17.87 51.33 159.3 1.512 0.999 0.09 F J Radio 1995 
Rylance, 1982 3 6 21.25 118 0.816 0.401 0.15 U NE Radio 1982 
Rylance, 1982 3 9 28.65 133 1.036 1.071 0.2 U NE Radio 1982 
Rylance, 1982 3 13 44 155 1.389 1.322 0.23 U NE Radio 1982 
Noda, 1997 6 0.27 6.25 61 0.297 0.178 0.08 U J Radio 1997 
Noda, 1997 6 1.475 11.1 81.25 0.469 0.281 0.05 U J Radio 1997 
Noda, 1997 7 3.34 15.05 97.5 0.584 0.426 0.09 U J Radio 1997 
Noda, 1997 10 7 23 121.5 0.891 0.597 0.22 U J Radio 1997 
Noda, 1997 8 13.78 48.25 159.25 1.347 1.024 0.21 U J Radio 1997 
Noda, 1997 17 18 63 170.75 1.61 1.114 0.19 U J Radio 1997 
Heinemann, 1999 3 5 17.5 118.5 0.773 0.634 0.19 M NE Autopsy 1999 
Heinemann, 1999 5 17.4 69.9 175.4 1.848 1.51 0.3 M NE Autopsy 1999 
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Heinemann, 1999 4 12.68 43.42 149.2 1.336 0.86 0.23 F NE Autopsy 1999 
Heinemann, 1999 5 5.949 22.25 109.65 0.8 0.651 0.51 F NE Autopsy 1999 
Heinemann, 1999 6 10.08 40.08 141.19 1.19 0.917 0.47 F NE Autopsy 1999 
 
 
